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PROTEIN BASED TECHNOLOGIES TO IDENTIFY, STUDY, AND CONTROL 
INTRACELLULAR PROCESSES  
 
 
Proteins are increasingly used as basic research tools and therapeutics. Their large size, 
complex structure, and functional group diversity, by virtue of amino acids, often permit 
recognition of surfaces that challenge small-molecules. Fundamentally, this thesis describes 
protein based solutions to identifying macromolecules that function inside mammalian cells, 
enabling visualization and the study of complex biological processes in cellular environments. It 
also describes the development of engineered polycationic cell-penetrating nanobodies that access 
the cytosol and thus possibly represent a general solution to intracellularly targeted biologics drug 
discovery. Collectively, the work described in this thesis reports on: (1) a prostate cancer cell-
selective cell penetrating peptide, and its optimization; (2) cell-penetrating nanobodies that access 
the cytosol of mammalian cells; (3) the use of engineered protein assemblies for bioanalytical 
reagents and to visualize transcription and translation in mammalian cells, and; (4) a new protein 
reassembly-based technology to measure cytosolic residence of intracellularly delivered proteins. 
Technologies and methods described in this work advance the use of proteins in basic science and 
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1.1 Introduction  
Currently, 7 of the top 10 selling drugs are biologics – all proteins. Their large size, structural 
complexity, and molecular diversity often results in surfaces capable of potent and selective 
recognition of receptors that challenge, or evade, traditional small-molecules. However, most 
proteins do not penetrate the lipid bilayer exterior of mammalian cells. This severe limitation 
dramatically limits the number of disease-relevant receptors that proteins can target and modulate. 
Given the major role proteins play in modern medicine, and the magnitude of this limitation, it is 
unsurprising that so much effort has been dedicated to overcoming this pesky impediment. In this 
first chapter, we summarize and evaluate current approaches for intracellular delivery of 
exogenous proteins to mammalian cells, and in doing so, aim to illuminate fertile ground for future 
discovery in this critical area of research and the potential impact of my graduate work.  
It is difficult to overstate the importance of intravenously or subcutaneously administered 
proteins play in improving human health, and fighting off disease. Over the course of the last two 
decades, we have been witness to rapid growth in the biologics sector (principally proteins 
(antibodies)) of the pharmaceutical industry.1-3 This is a very recent trend. For over a century, 
small-molecules were virtually the only game in town. Why have proteins emerged as major 
players in the pharmaceutical industry, as well as basic research? The answer to this question is 
                                                
1 Adapted from: Bruce, V.J. and McNaughton, B.R., Cell Chemical Biology, submitted 2017 
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simple: absolute necessity. The problem with small-molecules is that they are small and often 
require a hydrophobic binding pocket for recogniton.4 While small-molecules will likely always 
play a prominent role in pharmaceutical science, most protein receptors lack well-defined small-
molecule binding sites, and thus challenge or evade small-molecule recognition. In contrast, the 
relatively large size, structural diversity, and molecular complexity of proteins often generates 
surfaces capable of recognizing disease-relevant receptors that defy their small-molecule 
counterparts.5 In addition, the evolution of proteins that bind a targeted receptor, either in the 
laboratory or in vivo, is generally higher-throughput and simpler than the analogous small 
molecule discovery process. Finally, relatively recent advances in large scale protein expression 
and purification have made possible the production of protein drugs on pharmaceutically-relevant 
scales. However, it is widely known that most proteins do not appreciably penetrate the lipid 
bilayer exterior of mammalian cells. As a result, exogenously administered protein therapeutics 
are generally limited to acting on receptors that reside on the surface of mammalian cells.  
Small-molecule drugs that act on an intracellular receptor must be hydrophilic enough to 
dissolve in water – since we are mostly water – but hydrophobic enough to pass through the lipid-
bilayer membrane of mammalian cells.6-7 Practitioners of medicinal chemistry are familiar with 
the term ‘partition coefficient’ (logP), the distribution of a small-molecule in a mixture of water 
and octanol. This experiment essentially says something about the probability of a small-molecule 
to traverse the lipid bilayer membrane. Medicinal chemists can tinker with the atomic composition 
of a drug lead until cell penetration is optimized. However, analogous manipulation of proteins is 
daunting territory. Protein folding is largely driven by the collapse of hydrophobic residues to the 
interior, and concomitant display of hydrophilic residues on the surface. Dramatic resurfacing of 
proteins with hydrophobic amino acids, in an effort to mimic medicinal chemistry efforts in the 
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small-molecule world, often results in decreased protein stability and/or aggregation. As a result, 
researchers have been forced to develop conceptually new approaches for the delivery of 
exogenous proteins to the interior of mammalian cells. Here, we present several of these 
approaches, discuss their existing challenges and hopefully offer insight into the future of these 
research and discovery efforts. 
 
1.2 Taking a Step Back: Delivering Nucleic Acids to Mammalian Cells  
DNA, and mRNA, encode the amino acid composition of proteins. If either of these reagents 
can be delivered to the interior of a mammalian cell, it can be acted upon by endogenous 
transcription/translation machinery, ultimately resulting in the synthesis of a new intracellular 
protein. However, the polyanionic nature of nucleic acids prohibits direct passage across lipid 
bilayers. Common methods for intracellular nucleic acid delivery include: cationic lipids and 
polymers, viral carriers, and lipid bilayer deformation / physical insertion (Figure 1.1A-C). 
 
1.2.1 Cationic Lipids and Polymers  
Lipid cation transfection reagents are synthetic carriers that typically consist of a quaternary 
amine cation and lipid tail – usually alkyl chains or hydrophobic molecules like cholesterol.8 In 
aqueous solutions, these reagents spontaneously align into bilayer sheets with buried lipids and 
exposed cations. When mixed with DNA, ion-paired assembly between negatively charged 
phosphates on DNA and the cationic surface of the bilayer sheet enables capture and encapsulation 
of DNA (Figure 1.1A). DNA containing lipid vesicles can permeate lipid bilayers of mammalian 
cells, and essentially serve as a Trojan horse delivery reagent for DNA. The basic mechanism of 
lipid-cation transfection of DNA consists of: (A) formation of DNA-encapsulated lipid cation  
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Figure 1. 1 Common Methods for Achieving Intracellular Delivery of Protein-Encoding Nucleic 
Acids. A) DNA/lipid-cation assemblies; B) Viral carriers with encapsulated DNA, C) Lipid bilayer 
deformation / physical insertion. 
 
vesicles; (B) endocytosis of the lipid cation-DNA vesicles; (C) release of encapsulated DNA to 
the cytosol; (D) entry into the nucleus, followed by transcription and translation using endogenous 
machinery (Figure 1.2). 
The first example of lipid-cation mediated delivery of DNA to mammalian cells was only 
reported in 1980.9-10 Since then, a multitude of lipid cation transfection reagents have become 
available commercially, and this method remains popular in mammalian cell culture.11-12 While 
these reagents protect nucleic acids from endogenous nucleases, and facilitate cell uptake, perhaps 
the greatest hurdles for broad use in vivo include: efficient escape from endosomes and innate 
toxicity. Lipid-cation mediated uptake often proceeds via endocytosis. Thus, efficient delivery of 
DNA requires subsequent escape from the endosomes to the cytosol (and then nucleus).13  
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Figure 1. 2 Uptake Mechanism for Nucleic Acid Delivery with Cationic Lipids. A) First, polyanionic 
DNA is complexed with cationic lipids to form vesicles. B) External cations of the vesicles interact with 
the negatively charged membrane to induce endocytosis. C) DNA is released from the cationic vesicle and 
endosomes to reach the cytoplasm. D) From the cytoplasm, the DNA must enter the nucleus where it can 
be transcribed and translated into the desired protein.  
 
Researchers have recently shown that controlling vesicle composition, by virtue of mixtures 
of lipid cation reagents, can increase the delivery of nucleic acids that end up in the cytosol.14 As 
endosomes mature into lysosomes, the internal pH drops from ~6.5 to ~4.5.15-16 This change has 
been exploited as an environmental cue to enhance endosomal escape. For example, ionizable lipid 
nanocarriers are neutral at physiological pH (pH ~ 7) but become cationic in the acidic 
environment associated with late-stage endosomes / lysosomes. The resulting change in charge 
leads to favorable disruption of the endosomal membrane, and release of internalized nucleic acid 
into the cytosol (Figure 1.3). In one recent example, a new series of ionizable lipids were derived 
from naturally occurring aminoglycoside tobramycin and a biodegradable diester linker.17 
Alternatively, Mayworth, McKinlay and co-workers characterized so-called charge-altering 
releasable transporters (CARTs), which are predicted on the use of cellularly biodegradable 
materials for the delivery of mRNA into cells.18 Once endocytosed these lipids undergo 
degradation, releasing polyanionic nucleic acids that disrupt, and escape from, the endosome 
membrane.  
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When used in vivo, lipid cation transfection reagents can induce an unwanted immune 
response, and thus are appreciably toxic. To help mitigate these affects, biodegradable transporters 
have been reported. A recent example utilized poly (b-amino esters) (PBAE) for the delivery of 
DNA to the brain.19 Researchers reported that this rapidly biodegradable nanocarrier resulted in 
minimal cytotoxicity or inflammatory response, while providing highly efficient DNA delivery, 
and rapid diffusivity within the brain parenchyma. 
 
Figure 1. 3 Ionizable Lipid Nanocarriers. A) Ionizable lipids are mixed with typical cationic lipid 
reagents to form nanocarriers around DNA. A change in pH causes these once neutral lipids to become 
cationic. B) Cellular mechanism: Once endocytosed, the pH naturally becomes acidic within endosomal 
vesicles ionizing these lipids to their cationic form, thus promoting endosomal escape. 
 
Despite recent advances, lipid-cations are principally used for the delivery of nucleic acids in 
mammalian cell culture. However, as researchers better understand the molecular dictates of 
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endosomolytic release, and overcome toxicity, these reagents might find expanded use for in vivo 
delivery of nucleic acids that encode therapeutically-relevant proteins. 
 
1.2.2 Viral Carriers for the Intracellular Delivery of Protein-Encoding Nucleic Acids  
In order to proliferate, viruses infect mammalian cells and transfer their genetic material. 
Unsurprisingly, perhaps, researchers have exploited Nature’s solution of genetic transfer to 
mammalian cells as a method to deposit exogenous DNA across the lipid bilayer. Popular viral 
carriers include the retrovirus, lentivirus, adenovirus and adeno-associated virus (AAV).20-21 Some 
vectors, such as AAV, can stably integrate DNA into the host genome at a specific site. While 
retroviruses can also integrate their DNA into its hosts genome, its occurrence is far more random, 
presenting the possibility of deleterious random insertion, which, if unlucky, could lead to diseases 
such as cancer. 
Overall, the construction of viral carriers requires that the viral vector retains the necessary 
components for highly efficient genetic delivery, while at the same time being sufficiently mutated 
so that the pathogenic components have been silenced or replaced with therapeutic genes.20 
Viruses have had billions of years to evolve an ability to transfer genetic material to mammalian 
cells. As a result, they are highly efficient, and this approach has been the focus of a number of 
clinical trials. Leading clinical trials utilizing viral delivery include Hematopoietic-stem-cell gene 
delivery, liver directed gene therapy, T-cell immunotherapy for cancer and retinal gene therapy.22 
Viral delivery of protein-encoding nucleic acids is particularly useful for diseases in which a 
malfunctioning, or missing, enzyme is replaced (generally referred to as enzyme replacement 
therapy). Of course, it is likely that an enzyme is only malfunctioning or completely missing in 
certain cells, and as a result, DNA encoding the proper protein should only be delivered to those 
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particular cells. Cell-selective delivery of nucleic acids is a focus of modern research, and advances 
need to be made in this area. Liver-selective delivery of gene-encoding nucleic acids can be 
achieved with viral carriers. One example is the treatment for severe hemophilia B, a bleeding 
disorder resulting from genetic mutation of a serine protease critical for blood clotting (factor IX 
or FIX).23-24 Researchers have shown that a single peripheral-vein infusion with a FIX-encoding 
AAV vector led to liver specific uptake, long-term expression of FIX (enzyme replacement) and a 
decreased risk of spontaneous hemorrhage.25  
While transfer of genetic information to mammalian cells, via viral carriers, is efficient, 
limitations and challenges exist. Foremost among these limitations and challenges are toxicity 
(often in the form of immunogenicity), transient versus permanent transfer of genes, restricted 
recognition of specific cell types, neutralization by endogenous antibodies, and restrictions on 
DNA carrying capacity. To help mitigate unwanted toxicity/immunogenicity, researchers have 
designed hybrid delivery vectors through the combination of retrovirus-like particles with 
synthetic polymers or lipids, essentially hiding the virus carrier from the immune system. 
 
1.2.3 Lipid Bilayer Deformation / Physical Insertion  
Physical methods that transiently disrupt the cellular membrane can be utilized for the 
delivery of nucleic acids to the interior of mammalian cells without the need of a chemical or viral 
carrier. Two of the most common methods include electroporation and microinjection.  
Electroporation: Similar to lipid cation transfection, electroporation enjoys broad use as a 
method to deliver nucleic acids to the interior of cultured mammalian cells. Electroporation utilizes 
high-voltage electoral pulses to transiently disrupt the cell membrane. The resulting nanoscale 
pores in the plasma membrane allow relatively rapid uptake of exogenous materials, including 
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nucleic acids (and gene-encoding DNA). Perhaps unsurprisingly, electroporation is often toxic, 
and as a result, this approach to nucleic acid delivery is typically limited to mammalian cell culture. 
However, electroporation has also found use as a means of delivery for nucleic acids in ex 
vivo applications, wherein isolated calls are genetically modified (by addition of exogenous nucleic 
acids), and selected for function (such as expression of a new protein), then reintroduced or 
implanted into the patient to simulate or restore damaged tissues or induce an immune response.26 
One of the greatest limitations for physical methods such as electroporation is low-throughput. 
The advent of microfluidic technologies and methodologies for increasing efficiency and 
magnitude of targeted cells has become a focus. Lu, Geng, and co-workers recently developed a 
protocol for continuous cellular transfection, reaching a liter volume of cells. The electric pulse is 
not applied to stagnant cells as in a classic electroporation cuvette, but to a flowing population 
resulting in increased transfection efficiency.27 
Microinjection: As the name implies, the process of microinjection requires direct physical 
insertion of DNA to the cytoplasm or nucleus of a mammalian cell via microneedles. The first 
microinjection of non-native DNA occurred in 1980 when glass micropipettes were used to 
introduce the Herpes simplex virus thymidine kinase gene to cultured mammalian cells.28 
Although this method is laborious, requires a skilled practitioner, and is very low-throughput; 
highly efficient delivery is achieved. Nanofabrication methods have enabled platforms that 
facilitate much higher-throughput microinjection of nucleic acids to mammalian cells.29 For 
example, Shalek, Park, and co-workers utilized surfaced-modified vertical silicon ‘microneedle’ 
nanowires as a general platform for the introduction of nucleic acids and other biomolecules into 
immortalized and primary mammalian cells.30  
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Microneedle-based approaches have been used to deliver small-molecule drugs, peptides, 
proteins, inactivated virus particles as well as plasmid DNA to the interior of mammalian cells.29 
Researchers have used various fabrication methods to evaluate a variety of ‘microneedles’ with 
different properties, including composition. Microneedles that are solid, hollow, dissolving, or 
made from hydrogel frameworks have been evaluated. This method is particularly useful for the 
delivery of plasmid DNA, along with other molecules and materials, into cell lines that are difficult 
to transfect with commercially available reagents such as cationic lipids For example, researchers 
have used microneedles for the delivery of protein encoding plasmid DNA into primary neruons.31 
For the delivery of nucleic acids via microneedles a review by Yuan, Chen and co-workers has 
been recently published.29  
Additionally, outside the realm of nucleic acids that encode proteins (DNA and mRNA), 
delivery of single-stranded antisense oligonucleotides (ASOs) and small interfering RNA 
(siRNA), both for silencing the production of particular proteins (which will not be discussed here 
but has been elsewhere), is an exploding trend that utilizes many of the same methods for 
delivery.32 Excellent reviews for their delivery can be found here (ASOs33; siRNA34). 
 
1.3 Methods for Delivering Exogenous Proteins to Mammalian Cells  
Conceptually, in comparison to the delivery of gene-encoding nucleic acids, it is simpler 
to directly deliver an exogenous protein to the interior of a mammalian cell. However, like nucleic 
acids, the size and theoretical net charge of proteins (most often with surfaced exposed charged 
residues) limits their cellular uptake.35 Indeed, most naturally occurring proteins do not 
appreciably penetrate the lipid bilayer of mammalian cells. Concomitant with the rise in biologics 
as a major sector in the global pharmaceutical industry, researchers have dedicated an enormous 
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amount of effort to developing strategies for exogenous protein delivery to mammalian cells. Some 
of these methods are reviewed below.  
 
1.3.1 Cell-Penetrating Peptides  
Cell-penetrating peptides (CPPs) or protein transduction domains (PTDs) are relatively 
short peptides (<20 amino acids), which, when fused to a protein endow transport of that protein 
across the lipid bilayer membrane. First described in the 1980’s, this method is probably one of 
the most straightforward platforms for direct protein delivery to the cell interior.36 
A selection of the most widely utilized CPPs include: Tat peptide from the transactivating 
protein Tat of HIV-1 (GRKKRRQRRRPPQ)37-38; the third helix of the homeodomain of 
antennapedia called penetratin (RQIKIWFQNRRMKWKK)39; and polyarginine (R9)40. A quick 
glance at these sequences reveals a common theme: a high ratio of cationic residues (arginine 
and/or lysine). It has been known for some time that cationic residues interact favorably with the 
exterior of a mammalian cell membrane41, principally by engaging negatively charged 
glycosaminoglycans (GAGs) such as heparin sulfate (HS) and condrotinin sulfate (CS) on the 
surface of cells.42-45 Generally, arginine rich peptides are more potent carriers than their lysine rich 
counterparts, due to more favorable, bidentate interactions with sulfated proteoglycans on the cell 
surface. 
 
1.3.2 Cell-Selective Cell-Penetrating Peptides  
One limitation of polycationic CPPs is that they indiscriminately engage, and penetrate, 
mammalian cells (and drag in associated cargo). Ideally, CPPs would only penetrate, and deliver 
associated cargo, to diseased cells. One approach to achieving cell-selective delivery is cancer-
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cell-Activated CPPs, (ACPPs), which have been reported by Tsien and co-workers (Figure 1.4).46-
47 These reagents consist of three components: (1) a polycationic CPP; (2) a polyanionic 
biopolymer that binds to, and essentially quenches the polycationic CPP, and; (3) a linker that can 
be cleaved by an excreted protease associated with diseased (commonly cancer) cells. Since this 
reagent is entirely composed of polypeptides, it can be genetically fused to a protein of interest. In 
the absence of cancer cell associated proteases (such as matrix metalloprotease 9, MMP-9) the 
polyanionic portion quenches the charge of the polycationic portion – disabling cell-penetration. 
However, in the presence of a cancer cell associated protease, the linker is cleaved, ultimately 
   
Figure 1. 4 Cancer Cell Activated CPPs (ACPPs). A) In the absence of cancer cell associated proteases, 
ACPPs remain inactive and unable to penetrate mammalian cells. B) Activation of ACPPs by the presence 
of cancer cell associated proteases (ex: MMP-9), cleaves the anionic component from the cationic CPP – 
protein fusion component, allowing the cationic CPP-protein fusion to penetrate neighboring (diseased) 
cells. 
resulting in separation of polyanionic and polycationic-components. Following dissociation of the 
polyanionic component, the polycationic CPP-protein fusion can penetrate neighboring (diseased) 
cells.48 
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An alternative strategy is to use laboratory evolution to select for cell-selective uptake. A 
number of labs49-51, including our own52, have used rounds of positive and negative selection to 
evolve CPPs that selectively penetrate a cell line of interest. As an example, we performed 
positive/negative selections on a ~1012 bacteriophage (phage) display 12mer-linear peptide library 
to identify phage (peptides) that potently penetrate PC-3 prostate cancer cells, but do not 
appreciably penetrate a number of non-prostate, or prostate but non-cancerous cell lines (Figure 
1.5).52 Following multiple cycles of positive and negative selection, we identified Y-peptide, 
‘Ypep’ (YTFGLKTSFNVQ), which selectively penetrates PC-3 cells.53 Further efforts towards 
the optimization and characterization of this CPP will be more fully discussed in Chapter Two of 
this thesis. 
 
1.3.3 Protein Resurfacing  
As stated previously, the majority of reported CPPs contain a disproportionately high number 
of positively charged arginine and/or lysine residues, and have a high theoretical net charge. These 
positively charged residues facilitate interaction with negatively charged cell surface 
proteoglycans, such as sulfated proteoglycans – ultimately enabling cell uptake.54 Protein 
engineers have extended the concept of polycationic-mediated delivery to the protein surface itself. 
By performing dramatic mutagenesis of protein surface residues to positively charged arginine 
and/or lysine, researchers have created varied degrees of polycationic resurfaced proteins, which 
contain a disproportionately high number of positively charged residues on the surface. These 




Figure 1. 5 Evolution of a PC-3 Prostate Cancer Cell-Selective Cell Penetrating Peptide. In a positive 
selection, phage are incubated with PC-3 prostate cancer cells and enriched for cell penetration. Next, in a 
negative selection, cell-penetrating phage are incubated with off-target cells, and phage that don’t penetrate 
are enriched. 
 
In a seminal contribution, Raines and co-workers utilized a method they call ‘arginine grafting’ 
to turn proteins with no appreciable cell-penetration activity (RNase A or GFP) into potent cell-
penetrating proteins.55-56 Arginine grafting is achieved by mutating clustered solvent exposed 
acidic residues to arginine (Figure 1.6A – GFP is shown as an example). The resulting arginine 
cluster can engage sulfated proteoglycans on the surface of mammalian cells – ultimately enabling 
cell uptake. In a therapeutically-relevant example, internalized RNase A led to cellular 
cytotoxicity, through destruction of intracellular RNA. However, like their polycationic CPP 
relatives, internalized proteins (GFP as an example) appear as punctate foci, suggesting a 
proportion reside within endosomes (Figure 1.6B).57 Nonetheless, for highly efficient enzymatic 
 15 
proteins (such as RNase A), a little goes a long way; endosome entrapment of a significant 
percentage of the population might not be a great concern. 
In a conceptually related approach, Liu and co-workers pushed the limits of protein resurfacing 
by generating a series of ‘supercharged proteins’ – the result of extensive mutagenesis of surface 
residues to positively charged arginine and lysine (Figure 1.6C). In this case, the resulting proteins 
exemplified extreme stability, resistance to aggregation, and the ability to potently penetrate 
mammalian cells.58 For example, researchers in the Liu laboratory ‘supercharged’ GFPs to have a 
theoretical net charge of +15, +25, or +36.59-60 Theoretical charge matters (at least in this context), 
and resulting uptake of supercharged GFP increases as a function of theoretical net charge. 
Subsequently, researchers in the Liu lab demonstrated that engineered ‘supercharged’ GFPs, and 
naturally occurring ‘supercharged’ proteins (theoretical net charge: molecular weight ratio of 
+1.27/kDa) can deliver genetically fused proteins to the interior of mammalian cells.61 Of great 
concern, is while these superpositively charged proteins are efficiently taken up by cells, the route 
of entry relies on endocytosis. As a result, an appreciable percentage of internalized (endocytosed) 
proteins remain sequestered in endosomes and cannot act on cytosolic or nuclear targets (Figure 
1.6D).57 However, researchers have recently developed methods to get endocytosed exogenous 
proteins outside of the vesicles, and into therapeutically relevant environments, including the 
cytosol and nucleus (See section 1.3.4) . 
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Figure 1. 6 Protein Resurfacing Strategies and Cellular Uptake. A) GFP shown as an example of 
arginine grafting, where a small solvent exposed patch has been mutated to arginines. B) Raines’ arginine 
grafted GFP. Blue = cationic residues; red = anionic residues. Arginine grafted GFP penetrates mammalian 
cells, and largely appears as punctate foci, suggesting encapsulation within endosomes. C) Residues 
mutated to arginine (purple) and lysine (blue) to generate +36 GFP. D) Liu’s supercharged +36 GFP. Blue 
= cationic; red = anionic. +36 GFP potently penetrate mammalian cells, and largely appears as punctate 
foci, suggesting encapsulation within endosomes. In microscopy images, nuclei are stained blue with DAPI. 
E) Polycationic resurfacing of a nanobody (GFP binding nanobody shown as example). Residues mutated 
to arginine (purple) and lysine (blue) generate a theoretical net charge of +15. F) Fluorescence microscopy 
images of GFP fused nanobodies appear more evenly delivered, suggesting cytosolic delivery. (PDB: GFP: 
1GFL; nanobody: 3OGO).  
 
While polycationic protein resurfacing endows potent cell penetration, most proteins are not 
receptive to such extensive mutation. Additionally, CPPs are often limited in the amount of charge 
it can possess and still be beneficial for uptake, with polyarginine tags of greater than 20 residues 
decreasing uptake.62 Current work with ‘supercharged’ proteins suggests that polyarginines in the 
well-structured framework of a protein behave differently than polycationic CPPs.63 Ideally, cell-
penetrating drug leads and basic research tools could be prepared from a single polycationic 
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resurfaced protein architecture. Recently, we showed that nanobodies, the binding domain of 
camelid-derived heavy chain antibodies are amenable to cationic resurfacing.64 Chapter Three of 
this thesis describes the characterization of these polycationic resurfaced nanobodies and their 
potential use as therapeutic drug leads. 
Through a mechanism that is conceptually similar to nucleic acid delivery, Liu and co-workers 
recently showed that polyanionic resurfaced proteins (-30 GFP), when mixed with commercially 
available lipid cations, penetrate mammalian cells.65 Concomitant with a rise of interest in 
delivering gene editing technologies, such as CRISPR, they show the co-complexation of purified 
Cas9 protein (+22 theoretical charge) with sgRNA yields an overall highly anionic supramolecular 
unit for protein/RNA encapsulation by cationic lipids and cellular uptake. 
 
1.3.4 The Great Escape: Endosomolytic Peptides  
Delivery of exogenous proteins to mammalian cells can sometimes occur via direct membrane 
translocation, which results in high levels of cytosolic residence of internalized cargo. Often, 
however, delivery occurs through one of the many well studied pathways for the uptake of 
exogenous material (including: endocytosis, micropinocytosis, and phagocytosis).66-67 Many 
protein delivery technologies proceed by an endocytotic pathway, and as a result, internalized 
cargo ends up trapped within endosomes. Functional delivery to the cytosol or nucleus then 
becomes a multi-step process: endocytosis followed by release of the cargo from endosomes into 
the cytosol (endosomolytic release).68 In cases where nuclear delivery is required, fusion to a 
Nuclear Localization Sequence (NLS) is useful. Two of these three requirements (crossing the 
lipid bilayer and nuclear delivery, once in the cytosol) are, at least on a superficial level, solved 
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problems. What remains a significant challenge is deformation of the endosome and release of 
internalized cargo to the cytosol (or subsequently the nucleus, if necessary).  
As stated previously, early stage endosomes mature into late stage endosomes, which then fully 
mature into lysosomes. Along this maturation, the pH inside each of these vesicles changes 
dramatically (from pH ~6.5 to pH ~4.5). Peptides – some naturally occurring and some evolved in 
the laboratory – can respond to this change, and in doing so, disrupt the internalized vesicle. This 
disruption ultimately enables escape of internalized cargo, such as the internalized protein. The 
peptide HA2 (GLFGAIAGFIENGWEGMIDGWYG) is one such example. It is derived from the 
hemagglutinin HA2 subunit of the influenza virus and is rich in glutamate residues.69 In acidic 
environments associated with late stage endosomes/lysosomes, aspartate and glutamate residues 
become neutralized by protonation, and interact more efficiently with the endosomal membrane, 
resulting in deformation.70-71 Alternatively, hydrophobic residues – specifically phenylalanine, in 
a peptide segment called the penetration-accelerating sequence (Pas; FFLIPKG) have been shown 
to increase cytosolic delivery of fused proteins.72-73 It has been suggested that addition of 
hydrophobic residues in Pas, in combination with CPPs (like polyarginine), enables uptake and 
endosomolytic activity, presumably through hydrophobic residues in Pas interacting with, and 
disrupting, endosomal membranes.  
Recently, Liu, Li, and co-workers evaluated peptides classified under the umbrella of 
antimicrobial agents capable of penetrating microbial membranes, for an ability to enhance 
endosomal escape of exogenously delivered proteins (Figure 1.7).74 From this study, researchers 
identified a 13-mer peptide (GLFDIIKKIAESF) called aurein 1.2 which enhances cytosolic 
delivery genetically fused proteins, both in live cell culture and in vivo. Interestingly, this peptide 
can selectively disrupt the endosomal membrane – facilitating escape of fused cargo protein from 
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the endosome to the cytosol – without disrupting the mammalian cell membrane or exhibiting 
appreciable toxicity. Since many protein delivery methods proceed via endocytosis, the pairing of 
non-toxic and highly efficient cell-penetrating and endosomolytic technologies will likely have a 
significant impact on the field of exogenous protein delivery. 
 
Figure 1. 7 Identification of an Endosomolytic Peptide for Increased Delivery of Supercharged 
Proteins to the Cytosol of Mammalian Cells. In this system, supercharged GFP was attached to cre 
recombinase, thus if cytosolic delivery was achieved, recombination of a reporter gene will trigger 
expression of a red fluorescent protein. 
 
1.3.5 Employing Toxins to Deliver Exogenous Proteins  
Protein assemblies from bacterial and plant toxins, such as anthrax, diphtheria and botulinum, 
potently penetrate mammalian cells and access the cytoplasm.75 These toxins are of the type AB, 
and are comprised of two segments (Figure 1.8A). The A subunit typically referrers to the 
cytotoxic element, which, once internalized, acts on its intracellular target. The B subunit, 
however, binds to specific cell surface receptors and enables uptake of the toxin into the cell – 
often through endocytosis as well as recognition by the A subunit. Once endocytosed, the B subunit 
interacts with the endosomal membrane. It is this interaction that results in poration of that 
membrane, and release of the toxin to the cytosol. Given that these toxins have been evolved to 
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penetrate the lipid bilayer of mammalian cells, and, escape endosomes, it is perhaps unsurprising 
that they are been exploited for exogenous protein delivery (Figure 1.8B). 
 
Figure 1. 8 Cellular Delivery by Toxins. A) AB type toxins are composed of an A subunit which typically 
delivers a toxin (or in this case protein) and a B subunit that recognizes a cell membrane receptor. B) 
Exogenous protein is delivered by endocytosis once the B subunit recognizes its cellular receptor. Next, 
subunit B generates pores to promote endosomal escape, thus delivering the exogenous protein to the 
cytosol. 
 
Relatively recently, Botulinum neurotoxin type D (BoNT/D), inactivated by mutation of 
toxicity-inducing proteins, was exploited for the delivery of exogenous protein cargo to 
mammalian cells.76 By genetic fusion of cargo proteins to the N-terminus of BoNT/D, researchers 
successfully delivered functional firefly luciferase and GFP to the cytoplasm of neuronal cells. 
However, simple genetic fusion of cargo protein to the terminus of inactivated toxin proteins can 
result in rather large proteins, and assemblies. For example, each BoNT/D fusion weighs 
approximately 150 kDa. A minimalistic approach is to remove the toxic component of the A 
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subunit leaving only what is required for recognition by subunit B, and simply work with a fusion 
between minimized subunit A and protein cargo. As a representative example, researchers have 
used the anthrax toxin as a bacterial transport nanomachine that can deliver proteins to mammalian 
cells. This system also belongs to the AB-toxin group and is made up of a protective antigen (PA, 
subunit B) component that recognizes the cell and an A subunit called the lethal factor protein (LF, 
90 kDa) which is delivered to the cytosol of the cell through its recognition of PA. Recently the 
unnecessary cytotoxic components of subunit A (LF) were eliminated yielding a 30 kDa fragment 
(vs the wild type LF at 90 kDa) of the N-terminal domain (termed LFN) that is still recognized by 
PA.77 This system has been used to deliver antibody mimics as fusions between LFN with the 
desired protein for delivery.78 Recently, the Pentelute Laboratory commented on the functionality 
of this approach through the delivery of a monobody-LFN fusion, and the directed inhibition of 
Bcr-Abl kinase activity and apoptosis in cultured cells. 
Subunit B of bacterial and plant toxins initiates cellular internalization through selective 
recognition of cell surface receptors. These receptors include synaptotagmins enriched in neuronal 
cell surfaces for BoNT/D and tumor endothelial marker 8 or capillary morphogenesis gene 2 
(TEM9 or CMG2, respectively) for PA.76, 79 While it can be beneficial under certain circumstances 
that one domain of the toxin exhibits selective binding to target tissue, it is also limiting as only 
certain tissues can be delivered to via this system. Recently, the PA/LFN system has been modified 
to allow retargeting of the PA domain to receptors over expressed in tumor cells.80 By fusing an 
engineered minimalistic high-affinity protein (Affibody81) specific for the HER2 receptor (a 
tyrosine kinase receptor over expressed in 20-25% of breast, gastric, and ovarian carcinomas) to 
the C terminus of a receptor recognition-deficient PA subunit (B subunit), targeted delivery of 
cytocidal effectors was achieved to cell lines overexpressing HER2.82 Thus, such toxin platforms 
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might be highly tunable, as is the case with PA/LFN, but prior knowledge concerning the system 
and cellular receptors available for delivery is required. Of great interest, is that these systems 
appear to efficiently escape the endosomes as a function of subunit B. Perhaps of concern for the 
general use of this system is its multi-component architecture. In order to achieve delivery, fairly 
large and multifaceted structures must be simultaneously supplied to target cells (PA: 83 kDa, 
LFN: 30 kDa, + protein of interest). 
 
1.3.6 Membrane – Disruption Based Techniques  
Like electroporation and microinjection for the delivery of nucleic acids, membrane-disruption 
based techniques for the delivery of exogenous proteins act through transient disruption of the cell 
membrane. These methods take advantage of mechanical means, and include microneedles83, 
electrical pulses84, scrape/bead loading85, acoustic sonoporation86, chemical detergents and pore-
forming agents87-88 and instrumentational devises to make physical pores in the cellular 
membrane89 that then allow the direct delivery of proteins to the cytoplasm. Physical methods are 
quite inconsistent with the biochemical assemblies previously discussed in this chapter. 
Considerations for endosomal escape and knowledge of appropriate receptors or surface 
interactions can be effectively eliminated because the delivery is direct and does not require 
carriers or chemical modification for protein delivery. Similar benefits and draw backs are 
experienced with these methods as with the previously discussed physical methods for nucleic acid 
delivery (benefits: temporal control over delivery dynamics, volume, and dosage concentration; 
limitations: low-throughput and limited use in vivo). Clinically speaking, these methods often 
result in a high proportion of cell death and thus must be accomplished ex vivo. Instrumentation 
and procedures based on increasing the flow and output for these methods are required for their 
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use in the clinic, and are perhaps becoming a reality with microfluidic devices. A very recent 
review by Jensen, Stewart and co-workers nicely discusses the current methods for membrane 
disruption techniques in terms of intracellular delivery and its outlooks.90 
The method of bead-loading is one example of these physical membrane-disruption based 
techniques. This technique utilizes glass beads (75 – 500 uM diameter) in a solution containing 
the desired macromolecule to be loaded into cells.85 The solution of glass beads and protein are 
tapped onto the cells, creating transient pores in the cell membrane allowing macromolecules in 
the solution to be taken up by the cells. The glass beads, however, are too large for uptake and can 
be washed away from the cells. Recently, this technique was used deliver antibody Fab fragments 
for the imaging and detection of translation in living cells.91 A major advantage of this approach 
is that the loaded cells remain adherent and well-spread while endowing delivery of a large number 
of macromolecules to the cytosol of cells. However, while this technique is ideal for imaging 
cultured cells, it is not applicable for in vivo applications or methods requiring high-throughput. 
 The functional delivery of highly transient, nonreplicable protein agents as opposed to DNA 
sequences has many benefits and thus may offer improved specificity, increased safety and broader 
applicability. Through the delivery of folded proteins, control over therapeutic concentration and 
exposure time can be more precisely accomplished, as especially desired for many non-genetic 
disorders. Many of these methods must still overcome issues with cell selectivity and requirements 
concerning payload to become a validated means for the delivery of non-native therapeutic 
proteins, however the benefits afforded through the direct delivery of non-native protein 




1.4 Alternative Carriers for Protein Delivery  
Carrier methods for the delivery of proteins can broadly be defined as any of the methods 
discussed here, but for the purpose of this chapter are physical entities that either encapsulate or 
act as a solid frame to protect desired proteins and include examples from delivery platforms such 
as protein nanocages and phage as delivery vehicles. Protein nanocages, such as vault proteins 
have been heavily studied by the Wender Laboratory. They are composed of protein subunits that 
can self-assemble to form a hollow interior to create a protein complex (Figure 1.9).92 It is this 
hollow interior that can encapsulate hundreds to thousands of proteins. Because they are made of 
amino acids and can be recombinantly expressed, studies have focused on modifying specific 
residues for precise encapsulation of desired cargo as well as external features to improve cellular 
specificity. A recent paper from the Wender Laboratory utilized lysine and cysteine residues to 
modify the exterior of these vault complexes with specific cell targeting peptides and imaging 
reagents for optimized cellular recognition and in vitro studies.93 A conceptually similar procedure 
has been reported by the Hilvert Laboratory. They have engineered a capsid-forming enzyme 
lumazine synthase (AaLS-13) to create an altered electrostatic environment through the 
introduction of glutamate residues on the luminal surface giving the protein nanocarrier a highly 
negative charge.94-95 Upon mixing with proteins displaying a highly cationic charge (such as +36 
GFP), efficient encapsulation of the polycationic GFP was achieved by the AaLS-13 carrier. 
Recently, researchers in the Hilvert Laboratory have shown that these nanocarriers can organize 
into multiple shells with variable packaging densities per each enclosure.96-97 We believe further 
work in this area will include the investigation of the use of these platforms for targeted therapeutic 
delivery applications. Another encapsulation method for the delivery of proteins to mammalian 
cells has been developed by the Rotello Laboratory and employs the use of nanoparticle-stabilized 
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capsules (NPSCs). Specifically, this method utilizes gold nanoparticles (AuNPs) in the presence 
of desired protein for delivery and a fatty acid capsule interior. This results in a stabilized container 
based on co-assembled supramolecular interactions between the components.98 Recently, this 
scheme was used for the delivery of nanoassemblies consisting of Cas9 protein and sgRNA to cells 
for CRISPR gene-editing.99 To achieve delivery the Cas9 protein was rationally engineered to 
contain an N-terminal poly-glutamic acid chain (1-20 residues) for association with arginine 
coated AuNPs and a C-terminal nuclear localization sequence (NLS) for nuclear delivery. They 
show efficient delivery of these nanoassemblies to HeLa cells for functional genome editing. 
 
Figure 1. 9 Vault Nanoparticles for Protein Encapsulation. Nanoparticles are composed of 78 copies of 
the Major Vault Protein (MVP) and assembles into a 67 nm X 40 nm complex. Vaults can encapsulate and 
protect a variety of protein cargos as well as be engineered to display targeting moieties and cell-penetrating 
peptides. 
 
Phage are an example of a specific bacterial virus that can be engineered to become a 
genetically defined nanocarrier. Of particular interest for this chapter are filamentous M13 phage 
which display genetically defined coat proteins.100 This type of phage display one major coat 
protein called p8 and four minor coat proteins called p3, p6, p7, and p9, each rendering multiple 
copies of itself per a phage in a spatially defined manner. Through genetic and enzymatic 
manipulation of those displayed proteins our laboratory was able to generate nanocarriers for the 
intracellular delivery of functional exogenous protein to specific human prostate cancer cells (PC-
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3).52 Our strategy relied on genetic modification of p3 and p9, such that p3 displayed a potent PC-
3 CPP discussed above, and p9 displayed a biotin acceptor peptide (Figure 1.10).101 The acceptor 
peptide on p9 allowed us to accomplish in vitro biotinylation and further assemble via enzymatic 
conjugation any streptavidin fusion protein of imaging or therapeutic use to p9. As a proof-of-
concept study, we show that this phage nanocarrier system can cell-selectively deliver a functional 
enzyme (horseradish peroxidase, HRP) to the interior of cells. When paired with an HRP substrate 
and the pro-drug 3-indol-acetic acid (IAA), appreciable cell death results, demonstrating the 
therapeutic utility of phage assisted delivery of HRP. 
 
Figure 1. 10 Engineered Phage as Spatially Separated Nanocarriers. M13 phage can be genetically 
engineered to display a targeting peptide on p3 (CPP for PC3 cells in this example) and a biotin acceptor 
peptide on p9. Biotinylation of the acceptor peptide on p9 allows for conjugation of a streptavidin fusion 
protein (HRP in this case) to p9. Incubation of PC-3 cells with this phage functionalized nanocarrier and 
HRP substrate (TMB) results in a colorimetric reaction with increased color indicating increased delivery. 
This figure was adapted from Bioconjugate Chem, 2014, 25, 1620. 
 
The carrier methods described here yield a well-defined structure on which to deliver proteins 
to mammalian cells. A highlight of these methods is their multifaceted nature for true versatility 
in delivery. Their inherent nature of spatial differentiation within one subunit endow them with a 
multitude of possible functionalization outcomes. Designing them with optimized features for 
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cellular uptake, precise delivery, and efficient payloads while minimizing cytotoxicity and 
immunogenicity are of greatest concern. 
 
1.5 Conclusion  
Proteins are an extraordinarily valuable reagent, whether its use be clinical or for basic 
research. The methods presented here are of significant pharmaceutical interest because they are 
laying the framework for the transport of highly desired biologic therapeutics into cells that cannot 
in their own right afford effective delivery. Cells, by virtue of their outer membrane, have become 
adept at preventing untargeted or non-natural complexes from entering. The unique dynamics 
found in the cellular membrane has rightly been found of interest for many academic groups as 
well as research and pharmaceutical companies. Concomitantly, the ever-increasing discovery and 
characterization of intracellular disease targets and tools, such as CRISPR, to regulate or treat 
disease states will continue to fuel aspirations towards systems for the delivery of exogenous 
proteins that meet the standards of clinical efficacy and bioavailability.  
In this chapter, I have discussed methods for the indirect and direct delivery of exogenous 
proteins to mammalian cells and how each approach is in the process of overcoming limitations 
for increased efficiency and robustness. The first part of this thesis (Chapters Two and Three) 
highlight effort I have dedicated towards the obstacle of exogenous protein delivery through the 
optimization and characterization of a cell-penetrating peptide specific for prostate cancer cells 
and the use of polycationic resurfaced nanobodies as a potentially general scaffold for 
intracellularly targeted protein discovery. Finally, technologies for the analysis of exogenous 
protein delivery will be discussed in Chapter Six. This includes the design of a split nanoluciferase 
(NanoBit) assay for high-throughput characterization of the cytosolic delivery of proteins. We 
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believe this platform will allow for high-throughput screening and the identification of 
fundamentally novel methods for future exogenous protein delivery efforts. Moreover, advances 
within these techniques will be (and in some cases, are being) used to deliver gene-editing tools, 
including CRISPR, which requires the delivery of a two-part system including nucleic acid and 
protein reagents. As more tools and biologics are discovered that can greatly impact and treat 
human disease states, the methods for delivering these lifesaving reagents will play a prominent 
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2.1 Introduction  
Previous work in the McNaughton laboratory identified a prostate cancer cell-selective protein 
transduction domain or cell penetrating peptide (CPP), which penetrates PC-3 prostate cancer cells 
with uptake efficiencies controlled by multivalency effects (Figure 2.1).1 In order to assess the 
specific contribution each residue plays in cell uptake efficiency and cell-selectivity we completed 
alanine scanning mutagenesis of our reported prostate cancer cell-selective CPP, referred to as 
Ypep (N-YTFGLKTSFNVQ-C). Upon completion of these studies, we were able to identify two 
key residues. Extensive mutagenesis at these key residues generated multiple mutants with 
significantly improved uptake efficiency and ~4-fold improved cell selectivity for targeted cells. 
Our best mutant exhibited ~19-fold better uptake efficiency and ~4-fold improved cell-selectivity 
for a human prostate cancer cell line. In addition, while we could observe the delivery of functional 
fluorescent proteins to the interior of prostate cancer cells using Ypep, only modest functional 
enzyme delivery was achieved. In contrast, the most potent mutant, Ypep (G4N), was able to 
                                                
2 Adapted from: DePorter, S.M.; Lui, I.; Bruce, V.J.; Gray, M.A.; Lopez-Islas, M.; and 
McNaughton, B.R., Mol. BioSystems, 2013, 10, 18. This work was led by a senior graduate 
student Sandra DePorter, and is a continuation of efforts for the identification of a protein 
transduction domain specific for prostate cancer cells (referred to as Ypep), and its further 
optimization. I assisted in gene construction, molecular cloning, and the identification an 
enhanced variant of Ypep that yields improved uptake and selectivity profiles, and achieves 
efficient delivery of an active enzyme. 
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deliver large quantitates of a functional enzyme to the interior of human prostate cancer cells. 
Taken together, the research described below has significantly improved the efficiency, cell-
selectivity, and functional utility of a prostate cancer CPP.  
  
 
Figure 2. 1 Identification of Ypep. Evolution of a PC-3 prostate cancer cell-selective penetrating 
peptide. Phage are incubated with PC-3 prostate cancer cells enriched for cell penetration. Cell-penetrating 
phage are then incubated with a polyanionic tissue culture plate, and phage that don’t bind the tissue culture 
plate are enriched After three coupled rounds of positive and negative selections, the most abundant 
sequence enriched from this selection was “Ypep” (N-YTFGLKTSFNVQ-C). This figure was adapted from 
Chemistry and Biology, 2013, 20, 434. 
 
As discussed in Chapter One, proteins are of great value as research tools, therapeutics, and 
imaging reagents.2 The size and complexity of proteins can often endow these reagents with the 
ability to potently and selectively recognize disease-relevant macromolecules that confound drug 
discovery efforts limited to small molecules (<1,000 Da). In addition, a number of protein enzymes 
such as luciferase and horseradish peroxidase are commonly used for cellular imaging and basic 
research applications.3-4 In many ways, these reagents are ideally suited for imaging applications. 
For example, by virtue of their enzymatic activity, appreciable signal can be generated from a 
relatively small number of functional proteins. Despite clear advantages of protein-based 
approaches to therapy and cell imaging, the inability of most proteins to penetrate the lipid bilayer 
PC-3 prostate
cancer cells
enrich phage that penetrate 
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carboxylic acid
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membrane of mammalian cells largely limits the access of these reagents to cellular components 
displayed on the cell surface. The potential utility of functional proteins and enzymes with the 
ability to access the interior of mammalian cells has compelled researchers to address barriers to 
the intracellular delivery of these agents in mammalian cells. A more complete review of methods 
and technologies for intracellular protein delivery were discussed in Chapter One, but include 
electroporation,4 microinjection,5 liposomes,6 lipid-linked compounds,7 nanoparticles,8 fusions to 
receptor ligands,9 arginine grafting,10 supercharged proteins,11-14 and cell penetrating peptides 
(CPPs)15-17.  
In many ways, CPPs are ideally suited as protein delivery reagents. The proteinogenic amino 
acid composition and relatively small size (typically 7-20 L-amino acids) of these reagents allow 
researchers to express and purify soluble protein-CPP fusions with relative ease. A number of 
CPPs such as HIV-1 transactivator of transcription (Tat) peptide ,18 the Drosophilia Antennapedia-
derived penetratin peptide,19 and polyarginine20-21 have been used for intracellular protein delivery. 
However, the relatively modest uptake efficiency exhibited by some common CPPs, and a general 
lack of selectivity for diseased cells over healthy cells limits the full potential of these reagents. 
The development of new CPPs capable of both potent and cell-selective delivery of functional 
proteins, such as enzymes, to diseased cells would potentially expand the utility of protein-based 
approaches to cellular perturbation and imaging.  
PC-3 cells are one of the most commonly used human prostate cancer cell lines in basic and 
translation research, and are useful in investigating the biochemical changes in advanced prostate 
cancer cells and in assessing their response to chemotherapeutic agents.22 Reagents that selectively 
recognize PC-3 cells are of potential value, since these cells do not express appreciable levels of 
prostate-specific membrane antigen (PSMA) – the most commonly used marker for prostate cancer 
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cell detection and targeted delivery. Therefore, PC-3 cells, or prostate cancer cells with a similar 
phenotype would likely evade targeted imaging or drug delivery strategies centered on PMSA 
recognition.  
The work below describes our efforts to better understand the requirements for uptake of Ypep 
(Figure 2.2A) by PC-3 cells, in addition to its optimization in terms of potency and cell-selectivity. 
Starting with a significant number of Ypep mutants, these variants were assayed for their ability 
to deliver functional fluorescent protein or enzyme to PC-3 cells. We show that the best mutant 
delivers ~19-fold more fused protein to PC-3 cells than off-target non-cancer human embryonic 
kidney cells (HEK-293), with ~4-fold higher cell-selectivity, compared to native Ypep. In 
addition, the most potent and cell-selective mutant we identified delivers large quantities of 
functional enzyme to human prostate cancer cells. Similar to Ypep, uptake of the most potent and 
cell-selective mutant proceeds via energy-dependent endocytosis, suggesting that improvement in 
potency and cell-selectivity is not due to internalization via a different mechanism. 
  
2.2 Alanine Scanning of Ypep Illuminates the Importance of Each Residue for PC-3 Cell-
Specific Uptake  
To assess the specific contribution each residue in Ypep plays in cell uptake efficiency, we 
made a library Ypep alanine mutants and expressed these peptides as N-terminal fusions to GFP. 
PC-3 cells were treated with 5 µM of each Ypep-GFP mutant, a concentration previously shown 
to be sufficient for appreciable Ypep-GFP uptake. Cells were then exhaustively washed using 
conditions that we, and others, have previously shown to remove cell surface-bound protein. The 
amount of internalized GFP was measured by flow cytometry. As seen in Figure 2.2B, most 
mutations resulted in significantly lower GFP delivery, However, Ypep-Gly4Ala and Ypep-
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Thr7Ala delivered ~3.8- and ~6.8-fold more GFP to PC-3 cells than native Ypep, respectively 
(Figure 2.2B). A number of commonly used CPPs such as Tat, polyarginine and penetration are 
polycationic, and rely on high-theoretical net charge for cell uptake. In contrast, Ypep has a 
theoretical net charge of +1. Interestingly, mutating the single positively charged (Lys6) to alanine 
decreased GFP uptake ~4-fold (Figure 2.2B). Based on these initial findings, we prepared a 
focused library of mutants with molecularly diverse residues at position four or seven.  
 
2.3 Optimization of Ypep Mutants  
Ypep mutants containing either negatively charged (aspartic acid), positively charged (lysine), 
aromatic (phenylalanine), hydrogen bond donating (serine), or amide (asparagine) functional 
group positions four or seven were expressed as N-terminal fusions to GFP. As seen in Figure 
2.2C, the Gly4Asp mutant exhibited significantly lower uptake, and Gly4Phe and Gly4Ser mutants 
achieved only slightly higher uptake than Ypep-GFP. However, Gly4Lys and Gly4Asn mutants 
were significantly improved. Gly4Lys or Gly4 Asn mutants delivered ~3.2- and 19.2-fold more 
GFP to PC-3 cells, compared to native Ypep-GFP. Interestingly, small structural changes at 
position four significantly lowered uptake. While the surface receptor of Ypep and Ypep mutants 
is currently unknown, the fact that the addition of a methylene unit significantly lowers uptake 
supports a model wherein a well-defined interaction between Ypep-Gly4Asn and a cell surface 
receptor is required for efficient uptake, and not a less defined interaction that simply required 
sequence-defined functional group display on the CPP.  
We next performed identical experiments to optimize residue seven. The Thr7Asp mutant 
exhibited essentially identical uptake efficiency as native Ypep. However, Thr7Lys, Thr7Ser, and 
Thr7Asn mutants all showed significantly lower transduction efficiencies. In contrast, Thr7Phe 
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mutant was significantly improved, as was observed to deliver ~7.6-fold more GFP to PC-3 cells, 
compared to native Ypep (Figure 2.2D). Based on this finding, we measured uptake efficiencies 
for Ypep variants containing all possible proteinogenic aromatic residues at position seven (Figure 
2.2D). While both Thr7Tyr and Thr7Trp mutants significantly outperformed native Ypep, 
delivering ~6.8-fold and ~7.1-fold more GFP, respectively, neither outperformed the Thr7Phe 
mutant. In contrast, the Thr7His mutant showed significantly lower cell uptake compared to 
Thr7Tyr and Thr7Trp mutants, as well as native Ypep. Taken together, the reduced transduction 
we observed for the Thr7His and Thr7Lys mutants suggest that residues with positive charge, or 
partial positive charge, may not be tolerated at this position.  
Combined synergistic effects can play important roles in many biological processes and 
macromolecular – substrate interactions. To assess if combinations of beneficial mutants are 
synergistic, we prepared three Ypep double mutants that contain combinations of the most 
beneficial single mutations at residues four and seven. Ypep double mutants that contain alanine, 
lysine, or asparagine at position four and phenylalanine at position seven were expressed N-
terminal fusions to GFP and added to PC-3 cells as previously described. The Gly4Ala:Thr7Phe, 
Gly4Lys:Thr7Phe, and Gly4Asn:Thr7Phe double mutants were found to be ~3.5-, ~5.6-, and ~6.5-
fold more efficient at GFP transduction than Ypep-GFP, respectively (Figure 2.2E). Interestingly, 
however, none of these double mutants exhibited higher uptake compared to the single mutant 
Ypep variants from which they were derived. Representative flow cytometry data are shown in 




Figure 2. 2 Ypep ‘hot spot’ identification and optimization. (A) Amino acid sequence of Ypep. (B) Fold-
change in GFP uptake for alanine mutants of Ypep-GFP, relative to Ypep-GFP. (C) Fold-change in GFP 
uptake for Ypep-GFP mutants at residue 4, relative to Ypep-GFP. (D) Fold-change in GFP uptake for Ypep-
GFP mutants at residue 7, relative to Ypep-GFP. (E) Efficiency of GFP uptake for Ypep-GFP double 
mutants at residues 4 and 7. (B-E) In each example, PC-3 cells were treated with 5 µM mutant Ypep-GFP, 
and then washed to remove cell surface-bound protein. GFP internalization was measured by flow 
cytometry. Values and error bars represent the mean and standard deviation of three independent 
experiments. Blue bars represent the four most active mutants. 
2.4 Cytotoxicity and Mechanism of Uptake for Ypep Mutants  
Based on these data, the Gly4Asn, Thr7Phe, Thr7, Trp, and Thr7Ala mutants (bars are colored 
blue in Figure 2.2C and D) were most improved over Ypep, with increased transduction 
efficiencies of ~19, ~8, and ~7-fold, respectively. To assess the cytotoxicity of Ypep variants under 
conditions required for appreciable uptake, we performed 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay (MTT) on PC-3 cells after treatment with 5 µM Ypep(mutant)-
























































































































































(Figure S2.2). GFP uptake was confirmed for these four mutants by live-cell fluorescence 
microscopy. While only a very small amount of internalized GFP was observed in PC-3 cells 
following treatment with 5 µM Ypep-GFP (Figure S2.3), large amounts of internalized GFP was 
observed in cells following treatment with the same concentration of the four most active mutant 
Ypep-GFP fusions (Figure 2.3). Consistent with our flow cytometry data, the Gly4Asn mutant 
delivered the highest amount of GFP to the cell interior. 
In the initial discovery of Ypep, we performed extensive mutagenesis to elucidate the 
mechanism of Ypep uptake. We found that while Ypep is taken up at 37 °C, it is not appreciably 
internalized with PC-3 cells incubated with a Ypep solution at 4 °C. This finding suggests that 
Ypep internalization proceeds via an energy-dependent endocytotic pathway. In order to determine 
if Ypep (Gly4Asn) uptake is consistent with the parent peptide, or if internalization proceeds via 
an alternative pathway, we incubated PC-3 cells with 1 µM Ypep(Gly4Asn)-GFP at either 37 °C  
 
Figure 2. 3 Live cell fluorescence microscopy images of PC-3. Cells were treated with 5 µM of the most 
efficient mutant Ypep-GFP fusions, then washed to remove cell surface-bound protein. Green color 
represents internalized GFP. Scale bar is 50 µM. Lamp intensity was set at 50% with a 250 ms exposure 





or 4 °C, washed cells to remove surface-bound material, and measured GFP internalization by 
microscopy and flow cytometry. Interestingly, similar to our findings for Ypep-GFP uptake, high 
levels of cell fluorescence is observed following treatment at 37 °C; however, no appreciable 
fluorescence is observed when cells are treated at 4 °C (Figure S2.4). Taken together, these 
findings suggest that like the parent peptide, the Ypep(Gly4Asn) mutant also relies on energy-
dependent endocytosis for internalization.  
 
2.5 Gly4Asn Ypep Outperforms Tat and Penetration Protein Transduction  
To compare the uptake efficiencies of these reagents to commonly used CPPs, we treated PC-
3 cells with solutions containing either Tat-GFP, penetratin-GFP, or the four best Ypep variants 
identified as a result of the previously discussed mutagenesis studies. As shown in Figure 2.4, 
following treatment with 1 µM CPP-GFP fusion, and washing, all Ypep variants identified as a 
result of mutagenesis studies delivered significantly more GFP to the interior of PC-3 cells, 
compared to Tat-GFP fusions. Most notably, uptake efficiency in PC-3 cells treated with 1 µM  
 
 
Figure 2. 4 Flow cytometry data comparisons of Ypep with penetratin and Tat. Data showing amounts 
of GFP delivered to PC-3 cells following treatment with 1 µM Ypep(mutant)-GFP fusions, Tat-GFP fusion, 
or penetratin-GFP fusion then washed to remove cell surface bound protein. Values and error bars represent 
the mean and standard deviation of three independent experiments.  





















Ypep(Gly4Asn)-GFP was ~1.5-fold and 23-fold higher than cells treated with either penetratin-
GFP or Tat-GFP fusions, respectively. Representative flow cytometry data is shown in Figure 
S2.5. Interestingly, we were unable to express appreciable amounts of soluble (Arg)9-GFP, 
suggesting potential limitations to polyarginine-based approaches to protein delivery – at least in 
some cases.  
 
2.6 Mutations Beneficial to Uptake Efficiency Also Increase the Cell-Selectivity of Protein 
Delivery  
While the above mutational studies on Ypep resulted in numerous variants with improved 
transduction efficiency, the effect of those beneficial mutations on cell-selectivity was unclear. In 
order to assess the impact of these mutations on cell-selectivity, we compared CPP-GFP fusion 
uptake in PC-3 (target) and off-target non-cancer human embryonic kidney cells (HEK-293). Cells 
were treated with 0.1 – 1 µM CPP-GFP fusion, washed as previously described to remove cell 
surface-bound material, and internalized GFP was measured by flow cytometry. As shown in 
Figure 2.5, a majority of the most efficient Ypep mutants also exhibited increased selectivity for 
PC-3 human prostate cancer cells. Representative flow cytometry data for Figure 2.5 is shown in 
Figure S2.6. Consistent with our previous findings, Ypep delivered ~1.6-, ~1.8, ~1.7-, or ~2.8-
fold more GFP to PC-3 cells compared to HEK-293 cells, following treatment with 0.1, 0.25, 0.5, 
or 1.0 µM solutions, respectively. While the Thr7Phe mutant exhibited similar selectivity for PC-
3 cells (~1.6-, ~2.0-, ~2.6-, ~2.8-fold following 0.1 – 1.0 µM treatment), the Gly4Asn, Thr7Trp, 
and Thr7Ala mutants were significantly more selective for PC-3 cells. For example, Gly4Asn, 
Thr7Trp, and Thr7Ala Ypep mutants were ~5.3, ~5.8-, and ~5.0-fold more selective for PC-3 
prostate cancer cells compared to HEK-293 cells. Taken together, these studies demonstrate a 
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significant improvement in both the transduction efficiency and PC-3 cell-selectivity of multiple 
Ypep mutants found as a result of these studies. 
  
 
Figure 2. 5 Flow cytometry data showing the amount of internalized GFP in PC-3 cells or Hek-293 
cells. Cells were treatment with 0.1, 0.25, 0.5, or 1.0 µM mutant Ypep-GFP, Ypep(T7F)-GFP, Ypep(T7A)-
GFP, Ypep(T7W)-GFP, or Ypep(G4N)-GFP, then washed to remove cell surface-bound protein. Values 
and error bars represent the mean and standard deviation of three independent experiments.  
 
2.7 Gly4Asn Ypep Mutant Delivers Functional Enzyme to PC-3 Cells  
Perhaps the ultimate test of a CPP is the intracellular delivery of a functional enzyme. 
Luciferase is a class of enzymes that oxidize a photon-emitting substrate, resulting in 
bioluminescence. These enzymes enjoy extensive use as reporters and cell imaging reagents 
because of their high sensitivity, broad dynamic range, and operational simplicity.23 NanoLuc 
luciferase (nLuc) is a recently reported variant of the small luciferase subunit from the deep-sea 
shrimp Oplophorus gracilirostris.24As a simple test for functional intracellular enzyme delivery, 
we measured luciferase activity in PC-3 cells following treatment with 1 µM nLuc, Ypep-nLuc, 
or Ypep(Gly4Asn)-nLuc. Consistent with the overwhelming majority of proteins, appreciable 
amounts of nLuc do not penetrate mammalian cells. Cells treated with nLuc, washed to remove 
surface-bound protein, and treated with furimazine (nLuc specific substrate), exhibited very little 
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delivery was achieved via Ypep-dependent delivery. Cells treated with Ypep-nLuc, then washed 
as described above, were ~6.1-fold more luminescent than cells treated with nLuc alone (Figure 
2.6). In contrast, cells similarly treated with Ypep(Gly4Asn)-nLuc were ~42-fold more 
luminescent than cells treated with nLuc. These findings suggest that relatively large amounts of 
enzymatically active Ypep (Gly4Asn)-nLuc were delivered to the interior of PC-3 cells (Figure 
2.6). Importantly, cells are not lysed at any point during the luciferase assay. Therefore, 
luminescence generated during these experiments is the action of active nLuc enzyme within the 





Figure 2. 6 Efficiency of nanoluciferase (nLuc) delivery to human prostate cancer cells (PC-3). PC-3 
cells were treated with either nLuc or Ypep-nLuc or Ypep(Gly4Asn)-nLuc, then washed to remove cell 
surface-bound protein. Functional nLuc and Ypep-nLuc does not appreciably penetrate PC-3 cells; 
however, relatively high levels of internalized functional nLuc are observed in cells following treatment 
with Ypep(G4N)-nLuc.  
 
2.8 Conclusion  
In summary, we recently reported Ypep, a prostate cancer cell-selective CPP, with uptake 




















copy of Ypep is fused to GFP, modest uptake efficiency and cell-selectivity is observed. Fusion of 
a single Ypep peptide to the N-terminus of nLuc does not deliver appreciable functional protein to 
PC-3 cells. Mutational studies have revealed a number of Ypep variants with significantly 
improved protein transduction efficiency and selectivity for PC-3 human prostate cancer cells. 
Amazingly, a single mutation to Ypep (Gly4Asn) resulted in a variant with ~19.2-fold higher 
transduction efficiency and ~4-fold better selectively for PC-3 cells over off-target HEK-293 cells 
(Figure 2.6). In contrast to Ypep, Ypep(Gly4Asn) delivered appreciable levels of nLuc to the 
interior of PC-3 cells. Taken together, the findings described in this paper significantly improve 
the functional utility of Ypep-dependent delivery of exogenous proteins to the interior of PC-3 
prostate cancer cells. Our data suggest that the Ypep mutants described here are well suited to 
serve as reagents for PC-3 cell-selective delivery of imaging and enzymatic proteins for basic 
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Resurfaced Cell-Penetrating Nanobodies: A Potentially General Scaffold for 
 





As discussed prior, proteins can often recognize and modulate disease-relevant 
macromolecules that present a challenge to small-molecule reagents by virtue of their size, 
functional group diversity and complex structure. Additionally, high-throughput screening and 
evolution-based methods often make the discovery of new protein binders simpler than the 
analogous small-molecule discovery process. However, as thoroughly discussed in Chapter One, 
most proteins do not cross the lipid bilayer membrane of mammalian cells. This largely limits the 
scope of protein therapeutics and basic research tools to those targeting disease-relevant receptors 
on the cell surface or extracellular matrix. A common theme for endowing cellular uptake is to 
increase the theoretical net charge of the protein through cationic resurfacing of the desired protein. 
However, in our experience, many proteins are not amenable to such extensive mutagenesis. Here, 
we report that nanobodies – a small and stable protein that can be evolved to recognize virtually 
any disease-relevant receptor – are amenable to cationic resurfacing, which results in cell 
internalization. Once internalized, these nanobodies access the cytosol. Polycationic resurfacing 
                                                
3 Adapted from: Bruce, V.J.; Lopez-Islas, M.; and McNaughton, B.R., Protein Science, 2016, 25, 
1129. I led this effort for the delivery of polycationic resurfaced nanobodies to the cytosol of 
mammalian cells. Monica Lopez-Islas, an undergraduate research assistant, made contributions 
to the cloning and purification of proteins used in this work.  
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does not appreciable alter the structure, expression, and function (target recognition) of a 
previously reported GFP-binding nanobody, and multiple nanobody scaffolds are amenable to 
polycationic resurfacing. Given this, we propose that polycationic resurfaced cell-penetrating 
nanobodies might represent a general scaffold for intracellularly targeted protein drug discovery.  
One cannot overstate the unique opportunities proteins offer as therapeutics and basic research 
tools. While all small-molecules reported to date modulate a very small percentage of the proteome 
(~2%) – and only a handful of protein structural classes – the size, functional group diversity, and 
complex three-dimensional structure of proteins can enable much broader recognition.1 Moreover, 
various high-throughput screening and evolution-based methods make the discovery of new 
protein binders simpler than the analogous small-molecule focused process.2-4 
A forefront challenge to the broader use of proteins in biomedical applications is their general 
inability to efficiently cross the lipid bilayer of mammalian cells and access the cytosol. Thus, 
most current protein drugs and basic research tools target disease-relevant receptors that reside on 
the surface of the cell or the extracellular matrix. Efforts to unlock the full potential of proteins in 
biomedical applications by enabling potent and functional cell penetration have been a major focus 
of modern biologics research.5-9 Incorporation of polycationic linkages – such as polyarginine – 
has previously been described as a means to enable cell penetration of various cargo, including 
proteins.10 More recently, researchers have used protein engineering to generate polycationic 
features on the protein surface. For example, Raines and coworkers reported that “arginine 
grafting” – mutagenesis of clustered solvent exposed amino acids to arginine – enables cellular 
uptake.11 In a conceptually similar strategy, Liu and coworkers have shown that protein 
“supercharging” – extensive mutagenesis of a large number of solvent-exposed residues to 
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positively charged lysine or arginine as discussed in Chapter One – results in potent penetration of 
mammalian cells.12-14 
While these polycationic resurfacing methods endow potent cell penetration, a major challenge 
to their broader application is the lack of established and broadly applicable guidelines for this 
extensive mutagenesis. Relatively little is known about how to dramatically resurface a protein 
with a polycationic feature in a manner that does not dramatically alter or abolish its utility and/or 
function (stability, target affinity, expression in Escherichia coli). In our experience, even 
structurally similar proteins respond differently to such extensive mutagenesis, and many proteins 
of therapeutic interest were not amenable to polycationic resurfacing. Perhaps a simpler approach 
is to focus effort on developing a single resurfaced polycationic, cell-penetrating, protein scaffold 
that is stable, expresses in E.coli, maintains the function of the original protein, but can be evolved 
to bind virtually any disease-relevant intracellular target.  
Single-domain antibodies derived from camelids, referred to as nanobodies (Figure 3.1), have 
emerged as an alternative to traditional antibodies.15-16 Features of nanobodies make them well-
suited as a general scaffold for protein drug discovery and polycationic resurfacing. In contrast to 
monoclonal antibodies, nanobodies are produced in large amounts in bacterial expression systems, 
are small in size (~15 kDa), are usually very stable and often bind their target with excellent 
affinities (KD ~ 1 – 100 nM) through interactions involving well-defined antigen binding loops, 
referred to as the complementarity-determining regions (CDRs, Figure 3.1A, purple).17-18 
Maturation of amino acids within one or more of the CDR loops by high-throughput screening or 
evolution-based methods can lead to new proteins that bind virtually any macromolecular target.19-
21  
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The structure of nanobodies is highly homologous, and consists of the CDRs, where the 
nanobody recognizes its target, and a framework region that is rich in b-sheet and loop structure. 
Researchers have shown that CDR loops can be inserted in a particularly stable nanobody scaffold, 
resulting in a new nanobody that retains affinity (based on choice of CDR loops), but has improved 
stability (based on judicious choice of the nanobody framework).22 Based on this observation, we 
hypothesized that if we could engineer polycationic resurfaced nanobody scaffolds, the resulting 
framework region could likely serve as a generic scaffold for the discovery of cell-penetrating 
nanobodies that bind and modulate disease-relevant intracellular receptors. 
  
3.2 Polycationic Resurfacing of Three Previously Reported Nanobody Frameworks  
We began with a previously reported nanobody that binds the Green Fluorescent Protein (GFP, 
Figure 3.1A).17-18 Structural analysis of the nanobody that binds GFP (referred to as NB1, herein) 
revealed a large solvent-exposed surface consisting of a b-sheet and loop structure – within the 
framework region – that is distinct from the CDR loops. We hypothesized that extensive 
polycationic resurfacing within this region by mutation of a critical number of residues to arginine 
(R) or lysine (K) (Figure 3.1B, blue spheres) should endow cell penetration. The sequence and 
mutagenesis of the wild-type nanobody and resurfaced variant is shown in Figure 3.2A. 
Satisfyingly, the polycationic resurfaced GFP-binding nanobody (referred to as pcNB1, herein), 
which has a theoretical net charge of +14, expresses as a soluble protein in E. coli (Figure 3.2B). 
Expanding on this successful result, we performed analogous polycationic resurfacing on two other 
recently reported nanobodies, which bind HER221 or b-lactamase23, respectively (referred to as 
NB2 or NB3, herein). The sequence of the wild-type nanobodies and resurfaced variants is shown 




Figure 3. 1 Typical protein structure for nanobodies. (A) A previously reported nanobody that binds 
Green Fluorescent Protein (GFP), PDB: 3OGO. This nanobody is referred to as NB1 in this work. 
Complementarity-determining region (CDR) loops are highlighted in purple. (B) Residues on NB1 that 
were mutated to either arginine or lysine to generate the resurfaced polycationic nanobody (pcNB1) are 
highlighted with blue spheres. 
 
changes in the framework sequence of the wild-type nanobody exist, the resulting polycationic 
resurfaced nanobodies (referred to as pcNB2 or pcNB3, herein), which have a theoretical net 
charge of +14 and +15, respectively, express in E. coli as soluble proteins (Figure 3.2B and Figure 
S3.1). Our resurfacing design is summarized as follows: First, we set a goal of generating 
nanobodies with a theoretical net charge of approximately +15, based on previous cell-penetrating 
studies on supercharged or arginine grafted GFP’s.11, 13, 24 Second, we focused our mutation on 
residues that were well within the framework region, and not in or near the CDR loops. Third, we 
tried to space out mutations, so as to avoid cation/cation repulsion, which would likely effect 
protein folding and/or stability. Once candidate residues were identified, based on the above 
criteria, we considered whether a mutation should result in installation of an arginine or lysine. 
Since arginine results in better cell surface binding, and cell-penetration,10 compared to lysine, we 
favored mutation to arginine, unless the size of neighboring residues suggested that mutation to 
the relatively large arginine would potentially result in steric clashing. Interestingly, given this 
relatively simplistic resurfacing design, our initial attempt at polycationic resurfacing was 
A. B.
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successful for all three nanobody scaffolds. Since analogous attempts to resurface other protein 
scaffolds are often unsuccessful, in our experience, we conclude that nanobodies may be 
particularly amenable to such polycationic resurfacing.  
 
3.3 Polycationic Resurfacing Does Not Alter Structure, but does Endow Internalization of 
Mammalian Cells  
We next assessed structural features of the wild-type and resurfaced nanobodies by circular 
dichroism. All nanobodies examined – wild-type and resurfaced variants – have a circular 
dichroism spectra similar to a previously reported nanobody25 (Figure 3.2C). Collectively, 
expression of all resurfaced proteins in a soluble form, and similarities in the circular dichroism 
spectra of the wild-type and mutated variants, suggest that no dramatic structural changes occur as 
a result of polycationic resurfacing.  
To determine uptake efficiency we fused each of our polycationic to GFP and measured uptake 
by flow cytometry. 3T3 cells were first treated with 10-500 nM polycationic resurfaced nanobody-
GFP fusion, then washed with a phosphate buffered saline solution containing 20 U/mL heparin 
sulfate – which has been previously shown to remove cell surface bound protein especially 
supercharged protein.6-7, 12-14, 24 Following treatment with trypsin, which has also shown to remove 
and/or degrade surface bound protein,26 intracellular levels of nanobody-GFP was measured by 
flow cytometry. For each resurfaced nanobody we observed a concentration-dependent increase 
of internalized fusion protein, as seen in Figure 3.3A-C. In contrast, fusion proteins composed of 
the wild-type protein and GFP do not appreciably penetrate 3T3 cells (Figure 3.3A-C). 
Internalization was further analyzed by fluorescence microscopy (Figure 3.3D-F and Figure 
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S3.2). Significant levels of each resurfaced nanobody-GFP fusion protein were observed in 3T3 




Figure 3. 2 Resurfacing and purification of polycationic nanobodies. (A) Sequence of wild-type 
nanobodies (NB1-3) and resurfaced polycationic nanobodies (pcNB1-3) described in this work. (B) PAGE 
analysis of wild-type and resurfaced polycationic nanobodies described in this work. (C) Circular dichroism 
spectra of wild-type (NB1-3) and resurfaced polycationic nanobodies (pcNB1-3) described in this work.  
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3.4 Polycationic Resurfaced Nanobodies Access the Cytosol of Mammalian Cells  
Interestingly, internalized arginine grafted GFP and supercharged GFP appear as punctate foci 
in fluorescence microscopy images11, 14 (see Figure S3.3) – suggesting encapsulation within 
endosomes. However, the resurfaced nanobody-GFP fusions do not appear as such, suggesting 
that appreciable amounts of these internalized nanobodies might access the cytosol. This is critical, 
since the discovery of future cell-penetrating nanobodies based on these scaffolds would need to 
access the cytosol in order to engage therapeutically-relevant intracellular targets. This important 
aspect of cell uptake was further analyzed using a previously described method.27-28 3T3 cells were 
first treated with 250 nM nanobody-GFP or polycationic resurfaced nanobody-GFP fusions, then 
washed as described above to remove cell surface bound protein. Cells were then lysed with a 
solution containing digitonin – which breaks the cell surface lipid bilayer, but not endosomes. The 
cellular location of each internalized fusion protein (cytosolic or endosomal) was then assessed by 
Western blow, using as anti-GFP antibody (a marker for internalized fusion protein), anti-Erk 1/2 
antibody (a marker for the cytosol) or anti-Rab5 antibody (a marker for endosomes). No 
appreciable amount of GFP or wild-type nanobody-GFP fusion is found within the cytosolic 
extraction (following cell lysis with digitonin, Figure 3.3G, lanes 2-5), and no appreciable amount 
of Rab5 is observed (indicating that the lysis does not contain broken endosomes). In contrast, 
internalized resurfaced nanobody-GFP fusions appear in the cytosol – in the fraction that tests 
positive for the cytosolic marker Erk 1/2 but does not have any appreciable amount of the 
endosome marker Rab5 (Figure 3.3G, lakes 6-8). Thus, the polycationic resurfaced protein is 




Figure 3. 3 Polycationic Resurfaced Nanobodies Reach the Cytosol of Mammalian Cells. (A-C) Flow 
cytometry data that supports concentration-dependent uptake of resurfaced polycationic nanobody-GFP 
fusion proteins, but not GFP alone (black line) or wild-type nanobody-GFP fusion (gray line). Red line = 
10 nM treatment; green line = 250 nM treatment; blue line = 500 nM treatment. (D-F) Fluorescence 
microscopy images of 3T3 cells following treatment with 250 nM resurfaced nanobody-GFP fusions. (G) 
Western blot analysis of digitonin cell lysate for Erk1/2 (cytosolic marker), GFP (internalized resurfaced 
nanobody-GFP fusion protein), or Rab5 (endosome marker). Lane 1 = no treatment; lane 2 = wild-type 
GFP; lane 3 = wild-type NB1-GFP fusion; lane 4 = NB2-GFP fusion; lane 5 = NB3-GFP fusion; lanes 6-8 
= polycationic resurfaced nanobody-GFP fusions analogous to lanes 3-5. . (H) Western blot analysis of 
digitonin cell lysate for Erk1/2 (cytosolic marker), His6 (internalized resurfaced nanobody), or Rab5 
(endosome marker). Lane 1 = no treatment; lane 2 = wild-type NB1; lane 3 = NB2; lane 4 = NB3; lanes 5–
7 = polycationic resurfaced NB1, NB2, or NB3, respectively. (I) Western blot showing no Rab5 (endosome 
marker) in cell lysate following digitonin lysis, but in extract following RIPA lysis. For all figures, 
experiments were run in triplicate and representative data are shown. 
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Fusion to GFP is not required for polycationic resurfaced nanobodies to penetrate mammalian 
cells and access the cytosol. The same assay was repeated, but cells were incubated with 500 nM 
wild-type nanobodies or polycationic resurfaced nanobodies with a minimal His6 tag (for 
purification and identification by Western blot). As before, wild-type nanobodies do not appear in 
the cytosolic fraction (Figure 3.3H, lanes 2-4). In contrast, we observe appreciable levels of the 
His6 labeled polycationic resurfaced nanobodies in the cytosolic portion of cell lysate (which stains 
for cytosolic markers Erk 1/2, Figure 3.3H, lanes 5-7). As a positive control, when cells are lysed 
with RIPA buffer, which breaks apart the lipid bilayers of both the cell surface and endosomes, we 
observe the protein marker for endosomes (Rab5, Figure 3.3I). 
 
3.5 Polycationic Resurfacing Does Not Alter Nanobody Function and Stability  
Having established that the resurfaced nanobodies penetrate mammalian cells and accesses the 
cytosol, we next explored if this extensive mutagenesis alters function (compared to the wild-type 
nanobody). This is important, since we want to endow cell penetration, but maintain a structure 
capable of binding a target (ultimately an intracellular target following CDR affinity maturation). 
Among the set of starting nanobodies, retention of function is most easily assessed using the GFP-
binding nanobody17-18, since its binding partner (GFP) is easily expressed and observed, and this 
interaction is particularly well characterized. In order to determine if polycationic resurfaced GFP-
binding nanobody (pcNB1 in this work) still binds GFP in a living cell, we co-expressed His6-
labeled NB1 or pcNB1 and untagged GFP in E. coli from a pET-DUET plasmid. Following 
purification on nickel-NTA resin, purified proteins were analyzed by polyacrylamide gel 
electrophoresis (PAGE) and Coomassie staining. Unsurprisingly, untagged GFP co-purifies with 
His6-NB1 (Figure 3.4A, lane 2). Gratifyingly, untagged GFP also co-purified with the 
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polycationic resurfaced variant His6-pcNB1, suggesting that GFP affinity is retained, even in the 
chemically complex environment of a living cell (E. coli). In addition, we performed Isothermal 
Titration Calorimetry (ITC) experiments to measure affinity between NB1 or pcNB1 and GFP. 
Because of the high affinity (KD ~ 1 nM), it is difficult to use ITC to measure the equilibrium 
binding constant with precision. However, as previously reported17 NB1 binds GFP with 
essentially the same affinity (Figure S3.4).  
We next set out to determine how polycationic resurfacing affects protein stability and 
robustness – important features when considering proteins as basic research tools and therapeutic 
leads. As previously stated, nanobodies are highly stable and robust proteins. Previous reports have 
shown that some nanobodies – including the GFP-binding nanobody – can be thermally denatured, 
but refolded when cooled slowly. To see if the polycationic resurfaced GFP-binding nanobody 
(pcNB1) has the same level of stability and robustness, we tested its ability to recover from thermal 
denaturation. Both the wild-type His6-labeled GFP-binding nanobody (His6-NB1) and His6-
labeled polycationic resurfaced variant (His6-pcNB1) were heated to 100 °C for 2 minutes, then 
allowed to cool to room temperature over the course of 2 hours. After cooling, the samples were 
incubated with cell lysate from E.coli that expressed recombinant GFP lacking a His6 label. This 
solution was then incubated with nickel-NTA resin, the resin was washed, and nickel-bound 
protein was eluted with imidazole solution. Under these conditions, if His6-NB1 or His6-pcNB1 
recover from thermal denaturation and regain function (GFP affinity), elution from the column 
should include both NB1 or pcNB1 and bound GFP. Eluted solutions were analyzed by a long 
wave (365 nm) hand-held lamp for the presence of GFP. As expected, no appreciable GFP 
fluorescence is seen when illuminating elution from nickel-bound His6-NB1 and His6-pcNB1 
(Figure 3.4B, tubes 1-2). However, GFP fluorescence (indicating co-elution of the His6-nanobody 
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and bound GFP) is observed in elution from nickel-bound His6-NB1 and untagged GFP (Figure 
3.4B, tubes 3-4). As might be expected with supercharged variants, similar levels of GFP 
fluorescence is observed in elution from nickel-bound His6-pcNB1 and untagged GFP (Figure 
3.4B, tubes 5-6). As a positive control, elution from nickel-bound His6-GFP is similarly fluorescent 
(Figure 3.4B, tube 7). Collectively, these data show the nanobodies NB1 and pcNB1 are not 
appreciably fluorescent, and NB1 and pcNB1 are not appreciably fluorescent, and NB1 and pcNB1 
are able to recover from thermal denaturation and bind GFP. Thus, polycationic resurfacing does 
not appreciably alter protein nanobody stability and robustness. Unsurprisingly, GFP lacking a 




Figure 3. 4 Polycationic resurfaced nanobodies retain function and stability. (A) Lane 1: His6-NB1; 
Lane 2: co-purification of untagged GFP with His6-NB1 from E. coli cell lysate; Lane 3: co-purification of 
untagged GFP with His6-pcNB1; Lane 4: His6-GFP; Lane 5: His6-pcNB1. (B) Tube 1: His6-NB1; Tube 2: 
His6-pcNB1; Tubes 3-4: His6-NB1 and co-eluted GFP; Tubes 5-6: His6-pcNB1 and co-eluted GFP; Tube 
7: His6-GFP; Tube 8: untagged GFP. For all figures, experiments were run in triplicate and representative 
data are shown.  
 
3.6 Conclusion 
In conclusion, the inability of most proteins to penetrate mammalian cells greatly limits the 
identification of new protein therapeutics that bind and modulate disease-relevant intracellular 
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a lack in general guidelines for such extensive mutagenesis on a number of therapeutically-relevant 
proteins, limits the broader application of this approach. An alternative strategy is to identify a 
single protein scaffold that is amenable to polycationic resurfacing, is cell-penetrating, access the 
cytosol of mammalian cells, and can be evolved using in vitro and in vivo techniques to generate 
cell-penetrating proteins that bind and modulate intracellular disease-relevant targets. Here, we 
show that three previously reported nanobodies can be resurfaced to display an extended 
polycationic feature on the framework region. This mutagenesis results in a new nanobody that is 
potently cell-penetrating, while maintaining structure, function and stability/robustness. Based on 
these findings, we anticipate that polycationic resurfaced nanobodies might serve as a general 
scaffold for the discovery of protein basic research tools and therapeutic leads that target disease-
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4.1 Introduction  
Chapter One discusses the importance and thus great potential macromolecules including 
proteinaceous reagents have as clinical and basic research tools. One prime example includes 
antibodies. The immune system utilizes antibodies to recognize foreign or disease-relevant 
receptors, initiating an immune response to destroy unwelcomed guests. Because researchers can 
evolve antibodies to bind virtually any target, it is perhaps unsurprising that these reagents, and 
their small-molecule conjugates are used extensively in clinical and basic research environments. 
However, virtues of antibodies are countered by significant challenges. Foremost among these is 
the need for expression in mammalian cells (largely due to often necessary post translational 
modifications). In response to these challenges, researchers have developed an array of minimalist 
antibodies and mimetics, which are smaller, more stable, simpler to express in Escherichia coli, 
and are amendable to laboratory evolution and protein engineering. In this chapter, we describe 
these scaffolds and discuss recent applications of minimalist antibodies and mimetics.  
 
 
                                                
4 Adapted from: Bruce, V.J.; Ta, A.N.; and McNaughton, B.R.; ChemBioChem, 2017, 17, 1892. I 
co-authored this review article with Angeline Ta, a third-year graduate student at the time. Both 
of our individual projects deal with unique uses for minimalistic and stable antibody scaffold 
mimics giving us mutual knowledge and reason for collaborating on a review concerning the 
clinical and basic research applications for antibody derivatives and alternatives.  
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4.1.1 Antibodies: Structure, Function, Virtues, and Challenges 
The most predominant antibody type is the immunoglobulin of isotype G (IgG), which weighs 
approximately 150 kDa.1 Members of this antibody class each consist of two distinct regions: the 
fragment antigen-binding (Fab) and fragment crystallizable (Fc, Figure 4.1A). The Fab fragment 
consists of a constant light-chain domain (CL) and a variable light-chain domain (VL) (Figure 
4.1A, green), linked to the constant (CH1) and the variable (VH) heavy-chain domains (Figure 
4.1A, gray). When folded properly, six solvent-exposed loops from VL and VH domains are 
presented. Collectively these loops are referred to as the complementary determining regions 
(CDRs, Figure 4.1B), and this is where the antigen is bound. Both the VL and VH domains display 
three CDRs, with loops having an average length of ten amino acids.  
In contrast to the CDRs, the Fc has a greater sequence homology and common function. The 
Fcs of IgG1 and IgG4 each consist of two domains of the heavy chain (CH2 and CH3) connected 
to one another through two disulfide bonds in the hinge region (Figure 4.1A; all disulfide bonds 
are highlighted in red).2 Multiple regions within the Fc are critical to antibody function, and endow 
unique properties. For example, the in vivo half-life of an IgG (ca. 21 days) is much longer than 
those of most proteins.3 This is achieved through an epitope on the surface of the Fc that interacts 
with the neonatal Fc receptor, FcRn. FcRn mediates a salvaging pathway by binding and 
transporting IgG into and across cells, dramatically slowing its degradation.4-5 FcRN binds to the 
CH2-CH3 hinge region of IgG (Figure 4.1C) with high affinity under the acidic conditions 
typically found within endosomes (pH<6.5) and with virtually no affinity in environments outside 
endosomes (typically pH »7.4).6-7 This pH-dependent binding mediates the FcRn-IgG interaction 
after uptake into acidic endosomes, allowing IgG to piggyback with FcRn back to the plasma 
membrane and the complex to dissociate once returned to the circulatory system. This 
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sequestration/transport mechanism saves antibodies from degradation through the 
endosome/lysosome pathway. Regions of Fc also mediate immune system stimulation, such as 
antibody-dependent cellular cytotoxicity (ADCC)8-9or complement-dependent cytotoxicity 
(CDC)10-12. Fc gamma receptors (FcgRs) on the surfaces of immune effector cells such as natural 
killer (NK) cells and macrophages recognize the Fc regions of antibodies bound to a target cell 
(Figure 4.1D).13-15 Upon binding, the immunoreceptor tyrosine-based activation motif (ITAM) is 
phosphorylated; this then triggers the activation of the effector cell and release of perforin, lytic 
enzymes, tumor necrosis factor (TNF), and/or granzymes for cell destruction through ADCC. In 
CDC, C1q of complex C1 binds to the Fc region and triggers the complement cascade activation 
and eventual formation of membrane attack complex (MAC) at the surfaces of the target cells, 
leading to cell lysis.  
In addition to the proteinogenic amino acids that make up antibodies, extensive post-
translational modifications (disulfide-bond formation and glycosylation) are required to deliver a 
mature immunoglobulin. As a result of the large size and molecular complexity of an antibody, 
challenges arise in their production – fully modified antibodies must largely be prepared in 
mammalian cells.16-17 This form of production is relatively costly, slow, and low-yielding in 
comparison with expression of many recombinant proteins in E. coli.  
It is these challenges in the preparation and manipulation of antibodies that has motivated 
researchers to develop minimalist forms and mimetics with improved expression in E. coli and 
stability. Over the past few decades, researchers have developed a number of protein scaffolds that  
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Figure 4. 1 Typical Antibody Structure. (a) Immunoglobulin isotype G (IgG) consists of two heavy 
chains (grey and brown) and two light chains (green). The heavy chains contain the fragment crystallizable 
(Fc), the constant region (CH1) and variable region (VH). The light chain is made up of a constant region 
(CL) and variable region (VL), and is covalently attached to VH/CH by a single disulfide bond (highlighted 
by *). Collectively, the VL/CL-CH1/VH region is called the Fab fragment, and is where antigen binding 
occurs (antigen receptors are highlighted in blue, PDB: 1IGY). (b) Complementary determining regions 
(CDRs, blue) from a Fab fragment. (c) Interaction between CH3 and CH2 of Fc and the neonatal Fc receptor 
(FcRn), (PDB: 1I1A). (d) ADCC is initiated by the type III Fc gamma receptor binding to CH3 domains 






























are amenable to extensive mutagenesis and laboratory evolution to achieve new recognition and 
unique function with relative ease.  
Many new protein-protein interactions can be achieved and characterized through high-
throughput screening or in laboratory evolution by resurfacing helix or b-strand structural 
features.18-23 In this chapter, however we focus on minimalist forms of antibodies, and their 
mimetics, which, like antibodies, rely on maturation of loops to achieve recognition. Modern 
applications and protein engineering efforts to generate new properties and function are discussed 
throughout.  
 
4.2 Antibody Fragments  
Immunoglobulins, including the isotype IgG, have a modular architecture, and each module 
has a unique biological function. In particular, it is this modular architecture that allows researchers 
to minimize components, thus generating new proteins that retain certain desired properties, but 
intelligently lose others. For example, because the Fab fragment is solely responsible for antigen 
recognition and binding, this domain – and variations on that structural theme – have been used 
for recognition in clinical and basic research settings, as well as for targeted delivery of cargo.  
 
4.2.1 Fab Fragments  
Cartoon depictions of IgG and antibody fragments discussed in this chapter are shown in 
Figure 4.2. Full-length Fab fragments contain both CH1/VH and CL/VL fusions, connected by 
single disulfide bonds (denoted by asterisks in Figure 4.1). These minimalist antibodies have some 
advantages and disadvantages of immunoglobulins. For example, Fab fragments retain target 
recognition, but lose properties encoded within the Fc domain, such as immune response 
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stimulation and extended in vivo half-life. Because these fragments have a relatively short 
existence in plasma, in comparison with full-length antibodies, antibody fragments might be of 
particular value in applications that favor or require shorter biological lifetime (such as imaging). 
Moreover, their small size allows deeper tumor penetration, simpler expression in E. coli, and 
manipulation in the laboratory.24-26 
Fab fragments can be produced through chemical or protease digestion of full-length 
immunoglobulins.27 Additionally, these fragments can be produced by recombinant expression in 
bacteria.28 Fab fragments have been used as therapeutics, as well as in diagnosis, detection, 
imaging, and crystallography applications.24, 27, 29-30  
At present, a number of Fab fragments are in clinical trials. For example, citatuzumab bogatox 
(VB6-845) is a recombinant immunotoxin for use as a treatment for ovarian cancer and other solid 
tumors.31 In this drug lead, deBouganin – a de-immunized plant toxin – is fused to a humanized 
Fab fragment that targets epithelial cell adhesion molecules (EpCAMs). In addition, naptumomab 
estafenato (ABR-217620) is a fusion protein therapeutic for advanced renal cell carcinoma and 
other solid tumors.32 The fusion consists of a Fab fragment that binds 5T4 (a cell-surface tumor 
antigen), and superantigen staphylococcal enterotoxin A (a protein that binds to major 
histocompatibility complex calls II molecules and activates T lymphocytes).  
Fab fragments are also used as tools for imaging and detection. ThromboView is a radiolabeled 
Fab fragment that targets the D dimer region of crosslinked fibrin for deep-vein thrombosis 
imaging.33 In basic research applications, Fab fragments have been used for imaging inside 
mammalian cells. For example, Stasevich, Morisaki, and co-workers have utilized Fabs to study 
translation in living cells. Using a Fab fragment that recognizes the FLAG tag (DYKDDDK) they 
perform nascent chain tracking (NCT).34 mRNA encoding a 10X FLAG-tagged protein and 24X 
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MS2 tag in the 3’-untranslated region is produced in cells. Fluorescently labeled MS2 coat protein 
recognizes the mRNA, thus detecting its presence in a mammalian cell. By use of an orthogonally 
labeled FLAG binding Fab, translation of that encoded protein is detected, following translation 
of the FLAG tag from the ribosome. Collectively, these two fluorescently labeled components 
provide a glimpse into translational dynamics in living mammalian cells.  
 
Figure 4. 2 Cartoon depiction of IgG and fragments discussed in this Chapter. 
 
4.2.2 Single-chain Fragment Variables (scFvs) 
Single-chain fragment variable antibodies (scFvs) were first reported in 1988 as minimalist 
forms of Fab fragments.35 These » 28 kDa fragments result from the genetic linkage of VH to VC 
typically with a flexible 10-to-25-residue linker.24 Whereas antibodies can contain up to 25 
disulfide bonds and Fab fragments can require five disulfide bonds, scFv typically only contain 
two, thus simplifying their recombinant expression and stability in reducing environments (such 
as the cytosol of bacteria). New strains of E. coli with enzymes to facilitate disulfide formation 
further simplify the recombinant production of scFvs.36  
Similarly to other Fab-based antibody fragments, scFvs do not participate in immune response 
stimulation, and removal of the FcRn receptor results in substantially decreased in vivo half-lives. 
However, their small size and easy expression make scFvs relatively simple minimalist antibodies 












more rapid blood clearance, lower retention times in non-target tissue, and reduced 
immunogenicity.37  
Because functional scFvs can be expressed in the reducing environment of the cytosol, these 
reagents can be generated inside a cell for use in certain applications. For example, Kimura, Sato, 
and co-workers utilized a scFv specific for histone H3 lysine 9 acetylation (H3K9ac), fused with 
GFP to identify post-translational histone modifications in living cells.38 This approach enables 
tracking of the spatiotemporal dynamics of endogenous histone modification in a genetically 
encoded format.  
Recently, scFv-based technology called SunTag has been used for real-time detection of 
proteins in living cells and to amplify transcription.39 In the context of protein detection, cells are 
made to express a protein that displays many copies of a short peptide epitope. The cells also 
express a scFv that recognizes the epitope, fused to a fluorescent protein such as GFP. When 
concomitantly expressed, the scFv-GFP fusion selectively recognizes the epitope-tagged protein, 
resulting in the illumination of that protein in a living cell (Figure 4.3A). Additionally, SunTag 
has been used to enhance transcription. Vale, Tanenbaum, and co-workers made cells express a 
nuclease-inactive form of Cas9 (dCas9) fused to multiple peptide epitopes, as well as a scFv that 
binds the epitope while fused to VP64, a transcriptional activator. Complex formation between the 
peptide epitopes on dCas9 and the scFv-VP64 fusion led to recruitment of many copies of the 
transcriptional activator to transcriptional machinery on DNA – resulting in increased transcription 






Figure 4. 3 Utility of scFv fusions in SunTag Technology. (A) to illuminate and track proteins in living 
cells, and (B) to recruit a transcriptional activator (VP64), resulting in increased transcription of a gene in 
a cell.  
 
4.2.3 Minibodies  
A minibody is a single polypeptide consisting of scFv-CH3-CH3-scFv and can be expressed 
as a functional protein through recombinant expression in E. coli.40 The principal benefit of 
including the CH3 is an appreciable increase in biological half-life relative to scFv. Variants that 
contain the hinge region (flex minibodies) and variants that do not contain the hinge region (LD 
minibodies) have both been reported – with the flex minibodies showing higher tumor uptake and 
slower clearance times.40 Similarly to their scFv cousins, minibodies retain target affinity, but lose 
immune response stimulation.  
However, conjugates of minibodies have been used for targeted delivery of toxic proteins or 
























scFv domains with different target recognition can be encoded, and bispecific binding 
(concomitant recognition of two different targets) can be achieved.41  
Recently, the Wu lab developed an immunoPET (positron emission tomography) radiotracer 
for imaging of prostate cancer by targeting prostate stem cell antigens through affinity maturation 
of a previously developed hu1G8 minibody modified with 124I and 98Zr radiolabels.42-43 Marasco, 
Han, and co-workers reported a minibody as a potential therapy for cutaneous T-cell lymphoma 
(CTCL) that targets the CC chemokine receptor 4 (CCR4).44 In a creative modern application, 
Park, Lee, and co-workers prepared a polypeptide consisting of a polyarginine (Arg9) and an anti-
JL1 minibody. When this was noncovalently complexed with siRNA, through charge 
complementation, and then applied to mammalian cells, siRNA delivery was achieved specifically 
in leukemic cells.45  
In another innovative application, Marasco, Abdel-Motal, and co-workers examined the utility 
of an anti-gp120 minibody in protecting against sexual transmission of HIV-1.46 Through the use 
of an adeno-associated viral (AAV) vector, anti-HIV-1 gp120 minibody was introduced into 
cervico-vaginal epithelial cells. After secretion to the cell surface, the minibody binds HIV-1 
gp120, resulting in sequestration of the virus and decreased infection.  
 
4.2.4 Diabodies 
A diabody is a complex consisting of two unconjugated single-chain fragment variables.47-48 
Although scFvs can be engineered to be multivalent with the addition of either chemical or genetic 
cross-links, it was found that reducing the scFv linker allowed for multimerization and stability. 
As in the case of minibodies, because scFv domains with differing targets can be mixed, bispecific 
recognition can be achieved.  
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Similarly to their larger minibody relatives, diabodies have relatively short in vivo half-lives, 
and thus could be better suited for imaging, because they can illuminate their targets and then be 
degraded and cleared. Additionally, the smaller size of diabodies, in relation to IgG and larger 
fragments, endows improved accumulation and penetration of tumors expressing relevant 
antigens.49-50 With these characteristics in mind, most therapeutically relevant applications of 
diabodies have revolved around PET imaging. At present, diabody conjugates to PET labels have 
been validated for pancreatic cancer (anti-CAI9-9), anti-leukocyte cell-adhesion molecule 
(ALCAM/CD166), and breast cancer (anti-HER2).51-53  
Diabodies conjugates for imaging applications that involve binding of the extra domain-B 
(EDB) of fibronectin (a biomarker for angiogenesis/atherosclerotic plaque), carcinoembryonic 
antigen (CEA, a validated marker for gastrointestinal cancers), and Her2/Neu (a biomarker for 
both ovarian and breast cancers) have also been reported.54-56  
 
4.3 Nanobodies – A Camelid-Derived Scaffold  
Heavy-chain IgGs (hcIgGs) produced in camelids differ from IgGs produced in other 
mammals.57-58 Although hcIgG is also a homodimer of two disulfide-linked heavy chains, with 
familiar CH2, CH3, and variable domains, it lacks a light chain. Binding between antigen and 
hcIgG, as for their IgG cousins, relies entirely on amino acids residing in loops (complementarity-
determining regions, CDRs) of the single variable domain (referred to as VHH in hcIgG, Figure 
4.4A). Separating the CDR loops are four relatively sequence-homologous b-strands, which 
makeup the “framework region”.57 When separated from hcIgG, the VHH domain is called a 




Figure 4. 4 The Architecture of hcIgG and Nanobodies. (A) Heavy-chain IgG (hcIgG), which consists 
of two heavy chains (CH3, CH2, and VHH) connected by disulfide bonds in the hinge region. (B) A 
nanobody – GFP binding nanobody is shown as an example (PDB: 3OGO) – is the VHH domain of a hcIgG 
and consists of a framework region (purple) and CDRs (gray) where antigen recognition occurs.  
 
As discussed in Chapter Three, nanobodies have many properties that make them particularly 
well suited as scaffolds for the directed evolution of new recognition in the laboratory.60 These 
proteins are small (» 15 kDa), can be expressed in a folded and stable from with or with disulfide 
bonds in E. coli, and are easy to manipulate in the laboratory. An obvious difference between the 
variable regions of IgG and hcIgG is that binding is generated from amino acids in three loops in 
the hcIgG variant and in six loops in IgG (from heavy and light variable domains). However, hcIgG 
can compensate for this smaller apparent binding surface by expansion of CDR loops. For 
example, in comparison with IgG, nanobodies typically have longer CDR3 loops (ranging from 
eight to 24 residues) than those found in mouse or human antibodies (nine and 12 residues, 
respectively).61 The expanded CDR3 can dramatically increase the size of the paratope (the part 
of the protein that recognizes the epitope). This extended display architecture is generally credited 



















4.3.1 Recent applications of nanobodies  
Like their Fab fragment counterparts, nanobodies do not contain FcRn receptors and thus have 
relatively short in vivo half-lives. As a result, nanobodies can be used in situations such as 
bioimaging, in which relatively short half-lives and clearances are favored. Of course, this requires 
selective recognition of a disease-relevant cell surface biomarker. Probably one of the most widely 
studied and utilized biomarkers is the human epidermal growth factor receptor type 2 (HER2), 
which is overexpressed in » 20-30% of breast and ovarian carcinomas.63-64 This tyrosine kinase 
receptor is responsible for cell proliferation, reduction in apoptosis, and enhanced cell mobility, 
making it an ideal extracellular model protein. A nanobody for the HER2 receptors has been 
developed (termed 5F7, KD » 0.1 nM) and used extensively for imaging and proof-of-concept 
nanobody technologies.65-66  
With no receptors to recruit NK cells or other immune system components present in the Fc 
region, nanobodies cannot illicit immune responses such as ADCC or CDC. One approach would 
be to fuse a nanobody to a Fc dimer. However, post-translational glycosylation of Fc is necessary 
to induce ADCC or CDC, and this requires expression in mammalian cells, thus complicating its 
preparation in the lab. To overcome this obstacle, our lab has prepared conjugates of small-
molecule compounds and nanobodies that bind a target cell biomarker and recruit an antibody to 
the cell surface, resulting in ADCC (Figure 4.5A).67 Specifically, using a combination of lipoic 
acid ligase bioconjugation and reactivity between a hydrazine and a protein-bound aldehyde, we 
coupled dinitrophenyl (DNP) to a previously reported HER2-binding nanobody.68 As a result of 
human exposure to DNP, likely from DNP-containing dyes, preservatives, and/or pesticides, it is 
estimated that » 1% of IgGs and IgMs recognize DNP,69 and can thus recruit endogenous 
antibodies to a targeted cell.70-71 Satisfyingly, when HER2-positive breast cancer cells (SK-BR-3) 
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were treated with the nanobody activation immunotherapeutic, anti-DNP antibody and peripheral 
blood mononuclear cells (PBMCs) were recruited, triggering appreciable ADCC. Conversely, the 
nanobody activation immunotherapeutic did not induce ADCC for MB-MDA-231 breast cells that 
express low levels of HER2. Similarly, when either cell line was treated under conditions in which 
a component (the nanobody activation immunotherapeutic, anti-DNP antibody, or PBMC) was 
absent, no appreciable ADCC was detected (Figure 4.5B).67  
Chapter One discusses a huge limitation for most proteins, including antibodies, their 
fragments, and mimetics, in their inability to appreciably penetrate mammalian cells; nanobodies 
are no exception. This limits their recognition to cell-surface or excreted proteins. However, 
because of the robust nature of nanobodies, several intracellularly active nanobodies have been 
identified and remain functional in reducing environments, such as the interior of a mammalian 
cell.72 Chapter Three discusses our efforts to prepare nanobodies that actively penetrate 
mammalian cells, through polycationic resurfacing (mutation of solvent-exposed residues either 
to lysine or to arginine) on three separate nanobody frameworks (a resurfaced GFP-binding 
nanobody73-74 is shown as an example in Figure 4.5C).75  
Whereas nanobodies have largely been used to recognize large conformational regions on 
proteins, they can also be subjected to evolution to recognize small unfolded peptide epitopes. 
Recently, Rothbauer, Braun, and co-workers generated a nanobody called BC2 that recognizes a 
short linear epitope corresponding to residues 16-27 of b-catenin (BC2T).76 The structure of this 
complex was solved by X-ray crystallography, revealing complete encapsulation of the epitope by 
an extended CDR3 loop (Figure 4.5D). This nanobody has shown utility as a reagent for capture 
and detection of BC2T-tagged proteins. Chapter Five discuss effort by our laboratory to expand 
this nanobodies utility and evaluated it as protein fusions and bioconjugates to fluorophores and 
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enzymes as alternative bioanalytical reagents to antibodies in the capacity of enzyme-linked 
immunosorbent assays (ELISAs), flow cytometry, and Western blot analysis.77 This is the subject 
of Chapter Five.  
 
Figure 4.5 Recent Applications of Nanobodies. (A) Concept of a nanobody activation 
immunotherapeutic. A HER2-binding nanobody (orange) is chemically conjugated to dinitrophenyl (DNP, 
purple), which is recognized by endogenous antibodies in human serum (red). Recruitment of antibodies to 
the surface of HER2-positive breast cancer cells leads to antibody-dependent cellular cytotoxicity (ADCC). 
(B) ADCC of high HER2-expressing SK-BR-3 cells (blue), but not of low HER2-expressing MB-MDA-
231 cells (purple), triggered by the nanobody activation immunotherapeutic DNP-5F7. The unconjugated 
nanobody (LAP-5F7) is not toxic to SK-BR-3 cells (red). DNP-5F7 in the absence of anti-DNP antibodies 
(green) or PMBCs (orange) also does not trigger ADCC. Error bars represent standard error from three 
independent experiments. (C) Polycationic resurfacing of the nanobody framework region results in potent 
cell penetration and access to the cytosol. Residues highlighted with a blue sphere were mutated to either 
arginine or lysine (PBD: 3OGO). (d) Structure of a recently reported nanobody with an expanded CDR3 






























5F7-DNP + anti-DNP Ab + SK-BR-3 + PBMC
LAP-5F7 + anti-DNP Ab + SK-BR-3 + PBMC
5F7-DNP + SK-BR-3 + PBMC
5F7-DNP + anti-DNP Ab + MDA-MB-231+ PBMC
5F7-DNP + anti-DNP Ab + SK-BR-3
c.
resurfaced nanobody 











4.4 Monobodies – A Fibronectin-Derived Scaffold  
All of the above examples in this Chapter (variations on the theme of Fab fragments and 
nanobodies) are derived from immunoglobulins (either IgGs or hcIgGs). These are contrasted with 
monobodies – scaffolds from the human derived 10th fibronectin type III domain (FNfn10). With 
the aid of the FNfn10 scaffold, protein binding interactions can be fashioned to particular targets 
through loop interactions or side-and-loop interactions. Loops can be mutated and elongated with 
minimal stability loss, allowing for a large diversity of binding faces. Because they do not start 
from the usual protein scaffolds involved in adaptive immunity, monobodies can be made to bind 
to a variety of targets to serve many different functions while still being inherently nontoxic and 
immunogenic. First reported by the Koide lab in 1998, monobodies are essentially structurally 
simplified mimics of a heavy-chain fragment variable, in that both present three binding loops for 
antigen recognition (Figure 4.6).78 Monobodies do not contain disulfide bonds, are small (» 10 
kDa) and generally stable, express well as soluble proteins in E. coli, and, due to the nature of the 
fibronectin type III structure from which monobodies are derived can be used as a binding protein 
that mimics IgG VH (Figure 4.6 A-C). Similarly to Fab fragments and nanobodies, monobodies 
are useful in binding to a specific target, but do not contain an Fc region, therefore dramatically 
decreasing their serum stability in comparison to antibodies. This results in monobodies generally 
being used as diagnostic tools to identify cell-surface biomarkers (where relatively quick clearance 




Figure 4.6 Structural comparison of IgG and Monobodies. (A) Structural architecture of IgG VH. (B) 
Structural architecture of the tenth fibronectin type III (monobody). (C) Structure of a monobody. Antigen 
binding loops are colored (PBD: 1FNF).  
 
4.4.1 Recent applications of monobodies  
Monobodies have been used as proteinaceous regents to bind various disease-relevant 
macromolecules, resulting in the modulation, study, and characterization of complex cellular 
processes. For example, researchers have used monobodies that bind Fluc-type F- channels to 
validate its unique mechanism of action for controlling intracellular levels of fluoride ion.79-81 

































reported. For example, Kuhlman, Guntas, and co-workers used computational loop grafting of the 
BC and FG loops, together with phage display to engineer a monobody (R1) that binds to Kelch-
like ECH-associated protein 1 (KEAP1) with a KD of 300 pM. This monobody inhibits the 
interaction between KEAP1 and nuclear factor erythroid 2-related factor 2 (NRF2), resulting in 
activation of NRF282 – a key regulator of cellular oxidative environments and an interaction 
associated with several disease states.  
Monobodies have also been used as diagnostic reagents. For example, Hong, Park, and co-
workers developed a monobody that binds to human EphA2 (hEphA2), and early marker for 
various tumors.83 Whereas monobodies have largely been used to recognize and/or modulate the 
biological activation of specific proteins, they have more recently been applied to more diverse 
functions such as altered enzyme activity and biotechnology validation. In recent work, Koide, 
Tanaka, and co-workers showed that a monobody can alter as enzyme’s specificity for its target, 
without modifying the amino acid sequence of the enzyme.84 In particular, they found monobodies 
that were able to restrict b-galactosidease transgalactosylation yields of galacto-oligosaccharides 
(GOSs) to specific lengths rather than mixtures.  
Very recently, in the context of extending phage-assisted continuous evolution (PACE)85 to 
protein-protein interaction discovery, Liu, Badran, and co-workers re-evolved a monobody to bind 
the SH3 domain of ABL1. Beginning with a previously characterized mutant monobody 
(Tyr87Ala), which binds the SH2 domain target with dramatically lower affinity (100 -1000 –






Throughout this thesis, a common theme is the increasing use of proteins in basic research and 
clinical applications to modulate disease-relevant receptors and to control cell function and fate. 
At present, seven of the ten top selling drugs are biologics, and many of these are antibodies and 
their conjugates. Relative challenges associated with the expression of full-length and chemically 
mature (post-translationally modified) antibodies in mammalian cell culture have motivated 
researchers, including us (Chapter Five and Six) to develop an array of minimalist antibody forms 
and mimetics that still experience potent recognition of epitope. In this chapter, we have 
highlighted various forms of IgG fragments (Fab, scFv, minibodies, diabodies), hcIgG-derived 
nanobodies, and fibronectin-derived monobodies as alternatives to full-length IgGs.  
Specifically, scFvs, nanobodies, and monobodies are structurally simpler (lack disulfide 
bonds), easier to express in E. coli, and can be simpler to engineer and use in directed evolution 
than IgGs and IgG-derived counterparts. Moreover, the relatively small sizes of scFvs, nanobodies, 
and monobodies often correlate with greater tumor penetration, and thus, in some cases, this virtue 
could be used to improve the efficacy of tumor-targeted therapies (although challenges with 
relatively short in vivo lifetimes would remain an issue). Because long in vivo lifetimes are a key 
advantage of IgGs and derivatives that retain Fc, many applications of IgG and derivatives that 
retain, many applications of IgG derivatives lacking Fc, or of non-immunoglobulin-derived 
proteins such as nanobodies and monobodies, include diagnostic and bioanalytical applications. 
However, smaller IgG-derived proteins that lack Fc, as well as nanobodies and monobodies, are 
particularly well suited for some medically relevant applications, such as bioimaging, because 
rapid clearance is not a major issue, or even beneficial. Historically, full-length antibodies as 
bioanalytical tools – Western blot being an obvious example. However, relative challenges in the 
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expression of these molecular Winnebagos opens the door for smaller and simpler proteins, and 
nanobodies have recently been used in this context as well as other assays (discussed in Chapter 
Five).76-77  
Full-length antibodies continue to enjoy application in immunotherapy and as conjugates to 
small-molecule therapeutics and imaging reagents, in which their primary job is to deliver these 
cargos selectively to diseased cells.87 Owing to their simpler expression and ability for 
straightforward evolution in the laboratory, truncated structural forms of antibodies, and non-
immunoglobulin mimetics play an increasingly important role in human health. We believe the 
creative use of these proteins will continue to represent a growing area of protein science, 
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Evaluation of Nanobody Conjugates and Protein Fusions as Bioanalytical 
 




5.1 Introduction  
Enzyme-linked immunosorbent assay (ELISA), flow cytometry, and Western blot are common 
bioanalytical techniques. Successful execution traditionally requires the use of one or more 
commercially available antibody – small-molecule dyes or antibody – reporter protein conjugates 
that recognize relatively short peptide tags (<15 amino acids). However, the size of antibodies and 
their molecular complexity (by virtue of post-translational disulfide formation and glycosylation) 
typically require either expression in mammalian cells or purification from immunized mammals. 
As discussed in Chapter Four, the preparation and purification of chemical dye – or reporter protein 
– antibody conjugates is often complicated and expensive and not common place in academic 
laboratories. In response, researchers have developed comparatively simpler protein scaffolds for 
macromolecular recognition, which can be expressed with relative ease in E. coli and can be 
evolved to bind virtually any target. Examples of these reagents are thoroughly discussed in 
Chapter Four. One such illustration includes nanobodies, a minimalist scaffold generated from 
camelid-derived heavy-chain IgGs. A multitude of nanobodies have been evolved to recognize a 
diverse array of targets, including a short peptide. Here, this peptide tag (termed BC2T) and BC2 
nanobody-dye conjugates or reporter protein fusions are evaluated in ELISA, flow cytometry, and 
                                                
5 Adapted from: Bruce, V.J. and McNaughton B.R., Analytical Chemistry, 2017, 89, 3819. 
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Western blot experiments and compared to analogous experiments using commercially available 
antibody-conjugate/peptide tag pairs (Figure 5.1). Collectively, the utility and practicality of 
nanobody-based reagents in bioanalytical chemistry is demonstrated.  
 
Figure 5. 1 Crystal structure of BC2 nanobody interacting with its BC2T epitope. (BC2 nanobody, 
PDB: 5IVN).  
 
A multitude of bioanalytical techniques and sensor platforms rely on monoclonal antibodies 
with relevant examples even being utilized throughout this thesis. These antibodies are principally 
immunoglobulins of isotype G, IgG, and are depicted in Figure 5.2A.1-4 Antibodies are large 
proteins (~150 kDa) that can be evolved in vitro, or generated by immunization, to recognize 
virtually any small molecule or biopolymer target. Techniques such as enzyme-linked 
immunosorbent assay (ELISA)5, flow cytometry4, and Western blot3 commonly rely on 
monoclonal antibodies that bind a small (<15 amino acid) peptide. When conjugated to a small-
molecule dye or antibody—reporter protein fusion, recognition of proteins containing the peptide 
“tag” can occur, often in complex biological environments. Common peptide tags, for which 
excellent commercial antibodies and antibody – reporter conjugates exist, include FLAG6, 
myelocytomatosis viral oncogene (myc)7, synthetic streptavidin binding Strep-tag8 and influenza 
hemmaglutinin (HA)9.  
BC2T (PDRKAAVSHWQQ)
BC2 nanobody
nanobody/peptide tag platform 
facile expression/purification from E. coli 
facile conjugation or fusion to reporters 
matches or outperforms commercial antibodies
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While full-length IgG antibodies are very large (∼150 kDa), target recognition is achieved 
within a relatively small region, termed the fragment antigen-binding (Fab) region (Figure 
5.2A).10 Fab consists of a constant light-chain (CL) and a variable light-chain (VL) domain, linked 
to the constant (CH1) and the variable heavy-chain (VH) domains. When folded properly, six 
solvent-exposed loops from VL and VH are displayed, which participate in target recognition. 
Collectively, these loops are referred to as the complementary determining regions (CDRs). 
Historically, antibodies have been a reagent of choice in bioanalytical techniques and sensor 
platforms (largely out of necessity); however, their size and complexity require isolation from 
mammalian cells or immunized mammals (principally goat, mouse, or rabbit).1 This relatively 
complicated production greatly adds to the cost of antibody-based reagents, which has negative 
consequences in basic research and commercial diagnostics development and application.1 
Moreover, the inability of most academic laboratories to express and purify full-length antibodies, 
and chemically conjugate them to chemical dyes or reporter proteins, makes it challenging to 
prepare reagents “in house”. 
Chapter Four discusses the challenges encountered with antibody-based reagents and the 
development of non-immuno-globulin proteins, or minimalist forms of structurally simpler 
immunoglobulins, as scaffolds for tailored recognition.10 Many of these scaffolds mimic the 
structure of IgG Fab VH but are comparatively robust and simple to express as recombinant 
proteins in E. coli. One such scaffold is derived from heavy-chain IgGs (hcIgGs, Figure 5.2B). 
hcIgGs are produced in camelids, and in contrast to IgGs produced in other mammals, they lack a 
light chain. Thus, recognition is achieved through a single VH domain, as opposed to the 
combination of VH and VL domains in IgG. In isolation, the VH domain of hcIgG is referred to 
as a “nanobody”, a small (∼15 kDa) protein that can be expressed in E. coli with relative ease, and 
 108 
evolved in the laboratory to recognize a diverse array of targets, through interactions involving 
one or more CDR loops (CDR 1−3, Figure 5.2C).10-11 In contrast to full-length antibodies and 
their fragments, nanobodies often express well (>20 mg/L), as a folded and soluble recombinant 
protein, from E. coli. By virtue of their stability and ready expression, purification, and 
manipulation, researchers have used nanobodies in numerous applications, including therapeutic 
discovery12, bioimaging13, and sensors14-15. Rothbauer and co-workers recently reported a 
nanobody referred to as BC2 that binds a short peptide (PDRKAAVSHWQQ, referred to herein 
as BC2 tag, BC2T) with excellent affinity (KD ∼ 1.4 nM) and selectivity, principally through 
interactions involving CDR 3 (Figure 5.2C).16 Here, the utility of the BC2/BC2T recognition 
platform is evaluated in common bioanalytical techniques (ELISA, flow cytometry, and Western 
blot). Throughout, outcomes from the BC2 nanobody/BC2T platform are compared to those from 
analogous experiments using commercially available antibody−reporter conjugates and their 
peptide binding partners.  
 
Figure 5. 2 Comparisons of Antibodies and Nanobodies. (a) Structure of IgG. Disulfide bonds are 
highlighted in red. Constant heavy-chain region 1 (CH1), constant light-chain (CL), variable light-chain 
(VL), variable heavy-chain (VH), and fragment antigen-binding (Fab) regions are highlighted with a blue 
background (PDB: 1IGY). (b) Architecture of a heavy-chain IgG (hcIgG), consisting of two heavy chains 
(CH3, CH2, VH) connected by disulfide bonds in the hinge region. The “nanobody subunit is circled. (c) 




















5.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA typically requires (1) immobilization of a protein (“protein a”) onto a surface; (2) 
incubation with a binding partner (“protein b”) equipped with a small peptide tag; (3) treatment 
with an antibody−reporter protein conjugate, which recognizes the peptide tag and generates a 
signal following addition of a small-molecule substrate (Figure 5.3A). Horseradish peroxidase 
(HRP) is commonly used as a reporter protein.17	 Here, a direct comparison between the 
BC2/BC2T platform and commercially available antibodies that bind the myc tag (EQKLISEEDL) 
or His6 (HHHHHH) is provided. 	
First, green fluorescent protein (GFP) was immobilized onto the surface of a multiwell plate. 
Following a washing step, GFP-coated wells were treated with buffer (NT), HRX-BC2T (which 
has no appreciable affinity for GFP), or a GFP-binding nanobody-His6 fusion protein (GFPnb-
His6), which tightly binds GFP (KD ∼ 1 nM.
13, 18 After washing steps to remove unbound material, 
wells were incubated with a commercially available anti-His6 antibody-HRP conjugate and HRP 
substrate. Unsurprisingly, no appreciable signal is observed in wells incubated with HRX-BC2T 
(indicating no interaction between HRX and GFP, Figure 5.2B, black). However, strong signal is 
generated in GFP immobilized wells following treatment with GFPnb-His6 and subsequent 
incubation with anti-His6-HRP and HRP substrate (Figure 5.3B, black). Similarly, when GFP 
immobilized wells are treated with buffer (NT), HRX-BC2T, or GFPnb-His6, no appreciable 
signal is observed after subsequent incubation with anti-myc-HRP and HRP substrate (Figure 
5.3B, gray). However, signal that compares favorably to the analogous His6/anti-His6 experiment 
is observed in wells that contain immobilized GFP, following treatment with GFPnb-myc tag and 
subsequent incubation with anti-myc-HRP and HRP substrate (Figure 5.2B, gray). Satisfyingly, 
signal that compares favorably to the analogous experiments described above is observed when 
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wells containing immobilized GFP are treated with GFPnb-BC2T and subsequently incubated with 
“in house” prepared BC2nb-HRP conjugate and HRP substrate (Figure 5.3B, white, Figure S5.1). 
As expected, no appreciable signal was observed when GFP containing wells were treated with 
buffer (NT), HRX-BC2T, or GFPnb-His6, following subsequent treatment with BC2nb-HRP and 
HRP substrate  (Figure 5.3B, white). Additionally, no appreciable signal was observed in wells 
lacking immobilized GFP (Figure S5.1). 	
Fundamentally, this paper aims to accentuate practical remedies afforded by the use of 
nanobody-based reagents in bioanalytical chemistry. It therefore went unnoticed that  chemical 
conjugation of HRP to BC2 is likely an impediment to the broad use of this reagent, including 
laboratories without experience in bioconjugation. A more practical solution is expression of the 
BC2 nanobody as a fusion to a reporter protein. Unfortunately, the BC2 nanobody−HRP fusion 
does not express as a soluble protein in E. coli. However, a recently reported bioluminescent 
“nanoluciferase” protein (nLuc),19	developed by Promega, expresses as a fusion to BC2 nanobody 
(Figure S5.2). Satisfyingly, the BC2 nanobody−nLuc performed well in our ELISA analysis. First, 
biotinylated GFP was immobilized onto streptavidin-coated plates. Wells containing immobilized 
GFP were then incubated with buffer (NT), HRX-BC2T, GFPnb, or GFPnb-BC2T. Following 
washing steps to remove unbound material, wells were treated with the BC2- nLuc fusion protein, 
washed again, and then treated with the nLuc substrate (“NanoGlo”). As expected, no appreciable 
signal was generated in wells containing immobilized GFP but incubated with either HRX or GFP-
binding nanobody lacking the BC2T peptide (Figure 5.3C, red and orange, respectively). In 
contrast, we observed robust signal in lanes containing immobilized GFP in complex with the 
GFP-binding nanobody genetically fused to the BC2T peptide (Figure 5.3C, green).	 When 
immobilized GFP was treated with a solution containing equal parts GFP-binding nanobody-BC2T 
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peptide and GFP-binding nanobody (without the tag), a ∼50% decrease in luminescence is 
observed, compared to wells treated with only the GFP-binding nanobody equipped with the BC2T 
peptide (Figure 5.3C, blue). In contrast, no appreciable signal was observed in wells that were 
treated identically but lack immobilized GFP (Figure S5.2). Collectively, these data show that an 
“in house” prepared BC2 nanobody−nLuc fusion protein, when paired with binding partners 
containing the BC2 tag, is an excellent reagent for ELISA.  
 
Figure 5. 3 Analysis of Nanobodies in ELISAs. (a) Scheme of an enzyme-linked immunosorbent assay 
(ELISA). (b) ELISA data: immobilized GFP is treated with buffer (NT) and HRX-BC2T, GFPnb-His6, 
GFPnb-myc, or GFPnb-BC2T, then anti-His6-HRP, anti-myc-HRP, or the BC2nb-HRP conjugate, and HRP 
substrate. Signal is the observed absorbance at 655 nm. (c) ELISA data: GFP was immobilized onto 
streptavidin coated plates and then treated with buffer (NT, black), HRX-BC2T (red), GFP nanobody 
(GFPnb, orange), GFPnb-BC2T (blue), followed by nLuc substrate. All experiments were performed in 
triplicate. Error bars represent standard deviation of three experiments. a = anti; NT = no treatment. RLU 
= relative luminescence units.  
 
5.3 Flow Cytometry Applications  
The BC2 nanobody/BC2T platform was next evaluated in the context of flow cytometry, a 
commonly used technique to evaluate protein−protein and protein−nucleic acid interactions on the 






















































































activated cell sorting (FACS). In a typical flow cytometry experiment, bacteria20-22 or yeast23-25 
display a peptide or protein that is flanked by a peptide tag recognized by a commercial 
antibody−fluorescent dye conjugate. Interaction between the tag and antibody−reporter conjugate 
allows researchers to quantitate display efficiency. Concomitantly, the peptide or protein 
displaying cells are treated with a binding target that is also fluorescently tagged.  
Traditionally, yeast display efficiency has been measured using a commercially available 
antibody−dye conjugate that binds to either an N-terminal HA tag or a C-terminal myc tag.23-25 
Bacterial display efficiency on E. coli is typically measured using a commercial antibody that 
binds to a C-terminal myc tag. To permit direct comparative analysis, bacteria (E. coli) were 
engineered to display a small (∼15 kDa) well behaved protein (monomeric streptavidin, mSA2), 
with flanking N-terminal and C-terminal BC2T and myc tags, respectively (Figure 5.4A). Yeast 
were engineered to display a HA-mSA2-BC2T-myc fusion (Figure 5.4B).  
For E. coli, cells were induced to express the displayed protein/tag fusion (as a fusion to OmpX, 
an E. coli cell surface protein typically used for bacterial display) and then treated with a 
commercially available anti-myc-FITC antibody−fluorescent dye conjugate, an “in house” 
prepared BC2 nanobody-Cy5 conjugate (BC2nb-Cy5), or a BC2 nanobody-GFP fusion protein 
(BC2nb-GFP). Following washing steps to remove unbound material, cells were analyzed by flow 
cytometry, using a laser/detection channel specific to either Cy5 or FITC (GFP). Both the BC2nb-
Cy5 conjugate and BC2nb-GFP fusion compared favorably to the anti-myc-FITC 
antibody−fluorescent dye conjugate (∼98% display efficiency for each, Figure 5.4C). Co-
treatment with equal parts anti-myc-FITC and BC2nb-Cy5 show essentially identical fluorescence 
(recognition of their respective displayed peptide tag (Figure 5.4C)). Representative flow 




Figure 5. 4 Evaluation of Nanobodies for use in Flow Cytometry Experiments. (a) Representation of 
E. coli engineered for flow cytometry experiments. (b) Representation of yeast engineered for flow 
cytometry experiments. (c) Flow cytometry detection of displayed monomeric streptavidin (mSA2) on the 
surface of E.coli or yeast, as determined by commercially available antibody a-myc-FITC (for E. coli), 
nanobody reagents BC2nb-Cy5 or BC2nb-GFP (for E. coli), commercially available antibodies a-myc-
FITC or a-HA-FITC (for yeast), or nanobody reagents BC2nb-Cy5 or BC2nb-GFP (for yeast). All 
experiments were performed in triplicate. Error bars represent standard deviation of three experiments. a = 
anti; NT = no treatment.  
 
For yeast, cells were induced to express the displayed protein/tag fusion at the C-terminus of 
Aga2 (a yeast cell surface protein typically used for yeast display) and then treated with a 
commercially available anti-myc-FITC, anti-HA-FITC antibody−fluorescent dye conjugate, 
BC2nb-Cy5 conjugate, or BC2nb-GFP fusion. Again, the nanobody reagents compared favorably 
to commercially available antibody reagents. Individual treatment or co-treatment with equal parts 
























































































fluorescence (recognition of their respective displayed peptide tag, Figure 5.4C). Representative 
flow cytometry histograms are provided in Figure S5.3 and Table S5.2.  
 
5.4 Western Blot Applications  
As a final evaluative measure, the utility of the BC2 nanobody/BC2T platform was assessed 
in a Western blot, a commonly used technique to measure the presence of a specific protein (such 
as a tagged protein) in cell lysate. Execution of a Western blot typically requires: (1) denaturation 
of proteins from cell lysate; (2) separation of proteins based on their size via SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE); (3) electrophoretic transfer of separated proteins to a membrane; 
(4) treatment of the protein-bound membrane with a primary antibody that recognizes either a 
specific protein or a specific peptide tag; (5) treatment with a secondary antibody−dye conjugate, 
which serves to illuminate the primary antibody-bound protein. To function in this context, the 
BC2 nanobody must recognize the BC2T tag following a chemical denaturation step (and 
subsequent denaturation of the protein to which it is attached). For this reason, many antibodies 
(and nanobodies) are not suitable for Western blot analysis. 	
For comparison to IR dye 790-labeled commercially available secondary antibody, an IR dye 
800-labeled BC2 nanobody conjugate was prepared by reaction between a C-terminal cysteine and 
commercially available dye maleimide. First, 5 µM GFP lacking the BC2T peptide, or GFP-BC2T, 
was run on a polyacrylamide gel, transferred to PVDF membrane, and treated with BC2nb-IR800 
reagent. Only GFP-BC2T was detected, but not GFP lacking BC2T peptide, indicating that 
recognition relies entirely on the nanobody−tag recognition, in this context (Figure S5.4). Next, 
purified GFP-HA, GFP-myc, or GFP-BC2T was ran in duplicate on a polyacrylamide gel at 20, 
10, 5, and 1 µM concentrations. Following PAGE, one gel was stained by Coomassie to determine 
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protein purity. Proteins embedded in the other gel were transferred onto a PVDF membrane. 
Membranes containing GFP-HA or GFP-myc were first treated with commercially available anti-
HA or anti-myc primary antibodies suggested for Western blot experiments. Next, these 
membranes were treated with a secondary antibody−Alexa Fluor 790 dye. Following washing 
steps, membranes were imaged on a Li-Cor Odyssey instrument. All three proteins (GFP-HA, 
GFP-myc, or GFP-BC2T) were found to be pure, as determined by Coomassie staining (Figure 
5.5A-C, left gels). As expected, both anti-HA and anti-myc antibodies recognize HA or myc tagged 
proteins in the Western blot (Figure 5.5 A-B, right gels). Satisfyingly, the BC2nanobody-IR800 
dye conjugate recognized GFP-BC2T with excellent potency and selectivity (Figure 5.5C, right 
gels). In fact, the BC2nb/BC2T pair generated a more robust and cleaner signal, in comparison to 
the HA and myc platforms. SDS-PAGE analysis of additional purified proteins used in this work 
can be found in Figure S5.5.  
 
Figure 5. 5 Evaluation of Nanobodies for Western Blot Applications. (a-c, left gel) Coomassie stained 
polyacrylamide gels following loading with 20, 10, 5, or 1 µM GFP-HA, GFP-myc, or GFP-BC2T and 
electrophoresis. (a-c, right gel) Western blot data for GFP-HA/anti-HA, GFP-myc/anti-myc, or GFP-
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5.5 Conclusion  
In conclusion, antibodies and their conjugates play a central role in a multitude of bioanalytical 
methods and sensor platforms. However, their cost and complexity add to challenges with their 
use. Researchers have developed minimalist protein architectures, which mimic structural features 
found in the antigen binding region of antibodies. One minimalist scaffold is the nanobody, a 
camelid-derived protein that can be evolved to bind virtually any target, including relatively short 
peptides. In contrast to antibodies, nanobodies express well in E. coli and can be easily 
manipulated, such as conjugation to a small-molecule dye or genetic fusion to a reporter protein. 
Collectively, these features make nanobody-based reagents an attractive alternative to antibodies 
and their conjugates. Using a recently reported BC2 nanobody/BC2T peptide tag pair and “in 
house” prepared nanobody conjugates and fusion proteins, comparative analysis to commercially 
available antibodies and antibody conjugates has been conducted. In every platform tested (ELISA, 
flow cytometry, and Western blot), nanobody-based reagents compare favorably to, or outperform, 
antibody-based reagents. We hope these findings encourage the use of nanobody-based reagents 
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Part I: Intracellular NanoBit Assembly: A Facile Method to Measure  
 
Cytosolic Residence of Delivered Proteins and Part II: Innovative Platforms 
 




6.1 Introduction  
A major subset of my research in the McNaughton Laboratory has focused on the optimization 
and identification of cell penetrating peptides or whole proteins for the delivery of exogenous 
proteins to mammalian cells, and the evaluation of nanobodies as sensible antibody alternatives 
for bioanalytical assays. Concomitant with this, I have also had great interest in developing 
practical remedies, often resulting in straightforward and simplified methods, for assays utilized 
(or could have been utilized) in the first portion of this thesis. That additional work has resulted in 
continuing projects and manuscripts in preparation, two of which are described in this chapter.  
My previously discussed projects concerning exogenous protein delivery to mammalian cells 
(Chapters Two and Three) report initial determination of protein delivery through the fusion of 
that reagent (either CPP or nanobody) with GFP and then flow cytometry and fluorescent 
microscopy analysis of those cells using internalized GFP as an indicator for cellular uptake. While 
these methods (and other methods similar to it) ultimately yield useful information, they cannot 
easily comment on the subcellular location of these protein deliverables, a paramount distinction 
if these reagents are to act on therapeutically-relevant intracellular targets located in the cytosol. 
In response to this challenge, Jennifer Bjerke, a current fourth-year graduate student in the 
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McNaughton Laboratory, has been working with me to devise a technology platform based on 
intracellular reassembly of a recently reported split-nanoluciferase variant (NanoBit) for 
measurement of cytosolic residence of delivered proteins to mammalian cells. Effort towards this 
technology are described in Part I of this chapter. 
Part II of this chapter describes the start of collaboration work between our group and the 
Stasevich Laboratory of the Biochemistry Department at CSU. Work described below was 
completed with the assistance of Stsevich group members Tatsuya Morisaki (research scientist) 
and Ning Zhao (post-doctoral scientist). The Stasevich Laboratory utilizes high copy tandem 
repeats or amplification tags (12X tags) of short epitopes (such as FLAG-tag, DYKDDDDK) to 
flank proteins and sections of nucleic acids of interest for live-cell imaging. These constructs are 
then translated inside mammalian cells where exogenous reagents can tag the short epitopes 
allowing for the visualization and quantification of translation dynamics in living cells. 
Specifically, we are investigating expertise in the McNaughton Laboratory for the generation and 
characterization of biomolecular assemblies to produce ideal, orthogonal, and minimalistic 
reagents for investigation of in vivo assemblies in living cells. We believe these reagents can 
contribute significantly to single molecule spectroscopy. Initial work towards this goal are 
described in Part II of this chapter. 
 
6.2 Part I: Intracellular NanoBit Assembly: A Facile Method to Measure Cytosolic 
Residence of Delivered Proteins  
Proteins are increasingly used as basic research tools and therapeutics. However, as expressed 
in Chapter One, the inability of most proteins to cross the lipid bilayer of mammalian cells 
dramatically restricts their use. Unsurprisingly, methods for intracellular delivery of exogenous 
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proteins have received significant attention over the last decade. Multiple methods, as discussed 
in the first portion of this thesis, for intracellular protein delivery now exist, however, many of 
these routes proceed via endocytosis. Importantly, in order to engage their intracellular target, 
many exogenously delivered proteins must ultimately obtain residence in the cytosol. Therefore, 
simple and medium- to high-throughput methods to measure cytosolic residence, which rely on 
easy to access and relatively inexpensive reagents and/or equipment, are needed to evaluate 
functional delivery of exogenous proteins. Here, we report such a method, which relies on 
intracellular reassembly of a recently reported split-nanoluciferase variant (NanoBit) (Figure 6.1). 
The luminescent signal in this assay is only generated when a Small-Bit (SmBit) peptide tag on 
the delivered protein reassembles with a constitutively expressed Large-Bit (LgBit) protein. This 
assay can be performed at medium- to high-throughput efficiency using commercially available 
reagents and plate readers. We anticipate this method will prove useful to researchers interested in 
developing protein delivery methods, and measuring cytosolic residence of those proteins in 
mammalian cells.  
Because proteins typically cannot appreciably penetrate mammalian cells, exogenously 
administered proteins are typically limited to targeted cell-surface or circulating receptors, greatly  
 
Figure 6. 1 Overview of Intracellular NanoBit Reassembly. A luminescence response (indicating 
cytosolic delivery) is achieved only when proteins of interest fused with the ‘SmBit’ peptide reassemble 
with the cytosolically expressed ‘LgBit’ subunit of NanoBit. 
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limiting their broader use. The challenge to achieve cell-selective, safe, and efficient protein 
delivery to mammalian cells has encouraged the development of a vast array of methods; and, of 
current, has received enormous effort in these regards. Exogenous protein reagents must be capable 
of reaching the cytosol in order to behave as functional therapeutics and properly engage their 
target. Functional analysis of intracellular protein delivery technologies must include assays that 
report on cytosolic residence. At current, analysis of these delivery methods lack robust and 
meaningful interrogation procedures or techniques that can make judgement on the interior 
location of these delivered macromolecules. 
Current methods often rely on Western blot, flow cytometry, and fluorescence microscopy, 
which can be relatively low-throughput, require expensive equipment and expertise, and results in 
findings that are often difficult to comment on specific intracellular location. Alternatively, 
functional stipulations can be implemented, including assays where the protein deliverable has 
enzymatic activity that results in a phenotypic change.  One example is arginine-grafted RNaseA 
cytotoxin delivery which induces apoptosis.1 However, these methods require, (1) connection of 
the protein deliverable with a readable phenotypic change and (2) a great-deal of prior functional 
knowledge concerning that protein and its capabilities. 
More general assays along these lines include the use of reporter systems such as Cre-
recombinase.2-3 This system can comment on subcellular location because the enzyme Cre 
recombinase must translocate to the nucleus and recombine the reporter gene cassette to trigger 
expression of a fluorescent protein reporter. While this method essentially associates your protein 
of interest (deliverable) with phenotypic functionality, it requires the fusion of a rather large 
protein (Cre, ~ 38 kDa) to your protein in question as well as a cleavable linker between the two, 
as it has been noted that Cre fusions have little to no recombinase activity until the additional 
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protein moiety has been cleaved. Thus, this method results in greatly increased complexity to the 
system and an indirect response. These examples strongly illustrate the challenges in determining 
exogenous protein cellular delivery. 
Because fluorescent proteins, such as GFP, can act as stable, genetically encoded fluorophores 
that furthermore can function in mammalian cells, assays that utilize GFP have been heavily 
investigated. Specifically, the Schepartz Laboratory employs GFP induction or translocation as a 
readout to quantify cytosolic localization of proteins.4-5 However this method is highly dependent 
on expensive instrumentation and expertise and / or does not yield itself to high-throughput 
analysis. Another method based on GFP fluorescence was recently reported by the Dowdy 
Laboratory. They employ a split-GFP peptide complementation assay to comment on the 
subcellular location of proteins fused to the cell penetrating peptide Tat6-7 and a series of synthetic 
endosomal escape domains (EEDs).8 While these systems experiences several benefits to the afore 
mentioned methods, they still require chemical formation of the fluorescent chromophore to reveal 
cellular uptake, do not have an ‘on’ switch, and are fairly large in size (GFP is about a 1/3 of the 
size larger than NanoBit). Additionally, the size and spectral properties of GFP impose certain 
limitations for its use and circumstances or the desire of a readout to be something other than a 
fluorescent protein can be envisioned. The review of such assays highlights both the power and 
current limitations for determining cytosolic residence of exogenously delivered proteins. An ideal 
platform would include (1) minimal tags requirements, (2) a highly stable reporter with a well 
characterized readout, and (3) the capability of high-throughput analysis that is not reliant on 
expensive reagents and/or equipment.  
Part I of this chapter reports the design and development of a novel assay for measuring 
cytosolic residence of intracellularly delivered proteins. This assay relies on intracellular 
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reassembly of a recently reported split-nanoluciferase variant (NanoBit).9 The luminescent signal 
in this assay is only generated when SmBit, an 11-mer amino acid tag, on the delivered protein 
reassembles with a constitutively expressed, cytosolic LgBit (~ 18kDa) protein. The LgBit 
segment has been robustly designed for stability and use as a reporter protein under relevant 
physiological conditions inside living cells. Additionally, this assay is highly amenable to medium-
to high-throughput analysis, and relies on relatively inexpensive and commercially available 
reagents, and commercially available luminescence plate readers. 
 
6.3 Development of Intracellular NanoBit Assembly  
Initial development of the NanoBit technology by Promega as a complementation reporter for 
the measurement of protein-protein interactions in cells resulted in multiple LgBit and SmBit 
fragments with different binding affinities and stabilities. Because we were not interested in 
protein-protein interactions and desire quick intracellular reassembly if both fragments are present, 
we chose a combination of NanoBit complementarity fragments with the highest affinity for one 
another (KD = 0.7 X 10-9 M). We hypothesized that a luminescence signal could be generated 
through exogenous delivery of the SmBit peptide when attached to a protein of interest once 
brought into contact with the constitutively expressed, cytosolic LgBit protein (Figure 6.2). To 
facilitate this, we cloned the LgBit portion of NanoBit into a mammalian expression vector that 
would express LgBit as a fusion protein with a fluorescent protein (GFP). The purpose of a 
fluorescent protein here is to allow comment on the transfection efficiency achieved for LgBit 
production. Next, we made fusion clones of the 11-mer SmBit peptide to a variety of proteins, 
including proteins known to penetrate mammalian cells as well as some shown not to possess those 
capabilities (Table 6.1). Thereby, if a protein is capable of reaching cytosolic residence, the SmBit 
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peptide would likely engage with its LgBit binding partner, thus generating measurable and 
quantifiable luminescence signal that can be analyzed on a plate reader. 
Specifically, this system is ideal for intracellular protein delivery interrogation and benefits 
from a small size (total combined components ~19 kDa) and thus lower probability of steric 
hindrance or peptide impacting internalization, with a fully characterized reporter protein element 
that produces a bright luminescence readout. 
 
6.4 Design of Live-Cell Quantitative NanoBit Luminescence Transduction Assay  
Recently, we described a polycationic resurfacing strategy for the exogenous protein delivery 
of nanobodies to mammalian cells.10-11 In this account, we validated cellular uptake of GFP fusions 
of these reagents via fluorescence microscopy and flow cytometry. Interestingly, the results from 
these internalized reagents did not appear as punctate foci when visualized under a fluorescent 
microscope, as seen with arginine grafted GFP and supercharged GFP12-13, suggesting these 
polycationic resurfaced nanobodies achieved some degree of residence in the cytosol. This result 
was further analyzed using Western blot analysis of digitonin extracted cell lysate – which breaks 
the cell surface lipid bilayer, but not endosomes. While this assay commented on the cellular  
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Figure 6. 2 Overview of In Vivo Intracellular NanoBit Assay. A) Cells are transfected with a plasmid to 
express FP-LgBit; B) Cells are then incubated with exogenous proteins fused with SmBit. If cytosolic 
delivery occurs then reassembly of NanoBit will produce an active luciferase construct that can react with 
the cell-permeable NanoGlo small-molecule substrate to produce a luminescent signal. 
 
location of our polycationic resurfaced nanobodies, the method cannot be done in a high-
throughput format, and is often at a disadvantage from a lack robust antibodies for compartment 
and protein of interest identification. Specifically, we wished to compare the results gained from 
that analysis to our proposed NanoBit assay that can be completed at medium- to high- throughput. 
First we purified proteins containing the SmBit peptide (b-lactamase nanobody and its 
polycationic resurfaced variant)10 and investigated if they could associate with the purified 
fluorescent protein (FP)-LgBit fusion protein (Figure S6.1). In vitro mixing of the purified 
components, outside the complex environment of mammalian cells, resulted in a robust signal of 
luminescence. Additionally, similar results were observed when purified proteins were mixed in a 
solution containing mammalian cell lysate. Mixing of nanobodies containing the Sm-Bit fusion at 
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various concentrations (50 – 0.05 nM) in mammalian cell lysate with an excess of FP-LgBit (1 
µM) resulted in a decrease in luminescence signal as the predetermined concentration of the Sm-
Bit component decreased (Figure 6.3). Importantly, this suggests the luminescence signal is 
dependent on the concentration of the protein of interest-SmBit fusion (or how much of the 
exogenous protein reaches the cytoplasm). This key point endows the platform with a degree of 
quantification instead of a simple binary (internalization: yes or no) response. In particular, this is 
crucial, as enzymatic proteins such as Arg-RNase A might require much lower levels of delivery 
than non-enzymatic reagents. 
 
Table 6. 1 Proteins to be assayed for delivery and cytosolic residence. All will be made as fusion proteins 
with SmBit-86 on the C-term.  
  protein 
1 b-lac nanobody 
2 b-lac pcNanobody 
3 GFP 
4 Arg grafted GFP 
5 15 GFP  
6 34 GFP 
 
 
Next, we administered the SmBit tagged nanobodies (b-lac wild-type and polycationic 
resurfaced) to Hek293 cells that had been transfected with a plasmid encoding FP-LgBit to 
examine if we can quantitatively determine the cytoplasmic uptake of these proteins in live cells 
via luminescence signal. First, we plated Hek293 cells in a 24-well plate with black sides and a 
clear bottom. Using standard mammalian cell transfection techniques, these cells were then made 
to constitutively express the cytosolic FP-LgBit protein. After a 12-hour incubation with DNA and 
transfection reagents, Hek293 cells were washed and an OptiMem medium solution containing 
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500 nM exogenous SmBit tagged protein was added to those cells for another 24-hour incubation. 
These cells were then washed with phosphate buffered saline solution containing 20 U/mL heparin 
sulfate – which has been previously shown to remove cell surface bound protein especially 
supercharged proteins.13-18 Following washing, these cells were then imaged on a fluorescent 
microscope to comment on transfection efficiency. Significant levels of GFP were observed 
suggesting transformation efficiency was >90% (Figure S6.2). Finally, a 1:50 dilution of nano-
luciferase substrate (NanoGlo) in PBS was added to cells while gently shaking for ~10 min before 
reading luminescence. 
 
Figure 6. 3 In Vitro Mixing of Purified Proteins Produces Luminescence. Purified nanobody proteins 
fused to SmBit when reacted with sfGFP-LgBit produce luminescence upon adding substrate. As the 
concentration of nanobody-SmBit proteins decreases there is also a decrease in observed luminescence. 
 
As expected, wells containing the wild-type b-lac nanobody-SmBit did not produce 
appreciable luminescence signal (Figure 6.4A) suggesting no internalization. In contrast, cells 
incubated with the polycationic resurfaced b-lac nanobody-SmBit produce a robust signal 
suggesting further validation of cytosolic access for these engineered proteins. When any 
individual component is missing, (non-transfected cells, non-transfected cells treated incubated 
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with protein, transfected cells with no protein of interest added) no observable luminescence signal 
is achieved (Figure 6.4B). Overall, this data supports our hypothesis, that intracellular NanoBit 
assembly can be used as a facile method to measure cytosolic residence of delivered proteins. 
 
Figure 6. 4 In Vivo Intracellular NanoBit Assay. A) Hek293 cells incubated with exogenous proteins for 
24 hours before reading; B) Hek293 cells incubated with exogenous protein for 15 hours before reading for 
luminescence. NT = No transfection. 
 
Interestingly, when the same experiment was completed, but exogenous protein was only 
allowed ~15-hours of incubation instead of 24-hours with LgBit expressing mammalian cells, there 
was a notable decrease in luminescence signal from wells incubated with the polycationic 
resurfaced nanobody (Figure 6.4B). This supports an endocytic mode of uptake for these reagents 






6.5 Continuing Work – NanoBit  
To assess the contribution of endocytic entry, we produced fusion proteins of all protein 
candidates listed in Table 6.1 with an N-terminal endosomolytic peptide, aurein 1.2, recently 
developed by the Liu Laboratory.19 This particular sequence was initially identified because it 
belonged to a class of membrane-active peptides that also function as antimicrobial agents based 
on their ability to penetrate microbial membranes. Specifically, this 13-mer peptide 
(GLFDIIKKIAESF) has been shown to enhance cytosolic delivery of supercharged proteins in cell 
culture and in vivo. Our hypothesis, is that inclusion of this peptide on the N-termini of delivered 
proteins will result in increased exogenous protein delivery and an increase in observed 
luminescence signal.  
Additionally, refining ideal concentrations and time segments required to escape endosomes 
or achieve cytosolic localization of these delivered proteins for optimized luminescence will also 
be evaluated (concentration and time dependent readouts are expected). Efforts toward these 
analyses are underway and will be discussed in due time.  
 
6.6 Conclusion – NanoBit  
In conclusion, limitations due to the inability of proteinaceous reagents to access the cytoplasm 
greatly requires the invention of novel delivery methods. This challenge goes in hand with 
mandatory, straightforward, easy to use new technologies to robustly comment on the apparent 
success of those methods. As I have presented in this rather large initial data set, intracellular 
reassembly of NanoBit produces luminescence that appears to be well-behaved and reflective of 
concentrations of SmBit as a direct result of proteinaceous cellular uptake.  
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Consistent with Western blot analysis concerning our previously reported polycationic 
resurfaced nanobodies, we observed robust luminescent signal as an exact outcome of NanoBit 
intracellular reassembly. Based on this analysis, we believe this platform fulfills the general 
expectation for measuring cytosolic residence of exogenously delivered proteins. We trust, due to 
the facile set up this technology, its robust nature and readout, and the use of minimalist tags, that 
this platform will find great use for the high-throughput screening of proteins and peptides for 
exogenous protein delivery. 
 
6.7 Part II: Innovate Platforms for In Vivo Molecular Tagging and Imaging  
A common theme in chemical biology is the promotion of modular chemical attachment to 
biological reagents, such as proteins and nucleic acids, and whole biological systems. Such control 
would allow for unprecedented interrogation of such entities and a more complete understanding 
of disease states and novel routes for therapeutics and diagnostics. Here, we describe the initial 
investigation of minimalistic and orthogonal molecular assemblies for the visualization of in vivo 
protein and nucleic acid dynamics that readily function in living cells, while experiencing 
enhanced specificity and kinetics. 
As presented throughout this thesis, fluorescent proteins such as GFP have revolutionized 
chemical biology and fluorescence microscopy. In this chapter, GFP is a key player by its ability 
to function as a genetically encoded fluorophore, thus selectively lighting up proteins of interest.20-
22 However, GFP also has many short cummings, including its medium size (~25 kDa), slow 
chromophore formation, and a predisposition towards rapid photobleaching making high-speed or 
long-term single molecule tracking difficult. Additionally, permanent attachment of such large 
tags is feared to interfere with underlying biological processes, as well as the current inability to 
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discriminate or identify post-translational protein modifications once the ‘light’ is on. In response 
to these disadvantages, researchers have put effort into the manufacture of minimalistic probes and 
building blocks that can produce fluorescence in a highly-controlled fashion and rely on 
conceptually different fluorescence tagging schemes.  
One such method for intracellular imaging includes the use of cell-permeable biarsenical dyes 
called Fluorescein Arsenical Hairpin (FlAsH/tetracysteine) and ReAsH (resorufin) reagents.23-24 
These platforms utilize a genetically encoded peptide tag (tetracysteine epitope) on the protein of 
interest that can be recognized with the FlAsH or ReAsH small-molecule reagent. These reagents 
have been shown useful for visualizing mRNA translation in living cells,25-26 but because the 
reagent is based on arsenic there are concerns of cancer and other arsenic-related diseases as well 
as cell cytotoxicity.27 Alternatively, antibodies, which allow for specificity and selectivity and can 
be engineered to recognize and bind virtually any probe or epitope, might appear as ideal reagents 
for these purposes. However, in addition to their expensive manufacture and large size (~150 kDa), 
antibodies possess multiple disulfide bonds, making them ill-posed to function in the reducing 
environment of mammalian cells.28 For these reasons, as presented in Chapter Four, antibody-
based mimics including Fabs and scFvs have been investigated as alternatives for in vivo imaging 
(Figure 6.6A).29-32 Epitopes for which excellent antibodies and thus Fabs and scFvs exist, and 
include the FLAG33 and influenza hemmaglutinin (HA)34 tags (Figure 6.6B). These and other 
common epitopes consist roughly of 8-15 residues, however a single copy of such a tag is often 
insufficient for single molecule tracking due to dimness and background fluorescence. To 
overcome this limitation, Looger, Viswanathan and co-workers recently engineered GFP to 
contain numerous (10-12) copies of peptide epitopes (FLAG and HA), termed the spaghetti 
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monster (SM). This genetically encoded spaghetti monster tag endows simultaneous binding of 
fluorophore conjugated antibody derivatives as an amplification signal.35 
With such molecular assemblies, it is now possible to track proteins in living cells. An example 
of scFv-based technology for this purpose is the SunTag. It has been used for real-time detection 
of proteins in living cells and to amplify transcription.36 To visualize proteins, cells co-express a 
protein that displays many copies (~24+ repeats) of a short linear peptide epitope with concomitant 
expression of an scFv that recognizes the epitope fused to a fluorescent protein, such as GFP. 
When the amplification tag is recognized by 24+ scFvs a very bright fluorescent signal results. 
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Figure 6. 5 Amplification Tags for Imaging. A) Current options for protein probes. B) Widely used 
epitope tags. C) Current probe/tag platforms are shaded in the blues. As the size of the probe or tag increases 
there is generally an increase in specificity and selectivity as well as an increase in probe/tag options. Our 
goal is to increase the choices of probes and tags that fit within the designated target zones (pink and orange 
regions). 
Current work in the Stasevich Laboratory utilizes a spaciously resolved amplification tags (the 
previously discussed spaghetti monster in this case) to detect the manufacture of proteins of 
interest. mRNA encoding a 10X FLAG-SM tagged protein and 24X MS2 tag in the 3’ untranslated 
region is produced in cells. Exogenous delivery of fluorophore conjugated Fabs that recognize 
FLAG are used to detect proteins of interest following translation of the FLAG tag from the 
ribosome. Additionally, in order to visualize translation dynamics, the 3’ untranslated region of 
that protein containing the repeat MS2 stem loops (24X) can be detected by an orthogonal 
fluorophore conjugated MS2 coat protein (Figure 6.6).37-38 Collectively, co-localization of these 
two orthogonal fluorophores provide a glimpse into translation dynamics in living mammalian 
cells. 
 
Figure 6. 6 Imaging Translation Dynamics in Living Cells. DNA encoding a protein of interest is flanked 
with 1) a proteinaceous repeat epitope tag on the N-term for visualization of the protein and 2) a repeat 
mRNA stem-loop in the 3’ untranslated region for mRNA visualization. Typically, scFvs or Fabs are used 
for identifying the N-term epitope with MCP and PCP recognition on the 3’ end. Co-localization of both 
entities indicates translation. This figure was adapted from Trends in Genetics, 2017, 33, 322. 
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However, Fabs, like the antibodies they are derived from, are expensive and scFvs that are 
genetically encoded are often unstable and insoluble in the cytoplasm of cells. This makes finding 
a good probe that functions in vivo analogous to finding a robust antibody as for a Western blot, 
and once one is found, even harder to find two, thereby limiting multiplexing strategies for the 
visualization of multiple proteins and events. 
Our goal is to develop a new class of protein tags and probes which are minimalistic and 
orthogonal to natural biology to enable a new level of live-cell imaging (Figure 6.5C). These 
probes will bring pre-existing fluorescence to a protein rather than rely on fluorescence genetically 
encoded as a fusion protein with the protein of interest. Furthermore, these tags possess high 
specificity, high affinity and minimal interference when labeling their protein of interest. And 
finally, because the system does not rely on permanent genetically encoded fluorophores, 
photobleached probes are less detrimental as they can be substituted for unbleached ones and can 
potentially allow for different binders based on the stage of the protein’s lifecycle and displayed 
post translational modifications. Here, we describe the development of two examples, both 
utilizing protein reagents as probes to tag (1) mRNA and (2) short peptide sequences.  
 
6.8 Design of RNA Binders for Imaging Dynamics in Living Cells  
mRNA imaging in living cells has generally been accomplished through three methods: (1) 
exogenous delivery of fluorescently labeled RNA, (2) aptamer RNA labels and (3) recognition by 
RNA binding proteins that have been fluorescently labeled. Perhaps the most straightforward 
method is direct RNA microinjection. This method requires fluorophore conjugation of exogenous 
RNA, typically through chemical methods, and its injection into living cells. While this procedure 
enables live cell RNA imaging of virtually any RNA and the use of bright, stable fluorophores, it 
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relies on RNA that was not made in the cell. As a result it may lack interactions with regulatory 
binding proteins or post transcriptional modifications and furthermore may result in aberrant or 
abnormal behavior of the RNA or the protein it encodes.39  
Alternatively, reactive fluorescent dyes that bind specifically to genetically encoded RNA 
hairpins have been used to visualize RNA. An example of such probe is Spinach and Spinach2.40-
41 These reagents function conceptually similar to genetically encoded GFP, but require the 
delivery of an activatable fluorescent dye. A true advantage of these probes is that they only turn 
‘on’ upon binding RNA, greatly decreasing background fluorescence. These reagents have helped 
identify noncoding RNAs in cells that are now linked to neurodegenerative disease. Recent work 
in RNA aptamers is focused on the production of additional colors and minimizing sequence 
requirements. The current aptamer for Spinach recognition requires a 98 nucleotide (nt) RNA 
segment. RNA-Mango is one such improvement that requires only 39 nts and experiences higher 
affinity for its aptamer.42 Current shortcomings of this technology include the extended RNA nt 
requirements for recognition and live cell assay optimization.  
Finally, protein-RNA interactions have been exploited for their use of visualizing RNA. This 
procedure has two components: (1) an RNA binding protein typically fused to a fluorescent protein 
or conjugated with a fluorophore and (2) RNA engineered to contain the RNA protein binding 
sites. Perhaps the most widely used system includes phage coat proteins (MS2 coat protein (MCP) 
and PP7 coat protein (PCP)) that recognize short hairpins.43-44 Work in the Singer Laboratory 
formulated this platform for the visualization of mRNA in yeast during cell division by placing 
multiple MS2 binding sites in the 3’ untranslated region of an mRNA of interest.45 An advantage 
of this approach is the MS2 binding sites can be cloned into any mRNA of choice. The facile setup 
of this platform has yielded its incorporation into a number of systems that investigate mRNA, 
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including recent work in the Stasevich Laboratory (Figure 6.6).37 Other protein – RNA 
interactions have also been used to monitor RNA. An example is the RNA recognition motif 
(RRM) U1A.46 Human derived U1A selectively binds the U1hpII RNA hairpin with excellent 
affinity and selectivity (KD ~10 nM). Specifically, U1A is attractive because it is smaller than MS2 
and recognizes a slightly shorter nucleotide stem-loop with increased affinity (Table 6.2). 
However, since U1A is of mammalian origin, it’s RNA target is endogenously expressed in 
mammalian cells and therefore can only be used as an orthogonal tag in alternative systems such 
as yeast. 
 
Table 6. 2 Comparison of MS2 RNA binding protein with U1A and TBP6.7.  
Attribute MS2 U1A TBP6.7 
Length of RNA binding 
domain (aa) 134 95 109 
Molecular weight of 
RNA binding domain 14.5 10.9 12.5 
Affinity to cognate site ~39 nM ~10 nM ~0.5 nM 










Alternatively, effort in our lab has utilized the N-terminal RNA recognition motif (RRM) U1A 
as a protein scaffold to generate synthetic RRMs that recognize hairpins of therapeutic interest, 
such as the HIV transactivation response (TAR) element hairpin.47 Yeast display high-throughput 
screening and saturation mutagenesis generated an RRM we’ve named TAR Binding Protein 6.7 
(TBP6.7) that experiences potent and selective recognition of TAR RNA (apparent KD » 0.5 nM) 
(Figure 6.7).48 Because there is a limited number of alternatives to the MCP and PCP systems that 
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can function in mammalian cells (thus greatly restricting multiplexing efforts) we wished to 
investigate if our recently reported TAR RNA binding protein (TBP 6.7) and TAR RNA could be 
used in place of MCP/MS2 stem-loop. 
In order to experience a bright signal well above background, it is typical to use a 24X repeat 
of the MS2 stem-loop. As one might image, the cloning of a 24X nucleotide sequence repeat in a 
short segment is quite challenging. A great deal of effort went into the original making of the 24X  
 
  
Figure 6. 7 Evolution of U1A protein from U1hpII recognition to recognition of TAR RNA. Residues 
mutated to generate TAR binding protein are highlighted in blue. PDB: 1URN. 
 
MS2 repeat sequence, and as such they were able to make it with slight variations in the repeats to 
make cloning possible while still maintaining potent recognition by MCP. However, since our 
system is a fairly new discovery, we were skeptical of making changes in the stem loop in fear that 
it might diminish binding. Initial characterization of the TBP 6.7/TAR interaction investigated 
TAR RNA mutants with slight sequence and secondary structure variations. It was noted that in 
addition to recognition of TAR RNA, TBP 6.7 also has affinity for a variant of TAR (hp3) where 
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two guanine groups in the upper hairpin loop are changed to cytosine. To help with cloning, two 
repeats of the hp3 variant were mixed in with WT TAR RNA as well as two repeats with a modified 
bulge that can also be recognized by TBP 6.7 (unpublished data) (Figure 6.8). This generated a 
7X TAR repeat that was readily cloned into a plasmid obtained from the Stasevich Group 
(spaghetti monster (SM-FLAG) –b-actin – 7XTAR). U2OS mammalian cells were then imaged 
on the custom built Stasevich Laboratory microscope. Imaging of cells lacking the TAR RNA 
plasmid, but bead loaded with purified sfGFP-TBP 6.7 (Figure S6.3) yielded a similar 
fluorescence profile and probe distribution as MCP without its cognate RNA (Figure 6.9). 
Additionally, fluorescent recovery after photobleaching (FRAP) of cells bead loaded with sfGFP-
TBP6.7 showed quick recovery of fluorescence to that area, indicating minimal endogenous off-
target binding. 
 
Figure 6. 8 TAR RNA hairpins used to make 7X TAR repeat. WT TAR RNA experienced three repeats, 
while TAR RNA variants (modified bulge and hp3) experienced two apiece. Insert was flanked with 5’ 
AgeI and 3’ ClaI restriction enzyme sites for vector ligation.  
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Next, the SM-FLAG – b-actin – 7XTAR plasmid was transfected into U2OS cells. After 
~5 hours, cells were washed and sfGFP-TBP 6.7 was bead loaded in along with Fab that recognized 
the spaghetti monster FLAG construct. Figure 6.10A shows b-actin Fab staining as a result of 
SM-FLAG-b-actin. Staining indicative of b-actin was observed. This suggests that the 
incorporation of a 7X repeat of TAR RNA in the 3’ untranslated region did not interfere with the 
production of b-actin. Finally, Figure 6.10B shows the RNA tagging for imaging this cell using 
TBP 6.7. To measure the lifetime of sfGFP-TBP6.7 to TAR RNA, we once again performed FRAP 
experiments in cells transfected with the TAR RNA construct and bead loaded with sfGFP-
TBP6.7. We experienced little FRAP recovery in 10 minutes, implying that most sfGFP-TBP6.7 
remained bound. This is highly promising for further optimization of this platform, as extended 
binding kinetics are required for measuring translation elongation times on time scales ranging 
from ~10 s to ~5 minutes. While, we were unable to find an active translation event (co-localization 
of Fab and sfGFP-TBP6.7) the RNA binding results were similar to those observed with the 
MCP/MS2 system, suggesting optimization of delivery and imaging would very likely result in 
functionality of this system. 
 
Figure 6. 9 Image of Bead Loaded sfGFP-TBP6.7. Purified sfGFP-TBP6.7 was bead loaded into U2OS 
cells alone. Images are similar to images of bead loaded MCP-GFP alone. 
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Use of the MCP/MS2 system benefits from its relatively straightforward design and ability to 
be implemented as a tag for the visualization of any desired mRNA. Moreover, since it is derived 
from a virus it experiences orthogonality for imaging in mammalian systems. These same benefits 
are also apparent in the TAR RNA/TBP 6.7 platform. Additionally, because of similarities in 
experimental make up, we believe this system will be readily taken up by the general scientific 
community and will find use as a companion reagent with the MCP/MS2 platform allowing for 
the multiplexing investigations of RNAs in cells that are currently impossible with current 
technologies. 
 
Figure 6. 10 Use of TBP6.7 in Cells Generating TAR RNA Construct. A) Imaging channel for 
visualizing b-actin using Fabs that recognize SP-FLAG. B) Imaging channel for visualizing TAR RNA 
using sfGFP-TBP6.7. 
 
6.9 Design of Protein Binders for Imaging Dynamics in Living Cells  
Along with the generation of proteins that recognize RNAs, our lab also has experience with 
the generation of synthetic proteins for protein-protein interactions.49-50 Of particular interest for 
the purpose of this chapter is our work with helix bundles derived from HIV.49, 51 To gain entry 
into a host cell, binding of HIV-1 gp41 C-peptide interacts with a 5-helix bundle to drag viral and 
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cell membranes into close proximity, promoting fusion (Figure 6.11A).52 We hypothesized that 
replacement of canonical peptide epitopes with C-peptide (which experiences high affinity for the 
5-helix bundle), might represent a novel and highly orthogonal interaction for the tagging of 
proteins (Figure 6.11B). To test this concept we cloned a plasmid encoding the C-peptide fused 
to Histone H2B, a major histone protein for the packaging and maintaining of DNA. Next, we 
purified sfGFP-5 helix for tagging purposes (Figure S6.4). When the H2B fusion protein is 
expressed in mammalian cells it localizes to the nucleus. We hypothesized that upon delivery of 
sfGFP-5helix we would see localization of GFP to the nucleus. 
 
Figure 6. 11 HIV-1 Helix Bundle for Live Cell Imaging. A) The 5-helix/C-peptide platform is derived 
from HIV-1 gp41-mediated membrane fusion of HIV-1 with a host cell. Binding of a C-peptide (purple) to 
an N-terminal heptad repeat (NHR, orange) drags viral and cell membranes into close proximity, promoting 
fusion. B) Recognition of the 5-helix bundle with C-peptide acts as a potential probe/tag platform for non-
canonical probes. This figure was adapted from ChemBioChem, 2016, 17, 1945. 
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Once again, we started with testing the distribution of bead loaded sfGFP-5 helix without 
expression of its C-peptide. This test experienced slight localization to the nucleus, even without 
the C-peptide-H2B construct (Figure 6.12A). However, FRAP experiments of those cells resulted 
in quick fluorescence recovery indicating limited off target recognition. Next, U2OS cells were 
transfected with the plasmid encoding C-peptide-H2B. After a couple of hours, cells were washed 
and sfGFP-5helix was bead loaded into transfected cells. Imaging of cells showed greater 
(brighter) localization to the nucleus (this time expected since C-peptide-H2B was present) 
(Figure 6.12B-C). Satisfyingly, FRAP experiments of cells transfected with the C-peptide-H2B 
construct and bead loaded with sfGFP-5 helix yielded minimal fluorescence recovery well after 
10 minutes, also indicating ideal binding kinetics for imaging translation dynamics. 
 
Figure 6. 12 In Vivo Cell Imaging with 5-helix/C-Peptide System. A) U2OS cells bead loaded with 
sfGFP-5 helix alone to test probe distribution within a cell. B) Cells transfected with C-peptide-H2B and 
then bead loaded with sfGFP-5-helix. Bright fluorescent nuclear localization is observed. C) FRAP 
experiment to test the binding lifetime of 5-helix/C-peptide. Image is taken 10 minutes after photobleacing 
area within red box. 
 
As shown in Figure 6.5A, common protein probes are highly reliant on antibodies and their 
derivatives. Additionally, high-throughput methods for the identification of protein based reagents 
for the recognition of orthogonal epitopes can be generated. At present there is a lack in non-
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canonical, creative alternatives for probing mammalian cells that do not rely on antibody 
derivatives. With the current technologies for protein engineering available, the quest for the 
generation of minimalistic platforms and technologies for interrogating live cells is more of a 
question in creativity than possibility. While this analysis is still in its infancy, the case for creative 
solutions outside the antibody paradigm has been presented and is seemingly supported. Major 
issues with probes includes challenges of insufficient target specificity, especially in complex in 
vivo settings, insufficient binding dynamics (on/off rates), or insufficient target affinity. I believe 
answers to these problems can be assessed through the investigation and optimization of probes 
outside the world of typical antibodies and their derivatives/mimics and the C-peptide/5-helix 
platform might be one such example. 
 
6.10 Conclusion – Imaging Constructs  
There is a great need for orthogonal and efficient molecular assemblies that can label target 
epitopes while remaining functional in complex and crowded cellular environments. As a proof-
of-concept study for the novel use of orthogonal tagging schemes, we show that reagents outside 
the antibody-based paradigm exist and function comparatively similar (if not better) in complex 
cellular environments, while drastically reducing complicated manufacture and cost. Further 
optimization and successful design of these probes will be used to image translational and post-
translational gene regulatory dynamics in living cells. In conclusion, such orthogonal and novel 
tagging technologies that offer unique advantages in size, brightness, intracellular stability, and 
dynamics can enjoy rapid uptake by the general scientific community. Furthermore, this 
technology is agnostic to the proposed construct of interest, quantitative where feasible, and has 
the potential to produce robust dynamics for efficient tagging. We believe there will be great 
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Appendix A.1: Chapter Two – Methods  
 
Materials 
Phosphate buffered saline (PBS) – Hyclone/Thermo Scientific  
0.25% Trypsin – Hyclone / Thermo Scientific  
Brilliant Blue R-250 – J.T. Baker  
Bovine Serum Albumin (BSA) – Sigma Aldrich  
Fetal Bovine Serum (FBS) – PAA Laboratories  
Triton X-100 – Fisher Scientific  
Dulbecco’s Modified Eagle Medium (DMEM) – Hyclone / Thermo Scientific  
F-12K Nutrient Mixture (Kaighn’s Mod.) – Cellgro / Corning  
RPMI-1640 media – Hyclone / Thermo Scientific  
Mammalian cell culture dishes – Fisher Scientific  
B-PER Bacterial Protein Extraction Reagent – Thermo Scientific  
Imidazole – Sigma Aldrich  
Modified Lowry Protein Assay Kit – Pierce / Thermo Scientific  
Nano-Glo ® Luciferase Assay – Promega  
TACS MTT reagent – Trevigen  
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PageRuler Prestained Protein Ladder – Thermo Scientific  
All water was obtained from a Milli-Q water purification system 
Instrumentation  
All flow cytometry data was carried out on a MoFlo Flow Cytometer and High Speed Cell Sorter 
with a solid-state iCyt 488 nm laser.  
Relative luminescence units were measured on a Synergy Mx Microplate Reader from BioTek 
MTT assay absorbance was measured on a Synergy Mx Microplate Reader from BioTek.  
Fluorescence microscopy images were taken with EVOS FL from Advanced Microscopy Group.  
 
Mammalian Cell Culture  
Human prostate adenocarcinoma cells were cultured in F-12K with 10% Fetal Bovine Serum 
(FBS) and HEK-293 cells cultured in high glucose Dulbecco’s modified Eagle medium (DMEM) 
with 10% FBS. All cells were incubated at 37 °C with 5% CO2 environment. All cells were 
obtained from ATCC.  
 
Cloning  
All plasmids were constructed on a pETDuet-1 backbone. All peptides and GGS linkers on the 
N-terminus and C-terminus of sfGFP were assembled from a set overlapping oligonucleotides. 
The peptides were then amplified with the sfGFP or nLuc proteins and the constructs were ligated 





Protein Purification  
BL21 E. coli were grown in 500 mL LB cultures at 37 °C to OD600 =~0.6 and induced with 1 
mM IPTG at 30 °C overnight. Cells were then collected by centrifugation and stored at -20 °C. 
Frozen pellets were thawed and 20 mL B-PER was added to lyse cells. The lysate was cleared by 
centrifugation (17,000 rpm, 30 min) and the supernatant was mixed with 1 mL Ni-NTA agarose 
resin for 1 hour. The resin was collected by centrifugation (4750, 10 min). The resin was washed 
with 50 mL of phosphate buffered saline (PBS) with 300 nM NaCl and 20 mM imidazole. The 
protein was then eluted with 5 mL PBS containing 300 mM NaCl and 500 mM imidazole. The 
proteins were dialyzed against PBS and analyzed for purity by SDS-PAGE staining with 
Coomassie Blue. The proteins were then quantified using a modified Lowry protein assay kit. nLuc 
proteins were purified in the same way, except with Tris buffers (25 nM Tris-HCl, 100 mM NaCl, 
pH = 8.0) instead of phosphate buffers. 
  
Flow cytometry analysis  
Mammalian cells were grown to 90% confluency in a 12-well plate. Cells were then washed 
once with PBS and 500 µL of diluted protein in PBS was added. The cells were incubated with the 
protein solution for three hours at 37 °C, 5% CO2 environment. After the incubation period, cells 
were then washed once with PBS and two times with PBS-HS (heparin sulfate 20 U mL-1) for 10 
minutes at 37 °C, 5% CO2. The cells were then removed from the dish with 0.5 mL of 0.25% 
trypsin and collected by centrifugation. The cells were then resuspended in PBS-HS and taken for 




Live Cell Fluorescence Microscopy 
Mammalian cells were grown to 90% confluency in a 12-well plate. Cells were then washed 
once with PBS and 500 µL of diluted protein in PBS was added. The cells were incubated with the 
protein solution for three hours at 37 °C, 5% CO2 environment. After the incubation period, cells 
were then washed once with PBS and three times with PBS-HS (heparin sulfate 20 U mL-1) for 10 
minutes at 37 °C, 5% CO2. The cells were then imaged on the EVOS FL fluorescence microscope. 
For 4 °C experiments, the PC-3 cells were incubated at 4 °C for 30 minutes prior to the addition 
of diluted protein. The incubation period was carried out at 4 °C and washed as described above.  
 
MTT Assay  
PC-3 cells were grown to 90% confluency in a 12-well plate. Cells were then washed once 
with PBS and incubated with the protein in PBS for three hours at 37 °C, 5% CO2. The solution 
was removed and the cells were washed twice with PBS-HS (heparin sulfate 20 U mL-1). The cells 
were then incubated with 0.5 mL medium with 25 µL of MTT reagent for 4.5 hours. After the 
incubation, 250 µL detergent was added to the cells and they were incubated for an additional 30 
minutes. MTT assay readings were taken with a Synergy Mx microplate reader at 570 nm.  
 
NanoGlo Luciferase Assay  
PC-3 cells were grown to ~80% confluency in a 24-well plate (clear bottom, black well). The 
nLuc proteins were diluted in TBS (25 mM Tris-HCL, 150 nM NaCl, pH = 7.0) and added to the 
PC-3 cells. Cells were incubated with each solution for three hours at 37 °C, 5% CO2. The cells 
were then washed with TBS, TBS-0.1% tween-20, and TBS-HS (heparin sulfate 20U mL-1). This 
washing procedure was repeated a total of two times. Then, the cells were incubated with 200 uL 
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TBS and 200 uL Nano-Glo Luciferase Assay Reagent for 10 minutes. Luminescence was 
measured on a Synergy Mx microplate reader. 
 













































Appendix A.3: Chapter Two – Supplemental Information  
 
Figure S2. 1 Representative flow cytometry data from Figure 2.2. Flow cytometry data showing (A-B) 
GFP uptake for alanine mutants of Ypep-GFP. (C) GFP uptake for Ypep-GFP mutants at residue 4. (D) 
GFP uptake of Ypep-GFP mutants at residue 7. (E) GFP uptake of Ypep-GFP double mutants at residue 4 
and 7. (A-E) PC-3 cells treated with 5 µM mutant Ypep-GFP for 3 hours at 37 °C, then washed as described 




Figure S2. 2 MTT cell viability assay data. PC-3 cells in 12-well plates were treated with 5 µM protein 
in PBS or untreated in PBS alone (untreated sample) for 3 hours at 37 °C with 5 % CO2. The cells were 
then washed with PBS-heparin sulfate twice, followed by one wash with PBS. The MTT assay was then 
performed on the cells and the absorbance was read on Synergy Mx Microplate Reader from BioTek. Error 








Figure S2. 3 Fluorescence microscopy comparison of Ypep-GFP to mutant Ypep-GFP fusions. Live 
cell fluorescence microscopy images of PC-3 cells following treatment with 5 µM of the most efficient 
mutant Ypep-GFP fusions, then washed to remove cell surface-bound protein. Green color represents 




















Figure S2. 4 Penetration of G4N-GFP at 37 °C or 4 °C. Live cell fluorescence microscopy images of 
PC-3 cells following treatment with 5 µM of (G4N) Ypep-GFP fusions at either 37 °C or 4 °C for 30 
minutes. Cells were then washed to remove cell surface-bound protein. Green color represents internalized 
















Figure S2. 5 Representative flow cytometry data from Figure 2.4. Flow cytometry data showing GFP 
internalization of Ypep(mutant)-GFP fusions, Tat-GFP, and penetratin-GFP. PC-3 cells were treated with 





Figure S2. 6 Representative flow cytometry data from Figure 2.5. Flow cytometry data showing the 
amount of internalized GFP in PC-3 cells or HEK-293 cells following treatment with 100 nM, 250 nM, 500 
nM, or 1 µM Ypep-GFP, Ypep(T7F)-GFP, Ypep(T7A)-GFP, Ypep(T7W)-GFP, or Ypep(G4N)-GFP for 3 




Figure S2. 7 PAGE analysis of all proteins used in this work. Proteins were run on a 15% Tris-HCl gel 
























All chemicals obtained from Sigma-Aldrich unless specified  
LB Miller Broth – Fisher  
Phosphate buffered saline (PBS) – Corning Cell Grow 
0.25% Trypsin – Hyclone/Thermo Scientific  
Fetal Bovine Serum (FBS) – Atlanta Biologicals  
Dulbecco’s Modified Eagle Medium (DMEM) – Hyclone/Thermo Scientific  
Mammalian cell culture dishes – Fisher Scientific  
RIPA Buffer – Boston BioProducts  
5-alpha chemically competent E. coli – NEB  
BL21 (DE3) chemically competent E. coli – NEB  
Agar – GoldBio Technology  
Carbenicillin – GoldBio Technology  
Restriction Enzymes – NEB  
Isopropyl-b-D-1-thiogalactopyranoside (IPTG) – GoldBio Technology  
cOmplete ULTRA Tablets, Mini, EDTA-free – Roche  
Quick Ligation Kit – NEB  
Vent Polymerase – NEB  
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Oligonucleotides – IDT  
Miniprep Kits – OMEGA  
All antibodies obtained from Abcam unless specified  
Rab5 antibody – Cell Signaling Technologies  
iBlot Gel Transfer Stack Kit – Novex  
PageRuler Prestained Protein Ladder – Thermo Scientific  
Ready Gel Precast Gels – BioRad  
3T3 Cells –ATCC  
All water was obtained from a Milli-Q water purification system.  
 
Instrumentation  
MoFlo Flow Cytometer and High Speed Cell Sorter with a solid state iCyt 488 nm laser.  
Sonifer W-350 cell disrupter – Branson  
Fluorescence microscopy images were taken with EVOS FL from Advanced Microscopy Group 
MJ Mini Gradient Thermal Cycler – BioRad  
Molecular Imager Gel Doc XR+ System – BioRad  
Circular Dichroism Spectrometer – Aviv Model 202  
iBlot Apparatus – Invitrogen  
Odyssey Classic Infrared Imager – LI-COR  






All plasmids were constructed on a pETDuet-1 backbone. All proteins were assembled from a 
set of overlapping oligonucleotides. Proteins were amplified using vent and the constructs were 
ligated into NcoI and NotI restriction enzyme cleavage sites in the pETDuet-1 plasmid. Proteins 
containing GFP fusions were assembled from a set of overlapping oligonucleotides and ligated 
into NdeI and KpnI restriction enzyme cleavage sites in the pETDuet-1 plasmid.  
 
Protein Purification  
Plasmids were transformed into BL21s (DE3). Cells were grown in either 2500 or 500 mL LB 
cultures containing carbenicillin at 37 °C to an OD600 =~0.6 and induced with 1 mM IPTG at 25 
°C overnight. Cells were then collected by centrifugation and resuspended in either phosphate 
buffer with 150 mM NaCl for NBs (20 mM Sodium Phosphate, pH 7.4) or resuspended in 
phosphate buffer with 2M NaCl for pcNBs (20 mM Sodium Phosphate, pH 7.4) and sotred at -20 
°C. Frozen pellets were thawed and incubated with complete ULTRA protease inhibitor tablets 
then sonicated for 2 min. The lysate was cleared by centrifugation (9000 rpm, 20 min) and the 
supernatant was mixed with 1 mL Ni-NTA resin for 30 min. The resin was collected by 
centrifugation (4750 rpm, 10 min). The resin was washed with 50 mL buffer and 20 mM imidazole 
then 10 mL buffer and 50 mM imidazole. The protein was then eluted with 7 mL buffer containing 
300 mM imidazole. The proteins were dialyzed against buffer and analyzed for purity by SDS-





Circular Dichroism  
Proteins were purified as described above. Separately, each protein was diluted to 6-8 µM in 
Sodium Phosphate buffer (20 mM Sodium Phosphate, pH 7.4 and 150 mM NaCl). Wavelength 
data are the average of three scans from 250 to 200 nm in 1 nm steps at 25 °C.  
 
Mammalian Cell Culture  
NIH/3T3 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% Fetal 
Bovine Serum (FBS). All cells were incubated at 37 °C with 5% CO2 environment.  
 
Live Cell Fluorescence Microscopy 
Mammalian cells were grown to ~80% confluency in a six-well plate. Cells were then washed 
once with PBS and 2 mL of 250 nM protein fused with GFP was added. The cells were incubated 
with the protein solution for 3 hours at 37 °C, 5% CO2 environment. After the incubation period, 
cells were washed once with PBS and three times with PBS-HS (heparin sulfate 20 U/mL) for 10 
min at 37 °C, 5% CO2. The cells were then imaged on the EVOS FL fluorescence microscope.  
 
Flow Cytometry  
Mammalian cells were grown to 80% confluency in a six-well plate. Cells were then washed 
once with PBS and 2 mL of 10 nM, 250 nM, or 500 nM protein fused with GFP was added. The 
cells were incubated with the protein solution for 3 hours at 37 °C, 5% CO2 environment. After 
the incubation period, cells were washed once with PBS and three times with PBS-HS (heparin 
sulfate 20U/mL) for 10 min at 37 °C, 5% CO2. The cells were then removed from dish with 0.25% 
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trypsin-EDTA and collected by centrifugation. The cells were then suspended in PBS and taken 
for flow cytometry analysis.  
 
Cytosolic Protein Extraction and Whole Cell Lysate Preparation for Western Blot  
3T3 cells were plated in a six-well plate and grown to ~80% confluency. The cells were treated 
with 250 nM or 500 nM proteins (wtNB-GFP and pcNB-GFP or wtNB and pcNB, respectively) 
for 24 hours at 37 °C, 5% CO2. After treatment, cells were washed once with PBS and once with 
PBS-HS (heparin sulfate 20 U/mL) for 10 min at 37 °C, 5% CO2 then lifted with 0.25% trypsin-
EDTA and pelleted. For cytosolic protein extraction, cell pellets were resuspended in 100 µL of 
50 µg mL-1 digitonin in 75 mM NaCl, 1 mM NaH2PO4, 8 mM Na2HPO4, 250 nM sucrose 
supplemented with Roche protease inhibitor cocktail tablet and incubated on ice for 10 min. Cells 
were then centrifuged for 5 min at 13,000 rpm. Supernatant was then used as cytosolic protein 
extraction. Left over pellets were then re-suspended in 100 µL RIPA buffer supplemented with a 
Roche protease inhibitor cocktail tablet and incubated on ice for 5 min then further lysed through 
a 20-gauge needle. Supernatant was then used as whole cell lysate extraction. Both supernatants 
were collected and separated by SDS-PAGE and transferred to a nitrocellulose membrane via an 
iBlot Western blotting apparatus. The membrane was incubated with 1X TBS with 5% milk at 25 
°C for 1 hour. The membrane was then washed three times with 1X TBS and 0.1% Tween-20 (5 
minute incubations). Primary antibodies for GFP, Erk1/2 and Rab5 were incubated with the 
membrane containing GFP fused nanobodies overnight in 10 mL of 1X TBS, 5% BSA, and 0.1% 
Tween-20 at 4 °C. The Western blot containing unfused nanobodies were incubated with primary 
antibodies for His6, Erk1/2, and Rab5 overnight in the same mixture. Both membranes were 
washed 3X with 1X TBS containing 0.1% Tween-20 (5 minute incubations) and then incubated 
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with anti-Rabbit (Alexa Fluor 790) in 10 mL TBS, 5% milk and 0.1% Tween-20 for 1 hour at 25 
°C. The membrane was washed 3X with 1X TBS containing 0.1% Tween-20 (5 minute 
incubations) and imaged in 1X TBS using the Odyssey Classic Infrared Imager.  
 
Ni-NTA Pull Down Assay  
wtNB1 and pcNB1 (nanobodies for GFP) tagged with His6 were cloned into MCS1 of 
pETDuet-1 using restriction enzymes NcoI and NotI. Untagged GFP was cloned into MCS2 of 
pETDuet-1 using restriction enzyme NdeI and KpnI. Completed constructs were transformed into 
BL21s (DE3). Cells containing the co-cloned pair were inoculated and induced as described 
previously. Cells were pelleted and purified as described previously. The pull-down was analyzed 
by SDS-PAGE. 
 
Appendix B.2: Chapter Three – Proteins Used in this Work  
 


































Appendix B.3: Chapter Three – Supplemental Information  
 
 
Figure S3. 1 SDS-PAGE of Purified Proteins. PAGE analysis of purified WT nanobody and polycationic 















1    2    3    4    5     6 
Lane 1: NB1 
Lane 2: pcNB1 
Lane 3: NB2 
Lane 4: pcNB2 
Lane 5: NB3 
Lane 6: pcNB3 
15 kDa 
1    2    3    4    5     6 
Lane 1: NB1-GFP 
Lane 2: pcNB1-GFP  
Lane 3: NB2-GFP 
Lane 4: pcNB2-GFP 
Lane 5: NB3-GFP 





Figure S3. 2 Brightfield Images of Mammalian Cells. Microscopy images of 3T3 cells following 
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Figure S3. 3 Fluorescent Microscopy Images of Supercharged GFP Variants. GFP (green) appears as 























Figure S3. 4 ITC Data. Representative ITC binding isotherms involving NB1 and pcNB1 with EGFP.  
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Appendix C.1: Chapter Five – Methods  
 
Materials  
All chemicals were obtained from Sigma-Aldrich unless specified  
LB Miller Broth – Fisher  
Phosphate Buffered Saline (PBS) – Corning Cell Grow  
5 – alpha chemically competent E. coli – NEB  
BL21 (DE3) chemically competent E. coli – NEB  
Agarose A – Bio Basic Inc.  
Carbenicillin – GoldBio Technology  
Restriction Enzymes – NEB  
Isopropyl-b-D-1-thiogalactopyranoside (IPTG) – GoldBio Technology  
cOmplete ULTRA Tablets, Mini, EDTA-free – Roche  
Quick Ligation Kit – NEB  
Vent Polymerase – NEB  
Oligonucleotides – IDT  
Miniprep Kits – OMEGA  
All antibodies obtained from Abcam  
iBlot gel transfer stack kit – Novex  
PageRuler Prestained Protein Ladder – Thermo Scientific  
12% Ready Gel Precast Gels – BioRad  
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Snakeskin Dialysis Tubing 10K MWCO – Thermo Scientific  
BirA-Biotin Ligase Kit – Avidity  
Casamino Acids – Fisher  
Yeast Nitrogen Base without Amino Acids – BD  
Yeast Extract – Alfa Aesar  
Dextrose – Fisher  
D-Galactose – GoldBio Technology  
Peptone – Fisher  
Penicillin – Streptomycin – Fisher  
Gene Pulser/Micro Pulser Cuvettes 1 mm and 2 mm – BioRad  
Odyssey Blocking Buffer – LI-COR  
TMB One Substrate – Promega  
L-(+)-Arabinose – Sigma Aldrich  
Chloramphenicol – GoldBio Technologies  
Sulfo-Cyanine5 Maleimide – Lumiprobe  
IRDye800 CW Maleimide – LI-COR  
Albumin, Bovine Fraction V (BSA) – RPI 
Streptavidin Coated 96-well Plates (clear and black) – Pierce  
EZ-Link Maleimade Activated Horseradish Peroxidase –ThermoFisher Scientific  
NanoGlo reagent – Promega  





CyAn-ADP flow cytometry cell analyzer  
Sonifer W – 350 cell disrupter – Branson  
MJ mini gradient thermal cycler – BioRad  
Molecular Imager Gel Doc XR+ System –BioRad 
iBlot Apparatus – Invitrogen  
Odyssey Classic Infrared Imager – LI-COR  
Synergy Mx Microplate Reader – BioTek  




Purified proteins: All plasmids were constructed on a pETDuet-1 backbone. All proteins were 
assembled from a set of overlapping oligonucleotides or purchased g-block. Constructs were 
amplified using vent and then ligated into NcoI and KpnI restriction enzyme cleavage sites in the 
pETDuet-1 plasmid.  
Display vectors: EBY100 yeast (trp-, leu-, with the Aga1p gene stably integrated) and 
pCTCON2 plasmid were generously provided by the Wittrup lab (MIT). The gene coding for 
mSA2 flagged with C-terminal BC2T were PCR amplified using vent and the constructs were 
ligated into NheI and BamHI restriction enzyme cleavage sites in the pCTCON2 plasmid.  
MC1061 bacteria electrocompetent cells and pB33-eCPX plasmid were generously provided 
by the Daugherty lab (UCSB). The gene coding for BC2T-mSA2-myc were PCR amplified using 
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vent and the constructs were ligated into NdeI and XhoI restriction enzyme cleavage sites in the 
pB33-eCPX plasmid.  
 
Protein Purification  
Plasmids were transformed into BL21s (DE3). Cells were grown in either 2500 or 500 mL LB 
cultures containing carbinecillin at 37 °C to OD600 » 0.5 and induced with 1 mM IPTG at 20 °C 
overnight. Cells were then collected by centrifugation and resuspended in phosphate buffer with 2 
M NaCl (20 mM Sodium Phosphate, pH 7.4) and stored at -20 °C. Frozen pellets were thawed and 
incubated with cOmplete ULTRA protease inhibitor tablets then sonicated for 2 minutes. The 
lysate was cleared by centrifugation (8000 rpm, 20 minutes) and the supernatant was mixed with 
1 mL Ni-NTA resin for 30 minutes. The resin was collected by centrifugation (4750 rpm, 10 
minutes). The resin was washed with 50 mL buffer and 20 mM imidazole then 10 mL buffer and 
50 mM imidazole. The protein was then eluted with 7 mL buffer containing 400 mM imidazole. 
The proteins were dialyzed against buffer with 150 mM NaCl and analyzed for purity by SDS-
PAGE. Purified proteins were quantified using absorbance at 280 nm.  
 
Protein Conjugation  
Nanobody Dy Conjugation/HRP: Purifed BC2 nanobodies with a C-terminal Cysteine residue 
were reacted with maleimide dye conjugates or maleimide HRP as described by manufactures’ 
instructions. Briefly, ~10-20-fold molar excess of dye over protein was added to nanobody solution 
in PBS, mixed and incubated at room temperature for 2 hours to overnight. Final product was 
separated from unreacted materials via 30,000 MWCO centrifugal columns. The dye labeled 
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nanobody or HRP labeled nanobody was then purified by dialysis and analyzed via SDS-PAGE. 
It was stored, protected from light, at 4 °C until ready for use.  
 
Protein – Biotin Conjugation: GFP was conjugated using Avidity BioMix protocols and 
purified BirA Protein Ligase at 1.0 mg/mL.  
 
ELISA binding assay  
HRP: ELISA assays were performed using clear, streptavidin coated, 96-well plates (Pierce). 
The plate was washed 3 times with wash buffer (20 mM phosphate, 150 mM NaCl, 0.05% Tween-
20, and 0.1 mg/mL BSA, pH = 7.4). Following washing, 100 µL of biotinylated GFP at 10 µg/mL 
was incubated for 2 hours at RT. Wells were washed three times with 200 µL of wash buffer 
shaking for 5 minutes. Subsequently, wells containing GFP were then incubated for 1 hour at RT 
with 100 µL of buffer containing one of three different proteins, all at 50 nM: (1) a BC2 tagged 
protein that has no appreciable affinity for GFP (zinc finger protein HRX, referred to as HRX); (2) 
a GFP binding nanobody-His6 that tightly bind GFP (KD » 1 nM), but lacks the BC2T epitope, or 
(3) GFP binding nanobody fused to a C-terminal BC2T or myc tag, then washed three times with 
200 µL wash buffer. Following this, a 1:10,000 dilution of HRP-conjugated anti-His6X or anti-myc 
antibody were incubated in 100 µL Odyssey Blocking buffer separately for all samples and ~ 50 
nM solution of BC2nb-HRP in 100 µL Odyssey Blocking Buffer for a separate set of all constructs 
for 1 hour at RT, and washed 3 times with 200 µL wash buffer. Colorimetry was developed for 20 
minutes using 100 µL of TMB-One substrate. Absorbance was measured at 655 nm on a plate 
reader.  
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NanoLuciferase: ELISA assays were performed using black, streptavidin coated, 96-well 
plates (Pierce). The plate was washed three times with wash buffer (20 mM phosphate, 150 mM 
NaCl, 0.05% Tween-20, and 0.1 mg/mL BSA, pH = 7.4). Following washing, 100 µL of 
biotinylated GFP at 10 µg/mL was incubated for 2 hours at RT. Wells were washed three times 
with 200 µL wash buffer, shaking for 5 minutes. Subsequently, wells containing GFP were then 
incubated for 1 hour at RT with 100 µL of buffer containing one of three proteins, all at 50 nM: 
(1) a BC2 tagged protein that has no appreciable affinity for GFP (zinc finger protein HRX, 
referred to as HRX); (2) a GFP binding nanobody-His6X that tightly binds GFP (KD » 1 nM), but 
lacks the BC2T epitope, or (3) GFP binding nanobody fused to a C-terminal BC2T, then washed 
tree times with 200 µL wash buffer. Following this, 50 nM of BC2-nanobody-nLuc fusion protein 
in wash buffer was incubated for 1 hour, and washed four times with 200 µL wash buffer. Finally 
100 µL of NanoGlo reagent substrate diluted 1:50 in wash buffer was incubated with samples and 
allowed to shake for ~10 minutes at RT. Luminescence was measured on a plate reader.  
 
Flow Cytometry Analysis  
Bacteria: 50 mL culture of bacteria displaying mSA2 with BC2T and myc were grown in a 250 
mL baffled flask containing chloramphenicol at 37 °C with shaking (250 rpm) until an OD600 = 
~0.5 and induced with a final concentration of 0.02% (w/v) L-(+)-Arabinose at 20 °C overnight 
with shaking (250 rpm). Approximately 108 cells were pelleted and washed with 500 µL of 4 °C 
PBS-BSA. Bacteria were subsequently incubated with either BC2 nanobody – Cy5 (~10 µg/mL), 
FITC-conjugated anti-myc antibody (1:10,000 dilution), or both BC2 nanobody-GFP alone in 500 
µL PBS-BSA and rotated at RT for 1 hour. After incubation, two final washes with cold PBS-BSA 
were made to remove any unbound material and samples were taken to flow cytometry for analysis.  
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Yeast: 50 mL culture of yeast displaying mSA2 with BC2T were grown in a 250 mL baffled 
flask containing SD-CAA for 2-3 days at 30 °C with shaking. After 2-3 days of growth in SD-
CAA, the samples were subcultured in SD-CAA at an intial density of 1X107 cells/mL and grown 
to a density of 2-5 X107 cells/mL. Yeast were subcultured again to a concentration of 1.0X107 
cells/mL in SG-CAA (Galactose containing induction media) and grown for 2 days shaking at 250 
rpm at a temperature of 20 °C. Approximately 108 cells were pelleted and washed with 500 µL of 
4 °C PBS-BSA. Yeast were subsequently incubated with either BC2 nanobody – Cy5 (~10 
µg/mL), FITC-conjugated anti-myc antibody / FITC conjugated anti-HA antibody (1:10,000 
dilution), both the nanobody and one antibody, or BC2 nanobody – GFP (50 nM) alone in 500 µL 
PBS-BSA and rotated at RT for 1 hour. After incubation, two final washes with cold PBS-BSA 
were made to remove any unbound material and samples were taken to flow cytometry analysis.  
Western Blot Analysis  
Using commercially available antibodies: Purified proteins were separated by SDS-PAGe and 
transferred to PVDF membrane via an iBlot Western blot apparatus. The membrane was blocked 
with 1X PBS, 5% milk, and 0.1% Tween-20 for 1 hour at RT. Primary antibodies for myc and HA 
tag were incubated separately with the appropriate membranes overnight at a 1:10,000 dilution in 
10 mL of 1X PBS, 5% BSA, and 0.1% Tween-20 at 4 °C. Membranes were washed 3X with 1X 
PBS containing 0.1% Tween-20 and then incubated with Anti-Rabbit (Alexa Fluor 790) at a 
1:10,000 dilution in 10 mL PBS, 5% milk, and 0.1% Tween-20 for 1 hour at RT. The membranes 
were then washed 3X with 1X PBS containing 0.1% Tween-20 and imaged in 1X PBS using the 
Odyssey Classic Infrared Imager.  
Using “in-house” prepared nanobody-IR800 dye: Purified proteins were separated by SDS-
PAGE and transferred to a PVDF membrane via an iBlot Western blot apparatus. The membrane 
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was incubated with 1X PBS, 5% milk, and 0.1% Tween-20 for 1 hour at RT. The BC2 nanobody- 
IR800 dye conjugate was then incubated overnight at ~0.10 µM concentration in 10 mL of 1X 
PBS, 5% BSA, and 0.1% Tween-20 at 4 °C. The membrane was then washed 3X with 1X PBS 
containing 0.1% Tween-20 and imaged in 1X PBS using the Odyssey Classic Infrared Imager.  
 
Appendix C.2: Chapter Five – Proteins Used in this Work 
 

































































Appendix C.3: Chapter Five – Supplemental Information  
 
Figure S5. 1 ELISA-HRP. ELISA data using HRP conjugated antibodies or nanobodies for analysis. All 
wells were free (no immobilization on the plate’s surface). To test off-target binding of anti-His6 antibody-
HRP, anti-myc antibody-HRP, and BC2nb-HRP to non-immobilized well, wells were incubated with just 
buffer (NT), HRX-BC2T, the GFP nanobody with different tags depending on which antibody was used 
(anti-His6, colored black, anti-myc, colored grey, and BC2 nanobody-HRP, colored white) and washed to 
remove unbound material. After a 30-minute incubation with TMB-one substrate, plate was read at 655 nm. 
Signal is the observed absorbance at 655 nm. All experiments were performed in triplicate. Error bars 



















































Figure S5. 2 ELISA – NanoLuciferase. ELISA data using fusion protein BC2nb-nLuc for analysis. All 
wells were without anything immobilized on the plate’s surface. To test off-target binding of BC2nb-nLuc 
to non-immobilized wells, wells were incubated with just buffer (NT), HRX-BC2T, the GFP nanobody 
with either a His6x tag or BC2T and washed to remove all unbound material. Luminescence was read after 
a 10-minute incubation with NanoGlo substrate. All experiments were performed in triplicate. Error bars 







































Table S5. 1 Flow Cytometry Data – Bacteria. Cy5, FITC, and GFP detected by flow cytometry to indicate 
display. All experiments were completed in triplicate. Values represent the mean of those experiments.  
  construct induced  
incubated 






- - 0.87 1.73 
2 Yes - 1.72 1.23 
3 - Myc-ab-FITC 1.17 0.82 
4 Yes Myc-ab-FITC 3.11 94 
5 - BC2-nb Cy5 9.2 0.86 
16 Yes BC2-nb Cy5 98.6 1.9 
7 - BC2-nb-GFP 1.09 11.5 


































Table S5. 2 Flow Cytometry Data- Yeast. Cy5, FITC, and GFP detected by flow cytometry to indicate 
display. All experiments were performed in triplicate. Values represent the mean of those experiments.  






- - 0.63 6.11 
2 Yes - 0.17 1.1 
3 - Myc-ab-FITC 0.27 0.67 
4 Yes Myc-ab-FITC 0.53 71.7 
5 - HA-ab-FITC 0.28 0.71 
6 Yes HA-ab-FITC 0.58 69.3 
7 - BC2-nb Cy5 1.01 0.81 
8 Yes BC2-nb Cy5 71.1 1.61 
9 - BC2-nb-GFP 0.28 0.82 
10 Yes BC2-nb-GFP 0.57 59.6 
11 Yes 
BC2-nb Cy5 + 
Myc-ab-FITC 70.9 71 
12 Yes 
BC2-nb Cy5 + 






Figure S5. 3 Representative Flow Cytometry Histograms. Representative histogram of flow cytometry 
data for display of mSA2 on (a) bacteria and (b) yeast. In all cases, bacteria or yeast displaying mSA2 were 
detected after incubation with anti-HA antibody-FITC, anti-myc antibody-FITC, BC2 nanobody-Cy5, or 
BC2 nanobody-GFP. Non-induced samples are shown as dashed lines and induced samples as solid lines.  
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Figure S5. 4 Selectivity for Epitope Validated via Western blot. (a) 5 µM coomassie stained gel and 
Western blot analysis of GFP-BC2T and GFP. Western blot analysis used BC2 nanobody-IRdye800. (b) 5 
µM coomassie stained gel and Western blot analysis of GFP-HA and GFP. Western blot analysis used anti-





Figure S5. 5 SDS-PAGE of BC2 nanobodies utilized in this work. SDS-PAGE of purified BC2 nanobody 
and its fusion proteins and conjugates used in this work. BC2nb-HRP is the only construct to not receive 
complete conjugation, however because the assay is done in excess of reagent a significantly larger signal 










Appendix D.1: Chapter Six – Part I - Methods  
Materials  
All chemicals obtained from Sigma-Aldrich unless specified  
LB Miller Broth – Fisher  
Phosphate buffered saline (PBS) – Corning Cell Grow 
Lipofectamine 2000 – Life Technologies  
0.25% Trypsin – Hyclone/Thermo Scientific  
Fetal Bovine Serum (FBS) – Atlanta Biologicals  
Dulbecco’s Modified Eagle Medium (DMEM) – Hyclone/Thermo Scientific  
Mammalian cell culture dishes – Fisher Scientific 
Black Visiplate TC – PerkinElmer 
RIPA Buffer – Boston BioProducts  
5-alpha chemically competent E. coli – NEB  
BL21 (DE3) chemically competent E. coli – NEB  
Agar – GoldBio Technology  
Carbenicillin – GoldBio Technology  
Restriction Enzymes – NEB  
Isopropyl-b-D-1-thiogalactopyranoside (IPTG) – GoldBio Technology  
cOmplete ULTRA Tablets, Mini, EDTA-free – Roche  
Nano-Glo Live Cell Assay System – Promega  
Quick Ligation Kit – NEB  
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Vent Polymerase – NEB  
Oligonucleotides – IDT  
Miniprep Kits – OMEGA  
PageRuler Prestained Protein Ladder – Thermo Scientific  
Ready Gel Precast Gels – BioRad  
Hek293 Cells –ATCC  
All water was obtained from a Milli-Q water purification system. 
 
Instrumentation  
Synergy Mx Microplate Reader – BioTek  
EVOS FL Microscope – Advanced Microscopy Group 
Sonifer W – 350 cell disrupter – Branson  
MJ Mini Gradient Thermal Cycler – BioRad  
Molecular Imager Gel Doc XR+ System – BioRad 
 
Cloning  
Purified proteins: All plasmids were constructed on a pETDuet-1 backbone. All proteins were 
assembled from a set of overlapping oligonucleotides or purchased g-block. Constructs were 
amplified using vent and then ligated into NcoI and KpnI restriction enzyme cleavage sites in the 
pETDuet-1 plasmid.  
Mammalian expression: A mammalian GFP expression vector was generously provided by the 
Stasevich Lab (CSU). The gene coding for FP-LgBit was assembled from a set of overlapping 
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oligonucleotides and purchased g-block. FP-LgBit was amplified using vent and then ligated into 
NheI and BglII restriction enzyme cleavage sites in the mammalian GFP expression vector.  
 
Protein Purification  
Plasmids encoding GFP variants were transformed into BL21s (DE3) and plasmids encoding 
nanobody variants were transformed into Shuffle T7 Express cells. Cells were grown in either 1L 
or 500 mL LB cultures containing carbinecillin at 37 °C to OD600 » 0.5 and induced with 1 mM 
IPTG at 20 °C overnight. Cells were then collected by centrifugation and resuspended in phosphate 
buffer with 2 M NaCl (20 mM Sodium Phosphate, pH 7.4) and stored at -20 °C. Frozen pellets 
were thawed and incubated with cOmplete ULTRA protease inhibitor tablets then sonicated for 2 
minutes. The lysate was cleared by centrifugation (8000 rpm; 20 minutes) and the supernatant was 
mixed with 1 mL Ni-NTA resin for 30 minutes. The resin was collected by centrifugation (4750 
rpm, 10 minutes). The resin was washed with 50 mL buffer and 20 mM imidazole then 10 mL 
buffer with 50 mM imidazole. The protein was then eluted with 7 mL buffer containing 400 mM 
imidazole. The proteins were dialyzed against buffer with 150 mM NaCl and analyzed for purity 
by SDS-PAGE. Purified proteins were quantified using absorbance at 280 nm.  
Mammalian Cell Culture  
Hek293 cells were cultured in high glucose Dulbecco’s modified Eagle medium (DMEM) with 






In Vitro Analysis  
Individual aliquots of purified protein containing the SmBit tag were mixed at varying 
concentrations with excess purified FP-LgBit (1 µM) in a black walled 96-well plate with shaking 
at RT for ~10 minutes. Next, a 1:50 dilution of NanoGlo reagent was added to wells and let 
continue shaking at RT for ~10 minutes before reading luminescence on a plate reader.  
 
In Vivo Analysis  
Hek293 cells were grown to ~85% confluency in a 24-well plate (clear bottom, black well). 
Prior to transfection, mammalian expression plasmid encoding FP-LgBit was ethanol precipitated. 
Cells were transfected with Lipofectamine 2000 following manufacturers protocol with a 
mammalian expression vector engineered to produce FP-LgBit. After ~10 hours of transfection, 
cells were washed 1X with OptiMem and then incubated with OptiMem solution containing 
purified proteins for a specified time. Cells were then washed 1X with OptiMem and 2X with PBS 
containing heparin sulfate 20 U/mL. Each round of incubation with heparin sulfate was allowed to 
incubate at 37 °C, 5% CO2 environment for 10 minutes. Cells were then incubated with PBS and 
imaged on the EVOS FL fluorescence microscope to confirm transfection efficiency. After, cells 
were mixed with a 1:50 dilution of NanoGlo reagent and allowed to incubate with shaking at RT 










































































































Appendix D.3: Chapter Six – Part I: Supplemental Information  
 
 
Figure S6. 1 SDS-PAGE of Purified Proteins – NanoBit. PAGE analysis of purified wildtype and 






















Figure S6. 2 Live-Cell Fluorescent Microscopy Images – NanoBit. Cells were transfected with plasmid 
















Appendix D.4: Chapter Six – Part II - Methods  
Materials  
All chemicals were obtained from Sigma-Aldrich unless specified  
Phosphate buffered saline (PBS) – Hyclone/Thermo Scientific  
Brilliant Blue R-250 – J.T. Baker  
Imidazole – Sigma Aldrich  
PageRuler Prestained Protein Ladder – Thermo/Scientific  
LB Miller Broth – Fisher  
5 – alpha chemically competent E. coli – NEB  
BL21 (DE3) chemically competent E. coli – NEB  
Agarose A – Bio Basic Inc.  
Carbenicillin – GoldBio Technology  
Kanamycin – GoldBio Technology  
Restriction Enzymes – NEB  
Isopropyl - b-D-1 thioglalactopyranoside (IPTG) – GoldBio Technology  
cOmplete ULTRA Tablets, Mini, EDTA-free – Roche  
Quick Ligation Kit – NEB  
Vent Polymerase – NEB  
Oligonucleotides/gblocks – IDT  
Miniprep Kits – Omega  
12% Ready Gel Precast Gels – BioRad  
Snakeskin Dialysis Tubing 10 K MWCO – Thermo Scientific  
All water obtained from Milli-Q water purification system  
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Instrumentation 
Sonifer W – 350 cell disrupter – Branson  
MJ mini gradient thermal cycler – BioRad  
Molecular Imager Gel Doc XR+ System – BioRad  
NanoDrop 200 UV-Vis Spectrophotometer – Thermo Scientific  
Stasevich Laboratory Custom-Built Microscope 
 
Microscopy 
All cell images and videos were taken on the Stasevich Laboratory Microscopy, a custom-built 
widefield fluorescence microscope with a highly inclined illumination scheme.1 
 
Mammalian Cell Culture  
U2OS cells were prepared in the Stasevich Laboratory and cultured in DMEM media. Cells 
were incubated at 37 °C with 5% CO2 environment.  
 
Cloning  
Purified proteins: All plasmids were constructed on a pETDuet-1 backbone. All proteins were 
assembled from a set of overlapping oligonucleotides or purchased g-block. Constructs were 
amplified using vent and then ligated into NcoI and KpnI or BamHI and PacI restriction enzyme 
cleavage sites in the pETDuet-1 plasmid.  
Mammalian expression vector: A vector encoding 10XFLAG-tag (SM) beta-actin cut with 
restriction enzymes AgeI and ClaI was generously given by the Stasevich Laboratory. A 7X TAR 
DNA fragment was obtained as a g-block from IDT with flanking AgeI and ClaI cut sites. 
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Construct was amplified using vent and then ligated into AgeI and ClaI restriction enzyme 
cleavage sites in the mammalian expression vector.  
A vector encoding sfGFP-H2B was modified to make Cpep-H2B.  
 
Protein Purification  
Plasmids were transformed into BL21s (DE3). Cells were grown in either 2500 mL or 500 mL 
LB cultures containing carbinecillin at 37 °C to an OD600 » 0.5 and induced with 1 mM IPTG at 
20 °C overnight. Cells were then collected by centrifugation and resuspended in phosphate buffer 
with 2 M NaCl (20 mM Sodium Phosphate, pH 7.4) and stored at -20 °C. Frozen pellets were 
thawed and incubated with cOmplete ULTRA protease inhibitor tablets and then sonicated for 2 
minutes. The lysate was cleared by centrifugation (8000 rpm, 20 minutes) and the supernatant was 
mixed with 1 mL Ni-NTA resin for 30 minutes. The resin was collected by centrifugation (4750 
rpm, 10 minutes). The resin was washed with 50 mL buffer and 20 mM imidazole then 10 mL 
buffer and 50 mM imidazole. The protein was then eluted with 7 mL buffer containing 400 mM 
imidazole. The proteins were dialyzed against buffer with 150 mM NaCl and analyzed for purity 
by SDS-PAGE. Purified proteins were quantified using absorbance at 280 nm. 
 




































TATCGATAG (AgeI to ClaI restriction enzyme sites)  
 
Appendix D.6: Chapter Six – Part II: Supplemental Information  
 











ADCC   antibody-dependent cellular cytotoxicity  
Ala/A   alanine  
Antp   antennapedia-homeodomain-derived peptide  
Arg/R   arginine  
Asn/N   aspartic acid  
CD   circular dichroism  
CDC   complement-dependent cytotoxicity 
CDR   complementary determining region  
CPP   cell-penetrating peptide  
Cy5   cyanine dye number 5  
Cys/C   cysteine  
Da   Dalton  
DAPI   4’6-diamidino-2-phenylindole  
DNA   deoxyribonucleic acid  
ELISA   enzyme-linked immunosorbent assay  
FACS   fluorescence-activated cell sorting  
FITC   fluorescein isothiocyanate  
GFP   green fluorescent protein  
Gln/Q   glutamine  
Glu/E   glutamic acid  
Gly/G   glycine  
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HER2   human epidermal growth factor receptor 2 
His/H   histidine  
HIV   human immunodeficiency virus  
HRP   horseradish peroxidase 
IgG   immunoglobulin G   
Ile/I   isoleucine  
IPTG   b-D-1-thiogalactopyranoside  
ITC   isothermal titration calorimetry  
KD   dissociation constant  
Leu/L   leucine  
Lys/K   lysine  
MCS   multiple cloning site  
Met/M   methionine  
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
mRNA   messenger RNA 
MW   molecular weight  
NHR   N-heptad repeat 
nLuc   nano-luciferase  
nt   nucleotides  
PAGE   polyacrylamide gel electrophoresis  
PBS   phosphate-buffered saline  
PCR   polymerase chain reaction  
PDB   protein data bank 
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Pen   penetratin  
Phe/F   phenylalanine  
PSMA   prostate specific membrane antigen  
PPI   protein-protein interaction  
Pro/P   proline  
PTD   protein transduction domain  
RNA   ribonucleic acid  
RT   room temperature  
RPM   revolutions per minute  
SAV   streptavidin  
SDS   sodium dodecyl sulfate  
Ser/S   serine  
siRNA   small interfering ribonucleic acid 
TAT   trans-activating transcriptional activator  
TAR   trans-activating response element  
Thr/T   threonine  
TMB   3,3’,5,5’-tetramethylbenzidine  
Trp/W   tryptophan  
Tyr/Y   tyrosine 
U1A   human U1 snRNP protein  
U1hpII   U1 hairpin II of the human snRNP complex  
Val/V   valine  
WB   Western blot  
